WO2024109949A1 - 一种抗肿瘤化合物及其应用 - Google Patents

一种抗肿瘤化合物及其应用 Download PDF

Info

Publication number
WO2024109949A1
WO2024109949A1 PCT/CN2023/134190 CN2023134190W WO2024109949A1 WO 2024109949 A1 WO2024109949 A1 WO 2024109949A1 CN 2023134190 W CN2023134190 W CN 2023134190W WO 2024109949 A1 WO2024109949 A1 WO 2024109949A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
optionally substituted
unsubstituted
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/134190
Other languages
English (en)
French (fr)
Inventor
李傲
姚智理
陈以乐
朱丽媛
曹国庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minghui Pharmaceutical Hangzhou Ltd
Minghui Pharmaceutical Shanghai Ltd
Original Assignee
Minghui Pharmaceutical Hangzhou Ltd
Minghui Pharmaceutical Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minghui Pharmaceutical Hangzhou Ltd, Minghui Pharmaceutical Shanghai Ltd filed Critical Minghui Pharmaceutical Hangzhou Ltd
Priority to EP23894038.1A priority Critical patent/EP4623937A1/en
Priority to AU2023387509A priority patent/AU2023387509A1/en
Priority to CN202380079571.6A priority patent/CN120265326A/zh
Priority to JP2025530407A priority patent/JP2025538619A/ja
Priority to KR1020257021206A priority patent/KR20250111373A/ko
Publication of WO2024109949A1 publication Critical patent/WO2024109949A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Definitions

  • the present application relates to the field of biomedicine, and specifically to an anti-tumor compound and its application.
  • ADCs Antibody-drug conjugates
  • ADCs connect monoclonal antibodies or antibody fragments to biologically active cytotoxins through stable chemical linker compounds, making full use of the antibody's specificity for binding to surface antigens of normal cells and tumor cells and the high efficiency of cytotoxic substances, and have anti-tumor effects.
  • camptothecin derivative exatecan in antibody-drug conjugates (ADCs) has been reported in the literature, but further development of ADC drugs with better efficacy and higher safety is still needed in this field.
  • the currently marketed ADC drugs still have problems such as poor plasma stability and off-target toxic side effects, which affect the efficacy and safety of the products. It is still necessary to further develop new and stable linkers and/or linker-drug molecules to solve these problems.
  • the present invention provides a ligand conjugate with high stability, good efficacy and high safety, and a ligand conjugate precursor, a linker, a linker precursor and the like.
  • a ligand conjugate or its tautomer, mesomer, racemate, enantiomer, diastereomer, or its pharmaceutically acceptable salt or hydrate, wherein the ligand conjugate comprises the structure shown in Formula I:
  • L is an optionally substituted linker, which is connected to any O atom, S atom or N atom in the P structure;
  • Ab is a ligand, a is a number greater than 0, and a is a decimal or an integer;
  • P is a toxin, and the P has a structure shown in the following formula II:
  • n 0 or 1
  • X is selected from the group consisting of N or CR 0 ;
  • R 0 is selected from the group consisting of H, D, halogen, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, OH, NH 2 , N 3 or NO 2 ;
  • R 1 is selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxy group, a C 1 -C 8 haloalkyl group, a C 1 -C 8 haloalkoxy group, N 3 , NO 2 , NH 2 , NH-OH, -NR'R", -COOR', -CONR'R", -NHR"'NR'R”; wherein R', R" and R"' are each independently selected from the group consisting of hydrogen, deuterium, an alkyl group, an aryl group, an arylalkyl group, an acyl group, an alkoxycarbonyl group, an aryloxycarbonyl group;
  • R2 , R3 , R4 , R5 and R6 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a hydroxyl group, a cyano group, NH2 , NO2 , a substituted or unsubstituted C1 - C8 alkyl group, a substituted or unsubstituted C1 - C8 alkoxy group, a substituted or unsubstituted C1 - C8 alkylthio group, a substituted or unsubstituted C1 - C8 deuterated alkyl group, -( CH2 ) mtri ( C1 - C4alkyl )silyl group, -( CH2 ) m ( C3 - C8cycloalkyl group), -( CH2 ) m (3-12 membered heterocyclic group), -( CH2 ) mN ( R7 ) 2 , -( CH
  • R 2 and R 3 together with the carbon atom to which they are attached form a substituted or unsubstituted C 5 -C 8 carbocyclic ring or a substituted or unsubstituted 5-12 membered heterocyclic ring;
  • R3 and R4 , or R4 and R5 and the carbon atom to which they are connected together form a structure selected from the group consisting of a saturated or unsaturated 5-12-membered carbocyclic ring which is unsubstituted or substituted with one or more Re , a saturated or unsaturated 5-12-membered heterocyclic ring which is unsubstituted or substituted with one or more Re ;
  • Said R e is a substituted or unsubstituted substituent selected from the following group: a hydrogen atom, a deuterium atom, a halogen, a nitrile group, a nitro group, a hydroxyl group, an amino group, a C 1 -C 6 alkyl-NH-, a (C 1 -C 6 alkyl) 2 N-, a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, a C 2 -C 6 alkynyl group,
  • R7 is selected from the following group: a hydrogen atom, a deuterium atom, a halogen, a substituted or unsubstituted C1 - C8 alkyl group, a C1 - C8 haloalkyl group, a C1 - C8 deuterated alkyl group, a substituted or unsubstituted C1 - C8 alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a mercapto group, a substituted or unsubstituted C1 - C8 alkylene group-OH, a substituted or unsubstituted C1 - C8 alkylene group- NH2 , SO2Me , -OC(O)(substituted or unsubstituted C1 - C4 alkyl group), -C(O)(substituted or unsubstituted C1 - C4 alkyl group),
  • substituted refers to the substitution of one or more hydrogen atoms on a group with a substituent selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a nitrile group, a nitro group, a hydroxyl group, an amino group, a C 1 -C 6 alkyl-NH-, a (C 1 -C 6 alkyl) 2 N-, a C 1 -C 6 alkyl, a C 2 -C 6 alkenyl, a C 2 -C 6 alkynyl, a C 1 -C 6 alkoxy group, a halogenated C 1 -C 6 alkyl group, a halogenated C 2 -C 6 alkenyl group, a halogenated C 2 -C 6 alkynyl group, a halogenated C 1 -C 6 alkoxy group, an allyl group, a benzyl
  • the L has a structure as shown below: -L 1 -L 2 -L 3 -L 4 -L 5 -;
  • R d is H, C 1 -C 6 alkyl, C 1 -C 6 deuterated alkyl, C 3 -C 8 cycloalkyl or C 3 -C 8 deuterated cycloalkyl;
  • the L2 is a group selected from the group consisting of optionally substituted -(CHR) m1 - X1- ( CH2CH2O ) n3- (CHR) m2 -C(O)-, optionally substituted - (CHR) m1 - X1 - X2- ( CH2CH2O ) n3-(CHR)m2-C(O)-, optionally substituted -X1-(CHROCHR)m2-C(O)-, optionally substituted -(CHR)p1-C(O)-, optionally substituted -(CHR)m1-X1-(CHR)m2-C(O)-, optionally substituted -(CHR)m1-X1-(CHR)n3 - X2- ( CHR ) m2 - C(O)-, optionally substituted -(CH2CH2O)n3-(CHR) m2 -C(O)-, optionally substituted
  • X1 and X2 are each independently selected from the following group: -O-, -C(O)-, -C(O)-NR-, optionally substituted C6 - C10 aryl, optionally substituted 5-9 membered heteroaryl, optionally substituted 3-8 membered heteroalicyclic group and optionally substituted C3 - C6 alicyclic group;
  • each R is independently selected from the following group: H, D, (CH 2 ) n4 OH, (CH 2 ) n4 NH 2 , (CH 2 O) n4 (CH 2 CH 2 O) n5 H, (CH 2 O) n4 (CH 2 CH 2 O) n5 CH 3 , (CH 2 ) n4 OCH 3 , (CH 2 CH 2 O) n5 CH 3 , CH 2 C(O)NH(CH 2 O) n4 (CH 2 CH 2 O) n5 H, CH 2 C(O)NH(CH 2 O) n4 (CH 2 CH 2 O) n5 CH 3 ;
  • m1, m2, n3, n4 and n5 are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12; p1 is selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
  • the L 3 is a peptide residue; and the L 3 may be substituted by one or more substituents selected from the following group: CH 2 C(O)R c ; said R c is selected from the following group: wherein n1 and n2 are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12;
  • the L 4 is optionally substituted -L 4a -(NR b ) n6 -R 12 -L 4b -, wherein L 4a is absent, or L 4a is optionally substituted wherein n6 is 0 or 1; R 12 is a chemical bond, CH 2 , or CD 2 ;
  • L 4b is absent, or L 4b is optionally substituted wherein Ra and Rb are each independently selected from the following group: hydrogen, optionally substituted C1 - C4 alkyl, and optionally substituted C1 - C4 deuterated alkyl;
  • the L 5 is absent or optionally substituted wherein Y is selected from the group consisting of O, S or NH; v is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10; R 10 and R 11 are each independently selected from the group consisting of hydrogen, deuterium , optionally substituted C 1 -C 4 alkyl, optionally substituted C 1 -C 4 haloalkyl , optionally substituted C 3 -C 6 cycloalkyl and optionally substituted C 4 -C 8 cycloalkylalkyl, or R 10 and R 11 together with the atoms to which they are attached form an optionally substituted 3-6 membered cycloalkyl, and R 10 and R 11 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, optionally substituted C 1 -C 8 alkyl, optionally substituted C 1 -C 8 haloalkyl and optionally substituted C 1 -C 8
  • the L1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • X1 and X2 are each independently selected from the following group: -O-, -C(O)-, -C(O)-NR-, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted C3 - C6 cycloalkyl, optionally substituted or optionally substituted
  • L 2 is a group selected from the following group: optionally substituted -(CH 2 ) m1 -X 1 -(CH 2 CH 2 O) n3 -(CH 2 ) m2 -C(O)-; wherein X 1 is -C(O)-NH-; preferably, m1 and m2 are each independently selected from 1, 2 or 3; n3 is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.
  • L2 is a group selected from the group consisting of : optionally substituted -(CHR) m1 - X1 - X2- ( CH2CH2O ) n3- (CHR) m2 -C(O)-; wherein X1 is optionally substituted or optionally substituted X2 is -C(O)-NR-; preferably, m1 and m2 are each independently selected from 0, 1 or 2; n3 is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.
  • L 2 is a group selected from the following group: optionally substituted -X 1 -(CHROCHR) m2 -C(O)-; wherein X 1 is an optionally substituted aryl group or an optionally substituted heteroaryl group; preferably, m2 is selected from 0, 1, 2 or 3.
  • L2 is a group selected from the following group: optionally substituted (CHR) p1 -C(O)-; p1 is selected from 0, 1 or 2; R is selected from the following group: H, ( CH2 ) n4OH , ( CH2O ) n4 ( CH2CH2O ) n5H ; preferably, n4 and n5 are each independently selected from 0, 1 , 2 or 3.
  • L2 is a group selected from the following group: optionally substituted -( CH2 ) m1 - X1- ( CH2CH2O ) n3- (CHR) m2 -C(O)-; wherein X1 is -C(O)-; preferably, m1 and m2 are each independently selected from 0, 1 , 2 or 3; n3 is selected from 0, 1 or 2.
  • L 2 is a group selected from the following group: optionally substituted -X 1 -(CH 2 ) m1 -X 2 -(CHR) m2 -C(O)-; wherein X 1 is an optionally substituted aryl or an optionally substituted heteroaryl; X 2 is -C(O)-; preferably, m1 and m2 are each independently selected from 0, 1 or 2.
  • L2 is a group selected from the group consisting of: -(CHR) m1 - X1- (CHR) m2 -C(O)-; wherein X1 is an optionally substituted 3-8 membered heteroalicyclic group or an optionally substituted C3 - C6 alicyclic group; preferably, m1 is 0, 1 or 2, and m2 is 0.
  • the L2 is a group selected from the group consisting of: optionally substituted -(CHR) m1 - X1- ( CH2CH2O ) n3- (CHR) m2- C(O)-; wherein X 1 is O; preferably, m1, n3 and m2 are each independently 0, 1 or 2.
  • L 2 is a group selected from the following group: optionally substituted -(CHR) m1 -X 1 -(CHR) n3 -X 2 -(CHR) m2 -C(O)-; wherein X 1 is optionally substituted -C(O)-NR-, X 2 is O; preferably, m1, n3 and m2 are each independently 1, 2 or 3; R is as described above.
  • the L2 is an optionally substituted structure selected from the following group:
  • the above-mentioned L2 structure is selected so that the maleimide group of the obtained ligand conjugate can form an open-ring structure, thereby inhibiting the Retro-Michael reaction, improving the stability of the ligand conjugate, reducing the shedding of the small molecule part, and thus improving the safety of the ligand conjugate drug.
  • L 3 is a peptide residue consisting of amino acids selected from the following group which are unsubstituted or substituted with CH 2 C(O)R c : phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid and glycine.
  • L 3 is a peptide residue consisting of an amino acid selected from the following group and which is unsubstituted or substituted with CH 2 C(O)R c : glycine, alanine, lysine, phenylalanine, valine and citrulline.
  • L3 is a peptide residue selected from the following group which is unsubstituted or substituted with CH2C (O) Rc : -Gly-Phe-Gly-, -Gly-Gly-Phe-Gly-, -Val-Cit-, -Cit-Val-, -Cit-Ala-, -Val-Ala-, -Val-Arg-, -Val-Lys-, -Val-Lys(Ac)-(-Val-Lys(Ac)-).
  • the L 3 is a structure selected from the following group which is unsubstituted or substituted by CH 2 C(O)R c :
  • L 4 is a chemical bond, or an optionally substituted group selected from the following group:
  • the Ra and Rb are each independently selected from the following group: hydrogen, optionally substituted C1 - C4 alkyl, and optionally substituted C1 - C4 deuterated alkyl.
  • L4 is a chemical bond, or an optionally substituted structure selected from the following group:
  • the L 5 is a chemical bond, or a structure selected from the following groups: optionally substituted Optional Substituted Optional Substituted Optional Substituted Optional Substituted Optional Substituted Optional Substituted Optional Substituted Optional Substituted Optional Substituted and optionally substituted
  • the compound of formula II is selected from the following group:
  • the compound of formula II is selected from the following group:
  • the compound of formula II is selected from the following group:
  • R 4 is selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a hydroxyl group, a cyano group, NH 2 , NO 2 , a substituted or unsubstituted C 1 -C 8 alkyl group, a substituted or unsubstituted C 1 -C 8 alkoxy group, a substituted or unsubstituted C 1 -C 8 alkylthio group, a substituted or unsubstituted C 1 -C 8 deuterated alkyl group, -(CH 2 ) m (C 3 -C 8 cycloalkyl group), -(CH 2 ) m (3-12 membered heterocyclic group), -(CH 2 ) m N(R 7 ) 2 , -(CH 2 ) m S(O)(CH 2 ) p R 7 , - (CH 2 ) m S(O) 2 (CH 2 )
  • R 5 is selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, NH 2 , OH, a substituted or unsubstituted C 1 -C 8 alkyl group, a substituted or unsubstituted C 1 -C 8 alkoxy group;
  • R4 and R5 together with the carbon atom to which they are connected form a structure selected from the group consisting of a saturated or unsaturated 5-6 membered carbocyclic ring which is unsubstituted or substituted with one or more Re , and a saturated or unsaturated 5-6 membered heterocyclic ring which is unsubstituted or substituted with one or more Re ; wherein, Re is as defined above.
  • R 2 and R 3 are each independently selected from the following group: a hydrogen atom, a deuterium atom, a halogen, NH 2 , a substituted or unsubstituted C 1 -C 8 alkyl group, a substituted or unsubstituted C 1 -C 8 deuterated alkyl group, -(CH 2 ) m (C 3 -C 6 cycloalkyl group), -(CH 2 ) m (3-6 membered heterocyclyl group), -(CH 2 ) m N(R 7 ) 2 , -(CH 2 ) m OC(O)R 7 ; wherein m is 0, 1, 2, 3 or 4, and R 7 is as defined above;
  • R 2 and R 3 together with the carbon atom to which they are connected form a structure selected from the following group: a saturated or unsaturated 5-6 membered ring which is unsubstituted or substituted with one or more Re , a saturated or unsaturated 5-6 membered heterocycle which is unsubstituted or substituted with one or more Re ; wherein, Re is as defined above.
  • R 1 and R 6 are each independently a hydrogen atom.
  • said R 4 and R 5 are each independently selected from the following group: hydrogen atom, deuterium atom, halogen, hydroxyl, NH 2 , substituted or unsubstituted C 1 -C 4 alkyl;
  • R4 and R5 together with the carbon atom to which they are attached form an oxa-5-6-membered heterocyclic ring which is unsubstituted or substituted with one or more Re ; wherein Re is as defined above.
  • R 2 is selected from the following group: deuterium atom, halogen, NH 2 , substituted or unsubstituted C 1 -C 8 alkyl, substituted or unsubstituted C 1 -C 8 deuterated alkyl, -(CH 2 ) m (C 3 -C 6 cycloalkyl), -(CH 2 ) m (3-6 membered heterocyclyl), -(CH 2 ) m N(R 7 ) 2 , -(CH 2 ) m OC(O)R 7 ; wherein m is 0, 1, 2, 3 or 4;
  • R 3 is each selected from the following group: a hydrogen atom, a deuterium atom, a halogen, a substituted or unsubstituted C 1 -C 8 alkyl group, a substituted or unsubstituted C 1 -C 8 deuterated alkyl group, -(CH 2 ) m (C 3 -C 6 cycloalkyl group), -(CH 2 ) m (3-6 membered heterocyclyl group), -(CH 2 ) m N(R 7 ) 2 , -(CH 2 ) m OC(O)R 7 ; wherein m is 0, 1, 2, 3 or 4;
  • R 2 and R 3 together with the carbon atom to which they are connected form a structure selected from the group consisting of a saturated or unsaturated 5-6-membered ring that is unsubstituted or substituted with one or more Re , a saturated or unsaturated 5-6-membered heterocyclic ring that is unsubstituted or substituted with one or more Re ;
  • R 4 is selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a hydroxyl group, a cyano group, NH 2 , NO 2 , a substituted or unsubstituted C 1 -C 8 alkyl group, a substituted or unsubstituted C 1 -C 8 alkoxy group;
  • R 5 is selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, and a substituted or unsubstituted C 1 -C 8 alkyl group;
  • R 4 and R 5 together with the carbon atom to which they are attached form a group selected from the group consisting of -OCH 2 O- or -O(CH 2 ) 2 O- which is unsubstituted or substituted by one or more Re ;
  • R7 is selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen, a substituted or unsubstituted C1 - C8 alkyl group, a hydroxyl group, an amino group, a cyano group, a nitro group, and a mercapto group;
  • the compound of formula II is selected from the following group:
  • the above-mentioned ligand conjugate is selected from the following group:
  • the ligand conjugate is selected from the following group:
  • the ligand conjugate comprises a structure represented by formula (Ia):
  • R 4 , R 5 and L are as defined in the first aspect of the present invention, a is a number greater than 0, and a is a decimal or an integer.
  • the ligand conjugate is a structure selected from the following group:
  • a is a number greater than 0, and a is a decimal or an integer.
  • a is a non-zero integer or decimal from 0 to 8, preferably an integer or decimal between 1-8; more preferably, it is from 2 to 8, and can be an integer or a decimal; most preferably, it is from 3 to 8, and can be an integer, such as 4.0, or a decimal, such as 3.9.
  • the Ab is an antibody or an antigen-binding fragment thereof.
  • the antibody is selected from the following group: murine antibody, chimeric antibody, humanized antibody and fully human antibody.
  • the antibody is a monoclonal antibody.
  • the antigen-binding fragment is selected from the following group: Fab, Fab′, Fv fragment, F(ab′) 2 , F(ab) 2 , scFv, di-scFv, VHH and dAb.
  • the antibody is selected from the following group: Her-2 specific antibody (such as Trastuzumab), Trop2 specific antibody (such as Humanized RS7 or Sacituzumab in US7238785B2), PSMA specific antibody (such as PSMA specific monoclonal antibody AB-PG1-XG1-006 in WO2003034903A2), FR- ⁇ specific antibody (such as humanized LK26 antibody (Farletuzumab, MORAb-003) in US5952484), B7H3 antibody (such as antibody P7-C05-H4L3 in WO2021244590A1), or IGF-1R specific antibody.
  • Her-2 specific antibody such as Trastuzumab
  • Trop2 specific antibody such as Humanized RS7 or Sacituzumab in US7238785B2
  • PSMA specific antibody such as PSMA specific monoclonal antibody AB-PG1-XG1-006 in WO2003034903A2
  • FR- ⁇ specific antibody such as humanized LK26
  • the antibody is an IGF-1R specific antibody.
  • the IGF-1R comprises IGF-1R derived from primates.
  • the antibody is IgG1 or a mutation thereof.
  • the antibody comprises HCDR3, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3.
  • the antibody comprises HCDR2, and the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 2.
  • the antibody comprises HCDR1, and the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1.
  • the antibody comprises a heavy chain variable region VH
  • the VH comprises the HCDR1, HCDR2 and HCDR3
  • the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3
  • the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 2
  • the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1.
  • the antibody comprises a heavy chain variable region VH, and the VH comprises the amino acid sequence shown in SEQ ID NO: 4.
  • the antibody has a full-length sequence as shown in SEQ ID No.5.
  • the antibody is a variant of any of the above antibodies, and the variant includes the CDR region.
  • the variant is a sequence formed by replacing, deleting and/or adding one or more amino acids (e.g., 1-30, 1-20 or 1-10, for example, 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid substitutions, deletions and/or insertions) of the amino acid sequence of the antibody.
  • amino acids e.g., 1-30, 1-20 or 1-10, for example, 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acid substitutions, deletions and/or insertions
  • the variant is a homolog of the amino acid sequence of the antibody, and the homolog may be an amino acid sequence having at least about 85% (for example, at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) sequence homology with the amino acid sequence of the CDR.
  • the CDR is determined by the Kabat numbering scheme.
  • a ligand conjugate precursor or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a pharmaceutically acceptable salt or hydrate thereof, wherein the ligand conjugate precursor comprises a structure shown in Formula IA: LA -P(IA),
  • L is L 1A -L 2 -L 3 -L 4 -L 5 -;
  • L 1A is wherein R d , L 2 , L 3 , L 4 , L 5 and P are as defined in the first aspect of the present invention.
  • the ligand conjugate precursor is selected from the following structures:
  • L 1A is selected from
  • a linker as shown in formula (L), which connects a drug unit to a ligand to form a ligand-drug conjugate: L1 - L2 - L3 -L4 - L5 (L),
  • L 1 , L 2 , L 3 , L 4 and L 5 are as described in the first aspect of the present invention.
  • the linker is selected from the following group:
  • the linker is connected to the ligand through the L1 segment and to P1 through the L5 segment to form a ligand-drug conjugate; and the P1 is selected from the following group: glycopeptide antibiotics, such as bleomycin or bleomycin; DNA topoisomerase inhibitors, such as topoisomerase I inhibitors (such as camptothecin, hydroxycamptothecin, 9-aminocamptothecin, SN-38, irinotecan, isitecan, topotecan, belotecan or rubitecan, DXd, etc.), topoisomerase II inhibitors (such as actinomycin D, doxorubicin, duocarmycin, daunorubicin, mitoxantrone, podophyllotoxin or etoposide); drugs that interfere with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine,
  • Rg is H, OH, O( C1 - C6 alkyl); wherein LA is as defined in the third aspect of the present invention.
  • the linker precursor is selected from the following group:
  • the present invention also provides a synthesis scheme of another preferred embodiment of (L-1), which is described as follows:
  • Pg 1 is selected from wait
  • Pg2 is selected from Boc, Fmoc, Cbz, etc.
  • Pg 3 is selected from Boc, Fmoc, Cbz, etc.
  • Pg 1 is selected from wait
  • Pg2 is selected from Boc, Fmoc, Cbz, etc.
  • Pg 4 is selected from Me, Et, i Pr, Allyl, t Bu, Bn, 4-Methybenzyl, 4-Methoxybenzyl, 2,4-Dimethoxybenzyl, 2,6-Dimethoxybenzyl, Trimethylsilyl, tert-Butyldimethylsilyl, Pentafluorophenyl and the like.
  • the fifth aspect of the present invention provides a pharmaceutical composition, which contains the ligand conjugate described in the first aspect of the present invention, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and optionally a pharmaceutically acceptable carrier.
  • the sixth aspect of the present invention provides a ligand conjugate according to the first aspect of the present invention, or its tautomer, mesomer, Use of a racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug or solvate thereof, and/or the pharmaceutical composition described in the fifth aspect of the present invention in the preparation of a medicament for treating and/or preventing a disease or condition associated with target expression and/or abnormal expression of the ligand.
  • the disease or condition associated with the target expression and/or abnormal expression of the ligand is a tumor/cancer, an autoimmune disease or an infectious disease; preferably, the tumor/cancer is a tumor/cancer with high expression, medium expression or low expression of the target of the ligand.
  • the tumor is selected from tumors associated with the expression of the following group of targets: Her-2, Trop2, PSMA, FR- ⁇ , B7H3, or IGF-1R.
  • the tumor comprises a solid tumor and/or a blood tumor.
  • the tumor is a tumor associated with IGF-1R target expression.
  • the tumor is selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, endometrial cancer, urothelial cancer, lung cancer, prostate cancer, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, kidney cancer, pancreatic cancer, thyroid cancer and head and neck cancer.
  • Another aspect of the present invention provides a method for preparing a linker precursor as shown in formula (L-1), characterized in that it comprises the steps of:
  • L 1A is Preferably, L 1A is More preferably, L 1A is
  • L2 is as described in any of the above aspects; preferably, L2 is selected from the following group: More preferably, L2 is selected from
  • Selected from amino acids or dipeptide fragments preferably, Glycine or Gly-Gly fragment
  • Glycine-Glycine fragment Preferably, Glycine-Glycine fragment
  • Selected from amino acids or dipeptide fragments preferably, Glycine or Gly-Gly fragment
  • Glycine-Glycine fragment Preferably, Glycine-Glycine fragment
  • Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from Preferably, the Pg 1 is selected from
  • the It is prepared by the following method:
  • the reaction is carried out without or with the participation of a base; preferably, the reaction is carried out without the participation of a base; preferably, the base is selected from triethylamine, N,N-diisopropylethylamine, 2,4,6-trimethylpyridine, DMAP, DBU, NMM, NaHCO 3 ; preferably, the base is NaHCO 3 ;
  • Pg 5 is selected from Preferably, the Pg 5 is selected from Preferably, the Pg 5 is selected from Preferably, the Pg 5 is selected from Preferably, the Pg 5 is selected from Preferably, the Pg 5 is selected from Preferably, the Pg 5 is selected from Preferably, the Pg 5 is selected from Preferably, the Pg 5 is selected from
  • the Pg 1 OH is selected from Preferably, the Pg 1 OH is selected from Preferably, the Pg 1 OH is selected from Preferably, the Pg 1 OH is selected from Preferably, the Pg 1 OH is selected from Preferably, the Pg 1 OH is selected from
  • the It is prepared by the following method:
  • the method further comprises: obtaining by the following method (iii) or (iv)
  • the deprotection is carried out in the presence of a base; preferably, the base is an organic base; more preferably, the base is DBU; preferably, the deprotection is carried out in the presence of a reducing agent; preferably, the reducing agent is H 2 ; preferably, the deprotection is carried out in the presence of a catalyst; preferably, the catalyst is palladium carbon Pd/C;
  • the deprotection is carried out in the presence of a base; preferably, the base is an organic base; more preferably, the base is DBU; preferably, the deprotection is carried out in the presence of a reducing agent; preferably, the reducing agent is H 2 ; preferably, the deprotection is carried out in the presence of a catalyst; preferably, the catalyst is palladium carbon Pd/C;
  • Pg 2 is selected from Boc, Fmoc, and Cbz;
  • Pg 4 is selected from Me, Et, i Pr, Allyl, t Bu, Bn, 4-methylbenzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, 2,6-dimethoxybenzyl, trimethylsilyl, tert-butyldimethylsilyl, pentafluorophenyl.
  • the linker precursor is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Another aspect of the present invention provides a method for preparing the compound described in Formula 4:
  • the inert solvent is selected from the group consisting of dichloromethane, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, HMPA, or a combination thereof; preferably N,N-dimethylformamide;
  • the reaction is carried out in the presence of a condensing agent; more preferably, the condensing agent is selected from the group consisting of HATU, HBTU, TBTU, EDCI, HOAt, HOBt, CDI, TCFH, TFFH, DCC, DIC, BOP, AOP, PyAOP, BrOP, PyClOP, PyBrOP, DMTMM, or a combination thereof, more preferably, the condensing agent is HATU;
  • the reaction is carried out in the presence of a base; more preferably, the base is selected from the group consisting of TEA, DIPEA, DBU, DMAP, pyridine, 2,6-dimethylpyridine, 2,4,6-trimethylpyridine, imidazole, N-methylimidazole, or a combination thereof; more preferably, the base is 2,4,6-trimethylpyridine.
  • the base is selected from the group consisting of TEA, DIPEA, DBU, DMAP, pyridine, 2,6-dimethylpyridine, 2,4,6-trimethylpyridine, imidazole, N-methylimidazole, or a combination thereof; more preferably, the base is 2,4,6-trimethylpyridine.
  • Another aspect of the present invention provides a method for preparing a compound as described in Formula 15h:
  • the inert solvent is selected from the group consisting of acetonitrile, water, tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, or a combination thereof; more preferably, acetonitrile, water, or a combination thereof; more preferably, a combination of acetonitrile and water in a volume ratio of 10:1 to 1:10; more preferably, the inert solvent is a combination of acetonitrile and water in a volume ratio of 2:1 to 4:1; more preferably, the inert solvent is a combination of acetonitrile and water in a volume ratio of 3:1;
  • the reaction can be carried out in the presence of a base; preferably, the base is selected from TEA, DIPEA, NMM, sodium bicarbonate, DBU, or a combination thereof; more preferably, the base is DIPEA;
  • the compound of Formula 15g is subjected to a silicon-based removal agent to remove the protecting group to obtain a compound of Formula 15h;
  • the silicon-based removal agent is selected from the group consisting of an acid, a fluorination agent (fluorine-containing agent); preferably, the silicon-based removal agent is selected from the group consisting of hydrogen fluoride, an aqueous solution of hydrogen fluoride, triethylamine trihydrofluoride, pyridine hydrofluoride, formic acid, acetic acid, trifluoroacetic acid, dichloroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid; preferably, the silicon-based removal agent is formic acid;
  • the inert solvent is selected from the following group: tetrahydrofuran, N,N-dimethylformamide, acetonitrile, water, or a combination thereof; further preferably, acetonitrile, water, or a combination thereof; further preferably, the volume ratio of acetonitrile to water is 10:1 to 1:10, further preferably, the volume ratio of acetonitrile: water is 1:4 to 4:1, and further preferably, the volume ratio of acetonitrile: water is 1:1.5.
  • the present invention also provides a method for preparing the compound described in Formula 8e below:
  • the inert solvent is selected from dichloromethane, tetrahydrofuran, 2-methyltetrahydrofuran, or a combination thereof; more preferably, the inert solvent is dichloromethane;
  • the base is an organic base; more preferably, the base is dimethylamine, diethylamine, DBU, piperidine; more preferably, the base is DBU.
  • the inert solvent is selected from tetrahydrofuran, water, or a combination thereof; more preferably, the inert solvent is water; more preferably, the inert solvent is a combination of tetrahydrofuran and water in a volume ratio of 1:5 to 5:1.
  • the deprotection is carried out in the presence of a base; preferably, the base is an organic base; more preferably, the base is DBU;
  • the deprotection is performed in the presence of a reducing agent; more preferably, the reducing agent is hydrogen H 2 ; more preferably, the deprotection is performed in the presence of a catalyst; more preferably, the catalyst is palladium carbon Pd/C;
  • the present invention also provides a method for preparing the compound described in Formula 8c below:
  • the inert solvent is selected from dichloromethane, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, or a combination thereof; more preferably, the inert solvent is tetrahydrofuran.
  • the reaction is carried out in the presence of an acid or a base; more preferably, the acid is p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate; more preferably, the base is lithium hydroxide, lithium hydroxide monohydrate, potassium tert-butoxide, sodium tert-butoxide, or sodium hydroxide; more preferably, the base is lithium hydroxide; more preferably, the base is lithium hydroxide monohydrate;
  • the present invention also provides a method for preparing the compound described in Formula 8b:
  • reaction is carried out in the presence of a base; more preferably, the base is sodium bicarbonate;
  • the inert solvent is selected from ethylene glycol dimethyl ether, water, or a combination thereof; more preferably, the inert solvent is a combination of ethylene glycol dimethyl ether and water; more preferably, the inert solvent is a combination of ethylene glycol dimethyl ether and water in a volume ratio of 1:5 to 5:1. More preferably, the inert solvent is a combination of ethylene glycol dimethyl ether and water in a volume ratio of 1:2 to 2:1;
  • the inert solvent is selected from N,N-dimethylformamide, N,N-dimethylacetamide, and HMPA; more preferably, the inert solvent is N,N-dimethylformamide.
  • reaction is carried out in the presence of lead tetraacetate
  • reaction is carried out in the presence of copper acetate
  • reaction is carried out in the presence of acetic acid
  • reaction is carried out in the presence of acetic acid, lead tetraacetate and copper acetate;
  • reaction is carried out in the presence of acetic acid and lead tetraacetate
  • the present invention also provides a method for preparing the compound of formula 15f:
  • the inert solvent is selected from dichloromethane, tetrahydrofuran, and 2-methyltetrahydrofuran; more preferably, the inert solvent is dichloromethane;
  • the reaction is carried out in the presence of a condensing agent; more preferably, the condensing agent is selected from the following group: HATU, HBTU, TBTU, EDCI, HOAt, HOBt, CDI, TCFH, TFFH, DCC, DIC, BOP, AOP, PyAOP, BrOP, PyClOP, PyBrOP, DMTMM, or a combination thereof; more preferably, the condensing agent is DCC.
  • the condensing agent is selected from the following group: HATU, HBTU, TBTU, EDCI, HOAt, HOBt, CDI, TCFH, TFFH, DCC, DIC, BOP, AOP, PyAOP, BrOP, PyClOP, PyBrOP, DMTMM, or a combination thereof; more preferably, the condensing agent is DCC.
  • the inert solvent is selected from ethylene glycol dimethyl ether, water, or a combination thereof; more preferably, the inert solvent is a combination of ethylene glycol dimethyl ether and water; more preferably, the inert solvent is a combination of ethylene glycol dimethyl ether and water in a volume ratio of 1:5 to 5:1; more preferably, the inert solvent is a combination of ethylene glycol dimethyl ether and water in a volume ratio of 1:2 to 2:1;
  • the reaction is carried out without or with the participation of a base; more preferably, the base is selected from triethylamine, N,N-diisopropylethylamine, 2,4,6-trimethylpyridine, DMAP, DBU, NMM, NaHCO 3 ; more preferably, the base is NaHCO 3;
  • the inert solvent is selected from dichloromethane, tetrahydrofuran, and 2-methyltetrahydrofuran; more preferably, the inert solvent is dichloromethane;
  • the reaction is carried out in the presence of a condensing agent; more preferably, the condensing agent is selected from the following group: HATU, HBTU, TBTU, EDCI, HOAt, HOBt, CDI, TCFH, TFFH, DCC, DIC, BOP, AOP, PyAOP, BrOP, PyClOP, PyBrOP, DMTMM, or a combination thereof; more preferably, the condensing agent is DCC.
  • the condensing agent is selected from the following group: HATU, HBTU, TBTU, EDCI, HOAt, HOBt, CDI, TCFH, TFFH, DCC, DIC, BOP, AOP, PyAOP, BrOP, PyClOP, PyBrOP, DMTMM, or a combination thereof; more preferably, the condensing agent is DCC.
  • the reaction is carried out in the presence or absence of a base; more preferably, the reaction does not require the participation of a base ;
  • the present invention also provides a method for preparing the compound described in Formula 15c:
  • the inert solvent is selected from the group consisting of acetonitrile, DMF, DMA, THF, and dichloromethane; more preferably, the inert solvent is acetonitrile;
  • the reaction is carried out in the presence of a base; more preferably, the base is selected from DBU, imidazole, DIPEA, TEA; more preferably, the base is DBU;
  • the silicon-based reagent is TBSCl or TBSOTf; more preferably, the silicon-based reagent is TBSCl;
  • the inert solvent is selected from the group consisting of water, THF, DMF, or a combination thereof; more preferably, the inert tetrahydrofuran and water are in a volume ratio of 1:1;
  • the base is selected from the group consisting of sodium bicarbonate, sodium carbonate, triethylamine, and diisopropylethylamine; more preferably, the base is sodium bicarbonate.
  • the present invention also provides a method for preparing the compound described in Formula 1d below:
  • the inert solvent is preferably selected from toluene, acetic acid, chlorobenzene, or a combination thereof; more preferably, the inert solvent is a combination of toluene and acetic acid; more preferably, the inert solvent is a combination of toluene and acetic acid in a volume ratio of 1:5 to 5:1; more preferably, the inert solvent is a combination of toluene and acetic acid in a volume ratio of 1:2 to 2:1; more preferably, the inert solvent is a combination of toluene and acetic acid in a volume ratio of 1:1;
  • the reaction can be carried out in the presence of an additive; more preferably, the additive can be selected from the group consisting of p-toluenesulfonic acid, p-toluenesulfonic acid monohydrate, and p-toluenesulfonic acid pyridinium salt; more preferably, the additive is p-toluenesulfonic acid pyridinium salt.
  • the additive can be selected from the group consisting of p-toluenesulfonic acid, p-toluenesulfonic acid monohydrate, and p-toluenesulfonic acid pyridinium salt; more preferably, the additive is p-toluenesulfonic acid pyridinium salt.
  • the organic base is selected from secondary amines and tertiary amines; more preferably, the organic base is selected from piperidine, dimethylamine, and diethylamine; more preferably, the organic base is piperidine;
  • the inert solvent is selected from tetrahydrofuran and 2-methyltetrahydrofuran; more preferably, the inert solvent is tetrahydrofuran.
  • the present invention also provides a method for preparing the compound described in Formula 14g,
  • the inert solvent is selected from no solvent, water, tetrahydrofuran, or a combination thereof; more preferably, the inert solvent is water; more preferably, the inert solvent is no solvent;
  • the reaction is carried out in the presence of an acid; more preferably, the acid is hydrochloric acid; more preferably, the concentration of the hydrochloric acid is 3-9N; more preferably, the concentration of the hydrochloric acid is 6N;
  • the base is selected from an organic base and an inorganic base; more preferably, the base is selected from triethylamine, diisopropylethylamine, DBU, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate; more preferably, the base is potassium carbonate;
  • the inert solvent is selected from acetonitrile, DMF, DMA, dichloromethane, water, tetrahydrofuran, or a combination thereof; more preferably, the inert solvent is a combination of water and tetrahydrofuran in a volume ratio of 1:5 to 5:1; more preferably, the inert solvent is a combination of water and tetrahydrofuran in a volume ratio of 3:4;
  • the present invention also provides a method for preparing the compound described in Formula 14b below:
  • the silicon-based reagent is TESCl, TESOTf, TIPSCl, TIPSOTf; more preferably, the silicon-based reagent is selected from TESCl and TIPSCl;
  • the inert solvent is selected from N,N-dimethylformamide, N,N-dimethylacetamide, HPMA, tetrahydrofuran, and dichloromethane; more preferably, the inert solvent is selected from N,N-dimethylformamide;
  • the base is preferably selected from TEA, DIPEA, NMM, pyridine, 2,6-lutidine, 2,4,6-trimethylpyridine, imidazole, and DMAP; more preferably, the base is imidazole.
  • the present invention also provides a method for preparing the compound described in Formula 14c:
  • the inert solvent is selected from tetrahydrofuran, dioxane, 2-methyltetrahydrofuran, and toluene; more preferably, the inert solvent is toluene;
  • the reaction can be carried out in the presence or absence of a base;
  • the base is preferably selected from triethylamine, DIPEA, NMM, pyridine, 2,6-lutidine, 2,4,6-trimethylpyridine, DMAP, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, potassium tert-butoxide, sodium tert-butoxide; more preferably, the base is selected from sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate; more preferably, the base is sodium carbonate.
  • the present invention also provides a method for preparing the compound described in Formula 14d below:
  • the compound of formula 14c is used to remove the TIPS and TES silicon-based protecting groups with a silicon-based removing agent to obtain the compound of formula 14d.
  • the silicon-based removal reagent is selected from the following group: acid, fluorination reagent (fluorine-containing reagent); more preferably, the silicon-based removal reagent is selected from formic acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, dichloroacetic acid, hydrogen fluoride, hydrogen fluoride aqueous solution, triethylamine trihydrofluoride, hydrogen fluoride pyridinium salt; more preferably, the silicon-based removal reagent is hydrogen fluoride aqueous solution.
  • fluorination reagent fluorine-containing reagent
  • the silicon-based removal reagent is selected from formic acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, dichloroacetic acid, hydrogen fluoride, hydrogen fluoride aqueous solution, triethylamine trihydr
  • the inert solvent is selected from tetrahydrofuran, 2-methyltetrahydrofuran, and toluene; more preferably, the inert solvent is tetrahydrofuran.
  • Another aspect of the present invention provides a method for preparing a molecule as shown in Formula 7:
  • a compound described in Formula 7i and a compound described in Formula 1d are subjected to a condensation reaction to generate a compound of Formula 7:
  • the inert solvent is selected from the group consisting of dichloromethane, tetrahydrofuran, N,N-dimethylformamide, N,N- Dimethylacetamide, HMPA, or a combination thereof; preferably N,N-dimethylformamide.
  • the condensing agent is selected from the group consisting of HATU, HBTU, TBTU, EDCI, HOAt, HOBt, CDI, TCFH, TFFH, DCC, DIC, BOP, AOP, PyAOP, BrOP, PyClOP, PyBrOP, DMTMM, or a combination thereof, preferably EDCI.
  • the base is selected from the following group: TEA, DIPEA, NMM, DBU, DMAP, pyridine, 2,6-dimethylpyridine, 2,4,6-trimethylpyridine, imidazole, N-methylimidazole, or a combination thereof, preferably 2,4,6-trimethylpyridine.
  • Another aspect of the present invention provides a method for preparing a molecule as shown in Formula 7i below:
  • the inert solvent is selected from the following group: acetonitrile, water, tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, or a combination thereof; more preferably tetrahydrofuran.
  • the reaction is carried out without or with the participation of a base; preferably, the base is selected from triethylamine, N,N-diisopropylethylamine, 2,6-lutidine, 2,4,6-trimethylpyridine, DBU, NMM; more preferably, the reaction does not require the participation of a base ;
  • the present invention also provides a method for preparing a molecule as shown in the following formula 14j:
  • the inert solvent is selected from the following group: acetonitrile, water, tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, ethyl acetate, or a combination thereof; more preferably ethyl acetate.
  • the reaction is carried out without or with the participation of a base; preferably, the base is selected from triethylamine, N,N-diisopropylethylamine, 2,6-lutidine, 2,4,6-trimethylpyridine, DBU, NMM; more preferably, the reaction does not require the participation of a base;
  • the inert solvent is selected from the group consisting of dichloromethane, tetrahydrofuran, dioxane, ethyl acetate, Toluene, or a combination thereof; more preferably toluene.
  • the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, hydrogen chloride ethyl acetate solution, hydrogen chloride tetrahydrofuran solution, hydrogen chloride dioxane solution, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, dichloroacetic acid; preferably, the acid is selected from trifluoroacetic acid;
  • the condensing agent is selected from the group consisting of HATU, HBTU, TBTU, EDCI, HOAt, HOBt, CDI, TCFH, TFFH, DCC, DIC, BOP, AOP, PyAOP, BrOP, PyClOP, PyBrOP, DMTMM, or a combination thereof, preferably EDCI.
  • the inert solvent is selected from the following group: dichloromethane, tetrahydrofuran, 2-methyltetrahydrofuran, toluene, or a combination thereof; more preferably dichloromethane.
  • Another aspect of the present invention provides a compound as shown in the following formula 14b:
  • Another aspect of the present invention provides a compound as shown in the following formula 14c:
  • Another aspect of the present invention provides a compound as shown in the following formula 14g:
  • Another aspect of the present invention provides a compound represented by the following formula 14i:
  • Another aspect of the present invention provides a compound as shown in the following formula 14j:
  • Another aspect of the present invention provides a compound as shown in the following formula 14k:
  • Another aspect of the present invention provides a compound as shown in the following formula 15c:
  • Another aspect of the present invention provides a compound as shown in the following formula 15d:
  • Another aspect of the present invention provides a compound represented by the following formula 15f:
  • Another aspect of the present invention provides a compound as shown in the following formula 15g:
  • Another aspect of the present invention provides a compound as shown in the following formula 7c:
  • Another aspect of the present invention provides a compound as shown in the following formula 7e:
  • Another aspect of the present invention provides a compound as shown in the following formula 7h:
  • Another aspect of the present invention provides a compound as shown in the following formula 8b:
  • Another aspect of the present invention provides a compound as shown in the following formula 8e:
  • Another aspect of the present invention provides a compound as shown in the following formula 8g:
  • Another aspect of the present invention provides a compound as shown in the following formula 9b:
  • Another aspect of the present invention provides a compound as shown in the following formula 9c:
  • Another aspect of the present invention provides a compound as shown in the following formula 9e:
  • Another aspect of the present invention provides a compound as shown in the following formula 9f:
  • Another aspect of the present invention provides a compound as shown in the following formula 9g:
  • Another aspect of the present invention provides a compound as shown in the following formula 9h:
  • Another aspect of the present invention provides a compound as shown in the following formula 9i:
  • the inventors Based on long-term and in-depth research, the inventors have prepared a class of ligand-coupled drugs with novel structures, drug molecules (toxins) suitable for ligand-coupled substances, linker precursors suitable for ligand-coupled substances, and ligand-coupled substance precursors suitable for ligand-coupled substances, and the drugs have better stability, good efficacy, and higher safety. Based on the above findings, the inventors have completed the present invention.
  • alkyl includes linear or branched alkyl groups.
  • C1 - C8 alkyl groups represent linear or branched alkyl groups having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like.
  • alkenyl includes straight or branched alkenyl groups.
  • C2 - C6 alkenyl refers to straight or branched alkenyl groups having 2 to 6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.
  • alkynyl includes straight or branched alkynyl groups.
  • C2 - C6 alkynyl refers to a straight or branched alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, butynyl, or the like.
  • C 3 -C 10 cycloalkyl refers to a cycloalkyl group having 3 to 10 carbon atoms. It may be a monocyclic ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or the like. It may also be a bicyclic ring, such as a bridged ring or a spiro ring.
  • C 1 -C 8 alkylamino refers to an amine group substituted by a C 1 -C 8 alkyl group, which may be monosubstituted or disubstituted; for example, methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di-tert-butylamino and the like.
  • C 1 -C 8 alkoxy refers to a straight or branched chain alkoxy group having 1 to 8 carbon atoms; for example, methoxy, Ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy and the like.
  • the term "3-10 membered heterocycloalkyl having 1-3 heteroatoms selected from the group consisting of N, S and O” refers to a saturated or partially saturated cyclic group having 3-10 atoms, wherein 1-3 atoms are heteroatoms selected from the group consisting of N, S and O. It may be a monocyclic or bicyclic form, such as a bridged ring or a spirocyclic form. Specific examples may include oxetane, azetidine, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl and pyrrolidinyl, etc.
  • C 6 -C 10 aryl group refers to an aryl group having 6 to 10 carbon atoms, for example, phenyl or naphthyl and the like.
  • the term "5-10 membered heteroaryl having 1-3 heteroatoms selected from the group consisting of N, S and O” refers to a cyclic aromatic group having 5-10 atoms, of which 1-3 atoms are heteroatoms selected from the group consisting of N, S and O. It may be a monocyclic ring or a condensed ring.
  • Specific examples may include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3)-triazolyl and (1,2,4)-triazolyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl and the like.
  • the chain groups herein (such as alkyl, haloalkyl or deuterated alkyl) have 1-10 carbon atoms, preferably 1-6 carbon atoms, or 1-4 carbon atoms;
  • the non-aromatic cyclic groups herein (such as cycloalkyl, heterocycloalkyl, alicyclic, alicyclic, etc.) are 3-12 members, preferably 3-8 members, 3-6 members;
  • the aromatic cyclic groups herein (such as aryl, heteroaryl, etc.) are 5-15 members, such as 6-10 membered aryl, 5-7 membered heteroaryl, 5-10 membered heteroaryl, etc.
  • the groups described in the present invention may be substituted by substituents selected from the following groups: halogen, nitrile, nitro, hydroxyl, amino, C 1 -C 6 alkyl-amine, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, halogenated C 1 -C 6 alkyl, halogenated C 2 -C 6 alkenyl, halogenated C 2 -C 6 alkynyl, halogenated C 1 -C 6 alkoxy, allyl, benzyl, C 6 -C 12 aryl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, C 1 -C 6 alkoxy-carbonyl, phenoxycarbonyl, C 2 -C 6 alkynyl-carbonyl, C 2 -C 6
  • halogen or halogen atom refers to F, Cl, Br, and I. More preferably, the halogen or halogen atom is selected from F, Cl and Br. "Halogenated” means substituted with an atom selected from F, Cl, Br, and I.
  • tautomer means that structural isomers with different energies can interconvert across a low energy barrier.
  • proton tautomers i.e., prototropic
  • Valence tautomers include interconversion via reorganization of some bonding electrons.
  • hydrate refers to a complex formed by coordination of a compound of the present invention with water.
  • the compounds of the present application can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining specific embodiments with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.
  • the solvents used in this application can be obtained from commercial sources, and the compounds can be artificially or The software names were used, and commercially available compounds were named using the supplier's catalog names.
  • the term "ligand” generally refers to a macromolecular compound that can recognize and bind to an antigen or receptor associated with a target cell.
  • the function of the ligand may be to present the drug to a target cell population bound to the ligand, and these ligands include but are not limited to protein hormones, lectins, growth factors, antibodies or other molecules that can bind to cells, receptors and/or antigens.
  • the ligand may be represented by Ab, and the ligand antigen forms a connection bond with the connecting unit through the heteroatom on the ligand, and may be an antibody or an antigen-binding fragment thereof, and the antibody may be selected from a chimeric antibody, a humanized antibody, a fully human antibody or a mouse antibody; the antibody may be a monoclonal antibody.
  • the antibody may be an antibody or an antigen-binding fragment thereof that targets a target selected from the following groups: HER2, TROP2, PSMA, FR- ⁇ or B7H3 and IGF-1R.
  • Trop2 generally refer to a single-pass transmembrane type I cell membrane protein.
  • the term “Trop2” may also cover homologs, variants and isoforms of Trop 2, including spliced isoforms.
  • the term “Trop” also includes proteins having one or more sequences of Trop 2 homologs, variants and isoforms, as well as fragments of the sequence, as long as it is the variant protein (including isoforms).
  • Trop2 can be human Trop2. For example, Uniprot accession number P09758 provides a description of Trop2 and sequences.
  • HER2 generally refers to human epidermal growth factor receptor 2 (HER2).
  • HER2 refers to any natural HER2 from any human source.
  • the term also encompasses "full-length” and unprocessed HER2 and any form of HER2 (e.g., mature protein) derived from processing in a cell.
  • the term also encompasses naturally occurring variants and isoforms of HER2, such as splice variants or allelic variants.
  • Uniprot accession number P04626 provides a description of HER2 and sequences.
  • PSMA refers to glutamate carboxypeptidase II.
  • PSMA may also cover homologs, variants and isoforms of PSMA.
  • PSMA also includes PSMA homologs, variants and isoforms of various different origins (such as human origin), Variants and isoforms of proteins of one or more sequences, as well as fragments of the sequences.
  • Uniprot Accession No. Q04609 provides a description of PSMA and sequences.
  • FR- ⁇ refers to folate receptor ⁇ , encoded by FOLR1.
  • FR- ⁇ may also encompass homologues, variants and isoforms of FR- ⁇ .
  • FR- ⁇ also includes proteins having one or more sequences in FR- ⁇ homologues, variants and isoforms from various different sources (such as human), as well as fragments of the sequence.
  • Uniprot accession number P15328 provides a description of FR- ⁇ and sequences.
  • B7H3 refers to CD276.
  • the term “B7H3” may cover any homologs, variants and isoforms thereof, and may also include any possible expression forms thereof in humans (such as 2Ig and 4Ig).
  • the term “B7H3” also includes proteins having one or more sequences in B7H3 homologs, variants and isoforms from various different sources (such as human origin), as well as fragments of the sequence. For example, Uniprot accession number Q5ZPR3 provides a description of B7H3 (CD276) and sequences.
  • IGF-1R refers to insulin-like growth factor I receptor.
  • IGF-1R may also encompass homologues, variants and isoforms thereof.
  • IGF-1R also includes proteins having one or more sequences in homologues, variants and isoforms of IGF-1R from various different sources (such as human), as well as fragments of the sequence.
  • Uniprot accession number P08069 provides a description of IGF-1R and sequences.
  • peptide residue generally refers to a residue comprising one or more amino acid residues connected.
  • one or more amino acids in a polypeptide residue may be optionally substituted.
  • a polypeptide residue of the present application may comprise glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).
  • drug unit generally refers to a chemical moiety that is directly or indirectly conjugated to an antibody or antigen-binding fragment to form an immunoconjugate.
  • a drug unit includes, but is not limited to, a compound with anti-tumor activity described herein.
  • a drug unit includes a topoisomerase inhibitor.
  • the term "compound with anti-tumor activity” generally refers to a compound that has the ability to reduce the proliferation rate, viability or metastatic activity of tumor cells.
  • the anti-tumor activity can be shown by a reduction in the growth rate of abnormal cells that occur during treatment or a stabilization or reduction in tumor size, or a longer survival period due to treatment compared to a control without treatment.
  • the anti-tumor activity can be evaluated using recognized in vitro or in vivo tumor models, such as xenograft models.
  • the term "about” generally refers to a variation within a range of 0.5%-10% above or below a specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.
  • the compounds of the present application include tautomers, mesomers, racemates, enantiomers, and/or diastereomers of the compounds.
  • some atoms of the compounds of the present application may appear in more than one isotopic form.
  • hydrogen may exist in the form of protium ( 1H ), deuterium ( 2H ) and tritium ( 3H ), and carbon may exist naturally in three different isotopes ( 12C , 13C and 14C ).
  • Isotope examples that can be incorporated into the compounds of the present application also include but are not limited to15N , 18O , 17O , 18F , 32P , 33P , 129I , 131I , 123I, 124I , 125I , or similar isotopes.
  • the compounds of the present application can be in the form of one or more of these isotopically enriched.
  • isotopically enriched compounds can be used for a variety of purposes. For example, substitution with heavy isotopes such as deuterium ( 2H ) may provide certain therapeutic advantages, which may be due to higher metabolic stability.
  • the term "pharmaceutical composition” generally refers to a mixture containing one or more compounds described herein or their physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically/pharmaceutically acceptable carriers and excipients.
  • the pharmaceutical composition can promote administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
  • the preparation of conventional pharmaceutical compositions can be found in the common techniques in the art.
  • the term "pharmaceutically acceptable salt” or “pharmaceutically usable salt” generally refers to a salt of the compound or ligand-drug conjugate of the present application, or a salt of the compound described in the present application. Such salts may be safe and/or effective when used in mammals, and may have the desired biological activity.
  • the antibody-antibody drug conjugate compound of the present application may form a salt with an acid.
  • Non-limiting examples of pharmaceutically acceptable salts include: hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, sorbate, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, or p-toluenesulfonate.
  • conjugate generally refers to a compound prepared by one or more chemical reactions of the compounds of the present application, or connected to each other through one or more connecting structures such as a bridge, a spacer, or a connecting part.
  • the term "pharmaceutically acceptable carrier” generally refers to a carrier for administering therapeutic agents, such as antibodies or polypeptides, genes and other therapeutic agents.
  • the term refers to any drug carrier that does not itself induce the production of antibodies that are harmful to the individual receiving the composition and can be administered without excessive toxicity.
  • a pharmaceutically acceptable carrier can be distinguished from a nucleic acid vector used to contain a target gene in genetic engineering. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, lipid aggregates and inactivated viral particles. Those skilled in the art are familiar with these carriers.
  • Pharmaceutically acceptable carriers in therapeutic compositions may include liquids, such as water, saline, glycerol and ethanol.
  • Auxiliary substances, such as wetting agents or emulsifiers, pH buffer substances, etc., may also be present in these carriers.
  • antibody can generally cover monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies) and antibody fragments, as long as they exhibit the desired biological activity.
  • Antibodies can be mouse, human, humanized, chimeric antibodies or derived from other species.
  • Antibodies are proteins produced by the immune system that can recognize and bind to specific antigens.
  • Target antigens generally have a large number of binding sites, also known as epitopes, recognized by the CDRs of multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Therefore, an antigen can have more than one corresponding antibody.
  • Antibodies include full-length immunoglobulin molecules or immunologically active portions of full-length immunoglobulin molecules, i.e., molecules containing antigens or portions thereof that specifically bind to a target of interest, such targets including, but not limited to, cancer cells or cells that produce autoimmune antibodies associated with autoimmune diseases.
  • the immunoglobulins described in the present application may have any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2, or any mutation thereof), or subclass of immunoglobulin molecules. Immunoglobulins may be derived from any species.
  • the immunoglobulins are derived from humans, mice, or rabbits.
  • Antibody fragments may comprise a portion of a full-length antibody, generally its antigen binding region or variable region.
  • Examples of antibody fragments include: Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; minibodies; fragments prepared from Fab expression libraries; anti-idiotype (anti-Id) antibodies; CDRs (complementarity determining regions); and any of the above epitope-binding fragments that bind to cancer cell antigens, viral antigens, or microbial antigens in an immunospecific manner; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • the antibodies constituting the antibody-drug conjugates in the present application may retain their original antigen binding ability in the wild state. Therefore, the antibodies in the present application can, for example, specifically bind to antigens.
  • the antigens involved include, for example, tumor-associated antigens (TAA), cell surface receptor proteins and other cell surface molecules, cell survival regulators, cell proliferation regulators, molecules related to tissue growth and differentiation (such as known or predicted functional), lymphokines, cytokines, molecules involved in cell cycle regulation, molecules involved in angiogenesis, and molecules related to angiogenesis (such as known antibodies).
  • TAA tumor-associated antigens
  • the antigens bound by antibodies can be one or a subset of the above categories, while other subsets contain other molecules/antigens with special properties (compared with the target antigen).
  • the antibodies used in antibody drug conjugates include, but are not limited to, antibodies against cell surface receptors and tumor-associated antigens.
  • tumor-associated antigens are well known in the industry and can be prepared by antibody preparation methods and information well known in the industry.
  • targets can be specifically expressed on the surface of one or more cancer cells, and rarely or not expressed on the surface of one or more non-cancerous cells.
  • tumor-associated polypeptides can be more overexpressed on the surface of cancer cells relative to the surface of non-cancerous cells.
  • chimeric antibody generally refers to an antibody formed by fusing the variable region of a mouse antibody with the constant region of a human antibody, which can reduce the immune response induced by the mouse antibody.
  • a hybridoma that secretes mouse-specific monoclonal antibodies can be established, and then the variable region gene can be cloned from the mouse hybridoma cells.
  • the constant region gene of the human antibody can be cloned as needed, and the mouse variable region gene and the human constant region gene can be connected into a chimeric gene and inserted into an expression vector.
  • the chimeric antibody molecule can be expressed in a eukaryotic system or a prokaryotic system.
  • humanized antibody also known as CDR-grafted antibody
  • CDR-grafted antibody generally refers to an antibody produced by transplanting mouse CDR sequences into the human antibody variable region framework, that is, different types of human germline antibody framework sequences.
  • the heterologous response induced by chimeric antibodies due to carrying a large amount of mouse protein components can be overcome.
  • framework sequences can be obtained from public DNA databases including germline antibody gene sequences or published references.
  • germline DNA sequences of human heavy chain and light chain variable region genes can be found in the "VBase" human germline sequence database.
  • monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully human monoclonal antibodies.
  • the antibody or ligand described in this application can be a fully human monoclonal antibody.
  • the relevant technologies for the preparation of fully human antibodies can be: human hybridoma technology, EBV transformed B lymphocyte technology, phage display technology (phage display), transgenic mouse antibody preparation technology (transgenic mouse) and single B cell antibody preparation technology, etc.
  • CDR generally refers to one of 6 hypervariable regions that mainly contribute to antigen binding in the variable domains of antibody.
  • 6 CDRs One of the most commonly used definitions of the 6 CDRs is provided by Kabat EA et al., or Chothia et al. and MacCallum et al.
  • the Kabat definition of CDR can be applied to CDR1, CDR2 and CDR3 (LCDR1, LCDR 2, LCDR 3 or L1, L2, L3) of light chain variable domains, and CDR1, CDR2 and CDR3 (HCDR 1, HCDR 2, HCDR 3 or H1, H2, H3) of heavy chain variable domains.
  • group capable of coupling with a thiol group generally means that the compound A has a thiol group, and the compound B has a group capable of coupling with a thiol group, and compound B reacts with the thiol group of compound A through the group capable of coupling with a thiol group, thereby achieving the connection between compound A and compound B.
  • linker generally refers to a chemical structure fragment or bond that is connected to one group at one end and to another group at the other end, and may also be connected to other linkers before being connected to the drug and/or ligand.
  • the directly or indirectly connected ligand may refer to the group being directly connected to the ligand through a covalent bond, or may be connected to the ligand through a linker.
  • the linker may be the structure shown in the linker described in the present application.
  • a chemical structure fragment or bond containing an acid-labile linker structure e.g., hydrazone
  • a protease-sensitive linker structure e.g., peptidase-sensitive linker structure
  • a photolabile linker structure e.g., a dimethyl linker structure
  • a disulfide-containing linker structure e.g., a linker that bonds to an acid-labile linker structure
  • an acid-labile linker structure e.g., hydrazone
  • protease-sensitive linker structure e.g., peptidase-sensitive linker structure
  • a photolabile linker structure e.g., a dimethyl linker structure
  • a disulfide-containing linker structure e.g., a disulfide-containing linker structure
  • linking group generally refers to a group that has the ability to connect to another group.
  • a compound having a linking group can achieve connection with another group through a coupling reaction between the linking group and another group.
  • a maleimide group can be used as a linking group.
  • the term "disease associated with expression" of a target generally means that the occurrence and/or progression of the disease is associated with the expression level of the target.
  • the expression level of a certain target in cells from a disease area such as a specific tissue or organ of a patient is increased, i.e., highly expressed.
  • the expression level of a certain target in cells from a disease area such as a specific tissue or organ of a patient is reduced, i.e., lowly expressed.
  • cells from a disease area such as a specific tissue or organ of a patient express a certain target, i.e., positive.
  • cells from a disease area such as a specific tissue or organ of a patient do not express a certain target, i.e., negative.
  • the characteristics of target expression can be determined by standard assays known in the art.
  • the term "effective amount” generally refers to the amount of a therapeutic agent that treats, alleviates or prevents a target disease or condition, or an amount that exhibits a detectable therapeutic or preventive effect.
  • the precise effective amount for a subject depends on the subject's size and health, the nature and extent of the condition, and the therapeutic agent and/or combination of therapeutic agents selected for administration. Therefore, it is useless to specify an exact effective amount in advance. However, for a given condition, the effective amount can be determined by routine experiments, which a clinician is able to determine.
  • each chiral carbon atom can optionally be in R configuration or S configuration, or a mixture of R configuration and S configuration.
  • the term "compound of the present application” generally refers to the compound of the present application.
  • the term also includes various crystal forms, pharmaceutically acceptable salts, hydrates or solvates of the compound of the present application.
  • the trade name is intended to include the trade name product formulation, its corresponding generic drug, as well as the active pharmaceutical ingredient of the trade name product.
  • compositions and methods of administration are provided.
  • the compounds of the present invention have excellent tumor cell proliferation inhibitory activity
  • the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to prevent and/or treat (stabilize, alleviate or cure) diseases related to tumor cell proliferation.
  • the pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention and a pharmaceutically acceptable excipient or carrier.
  • safe and effective amount means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.
  • the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 1-200 mg of the compound of the present invention per dose.
  • the "one dose” is a capsule or tablet, or a unit dose of an injection preparation.
  • “Pharmaceutically acceptable carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility” here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds.
  • Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • cellulose and its derivatives such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
  • gelatin such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.
  • compositions of the present invention include (but are not limited to): oral administration, parenteral administration (intravenous administration, intramuscular administration or subcutaneous administration).
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as hydroxymethylcellulose, algae (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) dispersing agents, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example,
  • Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions may be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
  • an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottons
  • composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.
  • suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.
  • compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
  • the compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable therapeutic agents.
  • the pharmaceutical composition may also include one or more (2, 3, 4, or more) other pharmaceutically acceptable therapeutic agents.
  • One or more (2, 3, 4, or more) of the other pharmaceutically acceptable therapeutic agents may be used simultaneously, separately, or sequentially with the compound of the present invention to prevent and/or treat diseases associated with tumor cell proliferation.
  • a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 2000 mg, preferably 1 to 500 mg.
  • the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill of a skilled physician.
  • the present invention also provides a novel preparation process of a synthetic intermediate 14d (compound 1k in WO 2022262789 A1) of the toxin molecule 1d, and its specific preparation process is as described above.
  • the synthetic route disclosed in the prior art (WO 2022262789 A1) is as follows:
  • the preparation process of the present invention uses TIPS silicon-based protecting group to replace one of the two TES silicon-based protecting groups in the prior art, and the main advantages are:
  • the intermediates 14b and 14c of the synthetic route of the present application are more stable than the intermediates 1i and 1j of the above-mentioned prior art, and are easy to scale up production and store for a long time;
  • the intermediates 14b and 14c of the synthetic route of the present application can be separated and purified, and are easy to control in quality.
  • the intermediates 1i and 1j of the above prior art are used as crude products in the next step of the reaction.
  • the present invention also provides a new preparation process for toxin molecule 1d (compound 1n-P1 in WO 2022262789 A1), which is based on the existing The synthesis route in the technology (WO 2022262789 A1) is as follows:
  • the preparation process of the present invention uses Fmoc protecting group to replace the acetyl Ac protecting group in the prior art, and the main advantages are:
  • the step of deacetylation of the protecting group of compound 1m has harsh reaction conditions, poor repeatability, and incomplete removal of the protecting group during scale-up.
  • the step of removing the Fmoc protecting group of method 14k of the present application has milder reaction conditions and is more suitable for scale-up production.
  • N-hydroxysuccinimide (6.49 g, 56.37 mmol) was dissolved in N,N-dimethylformamide (36.5 mL), trifluoroacetic anhydride (11.84 g, 56.37 mmol) was added dropwise under ice bath, 2,4,6-trimethylpyridine (6.83 g, 56.37 mmol) was added dropwise after stirring for 30 min, and the mixture was stirred for 40 min after the addition was complete. The reaction solution was recorded as A and was set aside.
  • the aqueous phase was adjusted to pH 8-9 with ammonia water and extracted with ethyl acetate (100 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 3e (1.43 g), with a yield of 86%.
  • 7a (10.60 g, 30.00 mmol) was dissolved in a mixed solvent of tetrahydrofuran/toluene (200 mL/50 mL), and lead tetraacetate (17.30 g, 39.00 mmol) and pyridine (3.08 g, 39.00 mmol) were added.
  • the mixture was heated to 75 °C and stirred for 4 h.
  • the reaction solution was filtered to remove insoluble matter, and the filtrate was concentrated under reduced pressure to remove most of the solvent.
  • reaction solution was diluted with ethyl acetate (200 mL), and the organic phase was washed with water (50 mL x 2), saturated sodium bicarbonate aqueous solution (50 mL), and saturated brine (100 mL x 2) in turn, dried over anhydrous sodium sulfate, and filtered.
  • the aqueous phase was washed with dichloromethane (50 mL x 3) and then freeze-dried.
  • the reaction solution was quenched with water (50 mL), the aqueous phase was extracted with ethyl acetate (500 mL), and the organic phase was washed with saturated sodium bicarbonate aqueous solution (100 mL x 1), water (100 mL) and saturated brine (50 mL x 4) in turn, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product 8b (4.70 g).
  • the reaction solution was diluted with ethyl acetate (200 mL), and the organic phase was washed with water (50 mL x 1), saturated sodium bicarbonate aqueous solution (50 mL x 1), and saturated brine (50 mL x 2) in turn, dried over anhydrous sodium sulfate, and filtered.
  • reaction solution was diluted with dichloromethane (100 mL), and the organic phase was washed with dilute hydrochloric acid (2N, 50 mL x 1), water (50 mL x 1) and saturated brine (50 mL x 2) in sequence, dried, filtered, and the filtrate was concentrated under reduced pressure to obtain a white solid crude product 9b (6.80 g).
  • the reaction solution was diluted with ethyl acetate (200 mL), and the organic phase was washed with water (50 mL x 1), saturated sodium bicarbonate aqueous solution (50 mL x 1), and saturated brine (50 mL x 2) in sequence, dried over anhydrous sodium sulfate, and filtered.
  • reaction solution was diluted with water (100 mL), the aqueous phase was washed with dichloromethane (100 mL x 3), and the aqueous phase was lyophilized.
  • aqueous phase was extracted with ethyl acetate (100 mL x 2), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue.
  • aqueous phase was extracted with ethyl acetate (100 mL x 2), and the organic phases were combined. The organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain a residue, and methyl tert-butyl ether (10 mL) was added for pulping and purification to obtain compound 11c (2.00 g), with a yield of 47%.
  • 11d (500 mg, 0.50 mmol) was dissolved in 1,4-dioxane (5 mL), piperidine (5 mL) was added, and the mixture was stirred at room temperature for 2 hours. Petroleum ether (5 mL) was added dropwise to the reaction solution, and a large amount of solid precipitated. The solid was filtered, and the filter cake was collected and dried to obtain 11e (386 mg) with a yield of 94%.
  • aqueous phase was extracted with ethyl acetate (10 mL x 2), and the organic phases were combined.
  • the organic phases were dried over anhydrous sodium sulfate and filtered.
  • the filtrate was concentrated under reduced pressure to obtain a residue, which was purified by preparative HPLC to obtain compound 11 (38 mg) with a yield of 21%.
  • imidazole (161.60 g, 2373.68 mmol) was dissolved in anhydrous N, N-dimethylformamide (1.25 L), the mixed system was cooled to 0 ⁇ 5°C, triisopropylsilyl chloride (458.20 g, 2376.56 mmol) was added dropwise, the mixed system was kept at 0 ⁇ 5°C for stirring and reacting for 30 minutes, 14a (250.00 g, 949.67 mmol) in N, N-dimethylformamide (1250 mL) was added dropwise to the reaction system, after the addition was complete, the mixed system was kept at 0 ⁇ 5°C for stirring and reacting for 18 hours.
  • 14b (450.0 g, content: 93.5%, 788.13 mmol) was dissolved in toluene (4.5 L), sodium carbonate (25.10 g, 236.81 mmol) and Lawesson's reagent (382.50 g, 945.68 mmol) were added, and the mixture was heated to 110° C. and stirred for 3 hours.
  • the reaction system was cooled to 50-60° C., n-heptane (4500 mL) was added dropwise to the reaction system, and the mixture was filtered after stirring for 1 hour.
  • the crude product 14c (517.0 g) of the previous step was dissolved in anhydrous tetrahydrofuran (4.5 L), and hydrofluoric acid (295.50 g, 48 wt.%, 7092.00 mmol) was added at room temperature. After the addition was complete, the reaction was stirred at room temperature for 36 hours. The reaction solution was diluted with water (4500 mL), the aqueous phase was extracted with ethyl acetate (4500 mL x 2), and the organic phase was combined. The organic phase was washed with saturated brine (2250 mL x 2), the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain a residue.
  • hydrofluoric acid 295.50 g, 48 wt.%, 7092.00 mmol
  • the filter cake was slurried with ethanol (8L) at room temperature for 1 hour, filtered, and the filter cake was rinsed with ethanol (1000mL x 1). The filter cake was collected and dried at 50 ⁇ 5°C to obtain 14f (709.00g), with a yield of 91%.
  • Tetrahydrofuran (10200 mL), water (10200 mL) and 14f (680.00 g, 2779.03 mmol) were added to a reaction kettle (50 L). After the mixture was cooled to 0-10 °C, potassium carbonate (653.00 g, 4724.69 mmol) was added, and then a solution of 9-fluorenylmethyl chloroformate (733.31 g, 2834.60 mmol) in tetrahydrofuran (3400 mL) was slowly added dropwise (the temperature of the reaction solution was controlled at 0-10 °C during the addition process). The mixture was kept at 0-10 °C and stirred for 1 hour.
  • the reaction solution was extracted with 2-methyltetrahydrofuran (10200 mL x 2), and the organic phase was washed with water (10200 mL x 1) and saturated brine (10000 mL x 1) in turn.
  • the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain a residue.
  • Add methyl tert-butyl ether (6800 mL) to the residue stir at room temperature for 4 hours, filter, rinse the filter cake with methyl tert-butyl ether (680 mL x 1), collect the filter cake, and air dry the filter cake at 50 ⁇ 5°C to obtain 14 g (1090.00 g), yield: 91%.
  • the crude product was dissolved in methanol (30 mL), and ethyl acetate (450 mL) was added dropwise to the methanol solution. The mixture was stirred at room temperature for 24 hours, filtered, and the filter cake was dried to obtain compound 7i (10.20 g), with a yield of 81%.
  • toluene (3200 mL), acetic acid (3200 mL), 14d (320.00 g, 1145.68 mmol), 14g (592.00 g, 1375.21 mmol) and p-toluenesulfonic acid pyridinium salt (144.00 g, 573.02 mmol) were added to a reaction bottle (10 L) in sequence, and the mixed system was heated to 110 ° C and stirred for 24 hours.
  • the reaction solution was cooled to 30 ⁇ 10 ° C, transferred to an extraction kettle (80 L), 2-methyltetrahydrofuran (6400 mL) and water (6400 mL) were added in sequence, stirred for 10-20 minutes, separated, and the upper organic phase was retained.
  • the organic phase was washed with water (4800 mL x 3) and saturated aqueous sodium chloride solution (4800 mL x 1) in sequence, dried over anhydrous sodium sulfate and filtered, the filtrate was concentrated under reduced pressure (50 ⁇ 5°C) until almost no liquid dripped out, the residue was steamed twice with methyl tert-butyl ether (640 mL ⁇ 2), methyl tert-butyl ether (3200 mL) was added to the obtained crude product 1 and slurried for 2 to 2.5 hours, filtered, the filter cake was rinsed twice with tert-butyl ether (640 mL ⁇ 2), the filter cake was collected and dried to obtain the crude product 2.
  • the crude product 2 was dissolved in N,N-dimethylformamide (6400 mL), and methyl tert-butyl ether (25600 mL) was added dropwise. After the addition was completed, the mixture was stirred and crystallized at 20-30°C for 16-18 hours, filtered, and the filter cake was slurried with methyl tert-butyl ether (3200 mL) for 2-2.5 hours and filtered. The filter cake was rinsed twice with methyl tert-butyl ether (640 mL ⁇ 2), and the filter cake was collected and dried by air (50 ⁇ 5°C) to obtain 14k (490 g). The yield was 63%.
  • N,N-dimethylformamide (1200 mL) was added to the reaction flask, 1d (60.00 g, 132.89 mmol) and trifluoroacetic acid (15.20 g, 133.31 mmol) were added to the reaction flask, the mixed system was cooled to 0-10 ° C, stirred for ten minutes, and then 7i (115.10 g, 186.07 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (51.00 g, 266.04 mmol) and 2,4,6-trimethylpyridine (16.10 g, 132.86 mmol) were added, and the reaction system was stirred at 0-10 ° C for 1 hour.
  • the crude product was slurried with methyl tert-butyl ether (600 mL) for 1 to 1.5 hours, filtered, the filter cake was rinsed with methyl tert-butyl ether (300 mL x 2), and the filter cake was collected and dried on a rotary evaporator for 5 ⁇ 1 hours to obtain compound 7 (90.0 g), with a yield of 64%.
  • 15a (438.00 g, 904.0 mmol) was dissolved in ethylene glycol dimethyl ether (4380 mL), water (2630 mL) was added, the temperature of the reaction system was reduced to 0-5 ° C, diglycine (238.87 g, 1808.0 mmol) and sodium bicarbonate (151.87 g, 1808.0 mmol) were added in sequence, and after the addition was complete, the temperature of the reaction system was raised to 20-25 ° C and stirred for 1 hour.
  • the reaction solution was reduced to -5-0 ° C, dilute hydrochloric acid (0.5 M, 4380 mL) was added, stirred for 10 minutes, and the aqueous phase was extracted with 2-methyltetrahydrofuran (8760 mL x 1) and 2-methyltetrahydrofuran (4380 mL x 1) in sequence, and the above organic phases were combined.
  • the organic phase was washed with saturated brine (4380 mL x 1), dried over anhydrous sodium sulfate and filtered.
  • the filtrate was spin-dried to obtain a crude product.
  • the crude product was slurried with acetone (8760 mL) for 16 hours and then filtered.
  • the filter cake was dried to obtain 8a (375.00 g), with a yield of 83%.
  • the reaction solution was added to 2-methyltetrahydrofuran (7500 mL) and water (7500 mL), separated, the aqueous phase was extracted with 2-methyltetrahydrofuran (3750 mL x 1), the above organic phases were combined, the organic phases were washed with saturated sodium bicarbonate aqueous solution (3750 mL x 1), water (3750 mL x 1) and saturated brine (3750 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product, which was slurried with methyl tert-butyl ether (3750 mL) After 16 hours, the mixture was filtered and the filter cake was dried by air for 16 hours to obtain 8b (345.00 g). The yield was 89%.
  • the aqueous phase was extracted with ethyl acetate (3450 mL x 1), and the above organic phases were combined.
  • the organic phases were washed with water (3450 mL x 1) and brine (3450 mL x 1) in sequence, dried over anhydrous sodium sulfate, and then filtered.
  • 15b (43.00 g, 107.65 mmol) was dissolved in a mixed solvent of tetrahydrofuran (430 mL) and water (430 mL), the reaction system was cooled to 0-10 ° C, wet Pd/C (6.50 g) was added, hydrogen was replaced three times, and the reaction was stirred at 0-10 ° C for 24 hours under a hydrogen atmosphere. The reaction solution was filtered, and the filter cake was washed with tetrahydrofuran (43 mL) and water (43 mL) in turn.
  • reaction solution was cooled to 0-5 ° C, 5% citric acid aqueous solution was added dropwise to adjust the pH to 5-6, ethyl acetate (3.75 L) was added, and the liquid was separated by stirring.
  • the aqueous phase was filtered through ethyl acetate (1.50
  • the reaction solution was filtered, the filter cake was washed with dichloromethane (1050 mL), the filtrate was spin-dried to obtain a residue, methyl tert-butyl ether (2100 mL) was added to the residue, the mixture was stirred for 10 minutes and then filtered, the filter cake was rinsed with methyl tert-butyl ether (630 mL), the filtrate was concentrated to obtain a residue, n-hexane (2100 mL) was added to the residue and the mixture was slurried for 30 minutes and then filtered, the filter cake was washed with n-hexane (630 mL), filtered, and dried to obtain 15d (246.78 g), with a yield of 79%.
  • the reaction solution was washed with methyl tert-butyl ether (2450 mL x 2), 2-methyltetrahydrofuran (7350 mL) was added to the aqueous phase, and a pre-cooled citric acid aqueous solution (3920 mL, 2.5%) was added to adjust the pH to 5-6 (the temperature was controlled at about 0°C during the dropwise addition), the liquids were separated, the aqueous phase was extracted with 2-methyltetrahydrofuran (2450 mL x 1), the organic phases were combined, and the organic phases were washed with water (7350 mL x 4) and a saturated sodium chloride aqueous solution (3680 mL x 1) in sequence.
  • reaction solution was quenched with water (2300 mL), and the reaction solution was filtered to remove insoluble matter.
  • the filtrate was stirred and separated, and the aqueous phase was extracted with dichloromethane (1150 mL).
  • the organic phases were combined, washed with saturated brine (1730 mL x 1), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain a residue.
  • the residue was slurried with ethyl acetate (1150 mL) for 30 minutes and then filtered.
  • Methyl tert-butyl ether (830 mL) was added to the reaction solution, the liquid was separated, the organic phase was extracted with water (420 mL x 2), the aqueous phase was combined, and the aqueous phase was freeze-dried to obtain a crude product, dichloromethane (1660 mL) was added to the crude product, and it was concentrated under reduced pressure. This operation was repeated 5 times (to remove residual formic acid), and then water (830 mL) was added to dissolve it, and the aqueous solution was freeze-dried again to obtain 15h (65.30 g), with a yield of 94%.
  • reaction system was stirred at -10 to -5 ° C for 4 hours.
  • the antibody was prepared using the anti-IGF-1R antibody sequence, which has the following CDR regions (Kabat definition):
  • CDR2 AISGSGSRARYADSVKG (SEQ ID No. 2)
  • CDR3 NPRRATPDLTQYAY (SEQ ID No. 3)
  • the antibody was dialyzed into 50mM PB buffer to obtain an antibody intermediate.
  • TCEP tris(2-carboxyethyl)phosphine hydrochloride
  • DTPA diethylenetriaminepentaacetic acid
  • 50mM PB buffer to make the final concentration of the reaction system antibody 20mg/mL, the molar ratio of TCEP to antibody 4, and the final concentration of DTPA 1mM.
  • the reduction reaction temperature is 25 ⁇ 2°C
  • the speed 400rpm
  • the reduction reaction is 2 hours.
  • High performance size exclusion liquid chromatography SEC-HPLC
  • high performance liquid hydrophobic chromatography HEC-HPLC
  • DAR drug-to-antibody ratio
  • Tables 1 and 2 The purity and drug-to-antibody ratio of the prepared ADC are shown in Table 3.
  • the test results show that the prepared ADCs have high purity and the drug-to-antibody ratio is uniformly distributed.
  • the linker-payload of the present application is obtained by referring to the method of Example 1 of the present application, and the antibody-drug conjugate (ADC) of the present application is obtained by referring to the method of Example 2 of the present application.
  • ADC antibody-drug conjugate
  • ADC stock solution to be tested was added to 8 mL of anticoagulated human plasma to make the ADC concentration in the plasma 200 ⁇ g/mL.
  • the sample was collected after incubation at 37°C for 0 h, 24 h, 72 h or 168 h in a biochemical incubator and purified by protein A chromatography.
  • the purified ADC sample was concentrated by ultrafiltration centrifugation. After centrifugation, 5 ⁇ L of 5M tris(2-carboxyethyl)phosphine hydrochloride (TCEP) mother solution and an appropriate amount of ultrapure water were added to a total sample volume of about 200 ⁇ L.
  • TCEP tris(2-carboxyethyl)phosphine hydrochloride
  • the sample was ultrafiltration centrifuged again (12000 rpm, 15 min). After centrifugation, 100 ⁇ L of ultrapure water was added and mixed, and then RP-MS analysis was performed.
  • the mass spectrometer was set to positive mode, the mobile phase was A: 0.1% formic acid water, B: 0.1% formic acid acetonitrile, the column temperature was 40°C, and the flow rate was 0.4 mL/min.
  • the average coupling rate value calculation formula is:
  • the linker-payload of the present application is obtained by referring to the method of Example 1 of the present application, and the ADC of the present application is obtained by referring to the method of Example 2 of the present application.
  • Human tumor cells in the logarithmic growth phase were collected, digested, resuspended in fresh complete culture medium and adjusted to an appropriate concentration, added to a 96-well cell culture plate, and the cell culture plate was placed in a 37°C, 5% CO 2 incubator for overnight culture. The next day, different concentrations of the ADC samples to be tested (the highest final concentration was 1 ⁇ M, 1:4 or 1:8 gradient dilution) or buffer control were added to the corresponding wells of the cell culture plate, and the plates were continued to be placed in a carbon dioxide incubator for 168 hours.
  • Inhibition rate (%) (1–(RLU ADC –RLU blank )/(RLU buffer –RLU blank )) ⁇ 100%.
  • the drug efficacy inhibition rate curve was drawn using Graphpad Prism software and the EC 50 value was fitted. The EC 50 values of each ADC in different human tumor cells are shown in Table 5.
  • the ADC prepared in the present application exhibits excellent tumor cell proliferation inhibition activity in vitro.
  • the linker-payload of the present application is obtained by referring to the method of Example 1 of the present application, and the ADC of the present application is obtained by referring to the method of Example 2 of the present application.
  • TV tT represents the tumor volume of the drug administration group on the day of measurement
  • TV 0T represents the tumor volume of the drug administration group at the time of grouping
  • TV tC represents the tumor volume of the solvent control group on the day of measurement
  • TV 0C represents the tumor volume of the solvent control group at the time of grouping.
  • the ADC prepared in the present application exhibits excellent in vivo anti-tumor activity.
  • a healthy adult Sprague Dawley rat of 6-8 weeks old was selected and ADC was injected into the tail vein for about 1 min ⁇ 10 s.
  • the administration volume was 5mL/kg, the dosage concentration is 20mg/kg, blood is collected at 0.083h, 1h, 2h, 8h, 24h, 48h, 72h, 96h, 120h, 144h and 168h after the end of the administration, and the serum is separated by centrifugation within 30-120 minutes.
  • the concentration of total antibody (Tab) and ADC in the blood samples is detected by conventional ELISA method.
  • the detection method of total antibody is briefly described as follows: Trop2-His was coated overnight at 4°C with a concentration of 0.75ug/mL, and blocked with 5% skim milk powder at 37°C for 2h. The standard curve and quality control points were added and incubated for 2h. The detection range of the standard curve was 64ng/mL-0.5ng/mL, starting at 64ng/mL, and 2-fold gradient dilution. The quality control concentration points were set to 60ng/mL, 6ng/mL, and 0.6ng/mL. The recovery rate of the quality control points needed to be between 80% and 120%.
  • the anti-human K light chain peroxidase antibody produced in goats (manufacturer: Sigma, product number: A7164-1ML) was added as secondary antibody at a dilution of 1:8000, incubated for 1h, washed 8 times with PBST, added TMB for color development, terminated with 0.1M sulfuric acid, read the plate with an OD450 microplate reader, and calculated the blood sample concentration at different time points using the microplate reader analysis software SoftMaxPro.
  • the detection method of ADC is briefly described as follows: Trop2-His was coated overnight at 4°C with a concentration of 0.75ug/mL, and blocked with 5% skim milk powder at 37°C for 2h. The standard curve and quality control points were added and incubated for 2h. The detection range of the standard curve was 64ng/mL-0.5ng/mL, starting at 64ng/mL, and 2-fold gradient dilution. The quality control concentration points were set to 60ng/mL, 6ng/mL, and 0.6ng/mL. The recovery rate of the quality control points needed to be between 80% and 120%.
  • the anti-human K light chain peroxidase antibody produced in goats (manufacturer: Sigma, product number: A7164-1ML) was added as the secondary antibody at a dilution of 1:8000, incubated for 1h, washed 8 times with PBST, added TMB for color development, terminated with 0.1M sulfuric acid, read the plate with an OD450 microplate reader, and calculated the blood sample concentration at different time points using the microplate reader analysis software SoftMaxPro.
  • the ELISA was used to draw a curve of drug concentration changes in the blood.
  • the ADC concentration basically coincided with the total antibody concentration, with extremely low shedding and very stable in the blood.
  • KPL-4 tumor cells in the logarithmic growth phase were taken, and the cells were resuspended in fresh RPMI1640 culture medium, counted and the cell suspension was adjusted to 2 ⁇ 10 4 cells/mL.
  • the cell suspension was inoculated into a 96-well cell culture plate, 100 ⁇ L/well, and placed in a carbon dioxide incubator (37°C, 5% CO 2 ) for overnight culture.
  • a carbon dioxide incubator 37°C, 5% CO 2
  • one of the 96-well plates inoculated with cells was taken out, equilibrated to room temperature, and 100 ⁇ L of CellTiter-Glo reagent (Promega, USA) pre-equilibrated to room temperature and mixed was added to each well of the test plate.
  • the luminescence value (recorded as G 0 value) was read in an ELISA reader; another parallel plate was taken and different concentrations of the test compound or DMSO (final concentration 0.5%) were added to the corresponding wells of the test plate. After culturing in a carbon dioxide incubator for 72 hours, the test plate was equilibrated to room temperature and the cell activity was detected using CellTiter-Glo reagent, which was recorded as G 3 value.
  • Cell proliferation rate (%) (average value of G3 in test compound wells - average value of G0 ) / (average value of G3 in DMSO control wells - average value of G0 ) * 100.
  • Graphpad Prism software was used to fit the inhibition curve and calculate the GI 50 value.
  • the compound prepared in the present application exhibits excellent in vivo anti-tumor activity.
  • BxPC3 human pancreatic cancer cells, ATCC, CRL-1687
  • MiaPaCa2 cells human pancreatic cancer cells, biocytogen, B-HCL-014
  • RPMI1640 + 10% FBS fetal calf serum
  • DMEM/high glucose + 10% FBS fetal calf serum
  • the cells were digested with trypsin, neutralized with fresh culture medium, centrifuged at 1000rpm for 3 minutes, the supernatant was discarded, and the cells were resuspended with RPMI1640 + 10% FBS. After cell counting, the density of BxPC3 cells was adjusted to 6*10 4 cells/mL, and the density of MiaPaCa2-luc cells was adjusted to 1.5*10 4 cells/mL.
  • ADC samples were prepared into an intermediate solution (0.2 ⁇ ) with a concentration of 40x. 25 ⁇ L of each sample was added to the corresponding wells of a 12-well plate. A solvent control group was set up. Cultured at 37°C with 5% carbon dioxide for 6 days. The cells in the 12-well plate were digested with trypsin, neutralized with fresh culture medium, centrifuged at 1000rpm for 3 minutes, the supernatant was discarded, and the cells were resuspended with 1mL of FACS buffer (PBS+2.5% FBS). 20 ⁇ L of cells were added with 20 ⁇ L of trypan blue and counted.
  • FACS buffer PBS+2.5% FBS
  • the cells in plate 1 were centrifuged at 1000rpm for 3 minutes, the supernatant was discarded, the cells were resuspended with 100uL of FACS Buffer, 2 ⁇ L of monoclonal antibody was added, and incubated on ice for 30 minutes. Centrifuged at 2000rpm for 1 minute at 4°C, the supernatant was discarded, and the cells were resuspended with 150uL of FACS buffer. Detected with BD FACSVerse. Data were analyzed with Flowjo 7.6.
  • the ADC did not kill the target-expressing negative MiaPaCa2 cells.
  • the target-expressing BxPC3 cells were mixed with the negative cells MiaPaCa2 the ADC also had a killing effect on the target-expressing negative cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种配体偶联物，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体，或其可药用的盐或水合物，包含式I所示的结构，可以用作抗肿瘤药物。

Description

一种抗肿瘤化合物及其应用 技术领域
本申请涉及生物医药领域，具体的涉及一种抗肿瘤化合物及其应用。
背景技术
抗体-药物偶联物(antibody drug conjugate,ADC)将单克隆抗体或者抗体片段通过稳定的化学接头化合物与具有生物活性的细胞毒素相连，充分利用了抗体对正常细胞和肿瘤细胞表面抗原结合的特异性和细胞毒性物质的高效性，具有抗肿瘤作用。喜树碱衍生物依沙替康应用于抗体偶联药物(ADC)已有文献报道，但本领域仍需进一步开发疗效更好、安全性更高的ADC药物。但是目前已上市ADC药物仍然存在血浆稳定性差、脱靶毒副作用等问题，影响产品的疗效和安全性，仍然需要进一步开发新的、稳定性的的连接体和/或连接体-药物分子来解决这些问题。
发明内容
本发明提供了一种稳定性高、疗效好、安全性高的配体偶联物，及其配体偶联物前体、连接体、连接体前体等。
本发明的第一方面，提供了一种配体偶联物，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体，或其可药用的盐或水合物，其中所述配体偶联物包含式I所示的结构：
其中，L为任选取代的连接体，其与P结构中的任意O原子、S原子或N原子相连；
Ab为配体，a为大于0的数，a是小数或整数；
P为毒素，且所述的P具有如下式II所示的结构：
其中，n为0或1；
X选自下组：N或CR0；
R0选自下组：H、D、卤素、C1-C8烷基、C1-C8烷氧基、OH、NH2、N3或NO2；
R1选自下组：氢原子、氘原子、卤素、C1-C8烷基、C1-C8烷氧基、C1-C8卤代烷基、C1-C8卤代烷氧基、N3、NO2、NH2、NH-OH、-NR'R”、-COOR'、-CONR'R”、-NHR”'NR'R”；其中R'、R”和R”'各自独立地选自氢，氘，烷基，芳基，芳基烷基，酰基，烷氧羰基，芳基氧羰基；
R2、R3、R4、R5和R6各自独立地选自下组：氢原子、氘原子、卤素、羟基、氰基、NH2、NO2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基、取代或未取代的C1-C8烷硫基、取代或未取代的C1-C8氘代烷基、-(CH2)m三(C1-C4烷基)硅基、-(CH2)m(C3-C8环烷基)、-(CH2)m(3-12元杂环基)、-(CH2)mN(R7)2、-(CH2)mS(CH2)pR7、-(CH2)mS(O)(CH2)pR7、-(CH2)mS(O)2(CH2)pR7、-(CH2)mNH(CH2)pR7、-(CH2)mNHC(O)(CH2)pR7、-(CH2)mOC(O)(CH2)pR7、-(CH2)mC(O)(CH2)pR7、-CH＝N(OtBu)；其中，m和p各自独立地为0、1、2、3或4；
或者，R2和R3与其相连接的碳原子一起形成取代或未取代的C5-C8碳环或取代或未取代的5-12元杂环基；
或者，R3和R4，或R4和R5与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱和或不饱和的5-12元碳环、未取代或被一个或多个Re取代的饱和或不饱和的5-12元杂环；所 述Re为取代或未取代的选自下组的取代基：氢原子、氘原子、卤素、腈基、硝基、羟基、氨基、C1-C6烷基-NH-、(C1-C6烷基)2N-、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、烯丙基、苄基、C6-C12芳基、C1-C6烷氧基-C1-C6烷基、C1-C6烷氧基-羰基、苯氧羰基、C2-C6炔基-羰基、C2-C6烯基-羰基、C3-C6环烷基-羰基、C1-C6烷基-磺酰基、苯基、5-7元杂芳基、C3-C8环烷基、3-12元杂环基、-(CH2)mN(R7)2、-(CH2)mS(CH2)pR7、-(CH2)mS(O)(CH2)pR7、-(CH2)mS(O)2(CH2)pR7、-(CH2)mNH(CH2)pR7、-(CH2)mNHC(O)(CH2)pR7、-(CH2)mOC(O)(CH2)pR7、-(CH2)mC(O)(CH2)pR7；其中，m和p各自独立地为0、1、2、3或4，优选为0、1或2；
R7选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基、C1-C8卤代烷基、C1-C8氘代烷基、取代或未取代的C1-C8烷氧基、羟基、氨基、氰基、硝基、巯基、取代或未取代的C1-C8亚烷基-OH、取代或未取代的C1-C8亚烷基-NH2、SO2Me、-OC(O)(取代或未取代的C1-C4烷基)、-C(O)(取代或未取代的C1-C4烷基)、取代或未取代的苯基、取代或未取代的5-7元杂芳基、取代或未取代的C3-C8环烷基、取代或未取代的3-12元杂环基；
除非特别说明，所述的各个“取代”指基团上的一个或多个氢原子被选自下组的取代基所取代：氢原子、氘原子、卤素、腈基、硝基、羟基、氨基、C1-C6烷基-NH-、(C1-C6烷基)2N-、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、卤代C1-C6烷基、卤代C2-C6烯基、卤代C2-C6炔基、卤代C1-C6烷氧基、烯丙基、苄基、C6-C12芳基、C1-C6烷氧基-C1-C6烷基、C1-C6烷氧基-羰基、苯氧羰基、C2-C6炔基-羰基、C2-C6烯基-羰基、C3-C6环烷基-羰基、C1-C6烷基-磺酰基、苯基、5-7元杂芳基、C3-C8环烷基、3-12元杂环基。
在另一优选例中，所述L具有如下式所示的结构：
-L1-L2-L3-L4-L5-；
其中，所述L1为任选取代的Rd为H、C1-C6烷基、C1-C6氘代烷基、C3-C8环烷基或C3-C8氘代环烷基；
所述L2为选自下组的基团：任选取代的-(CHR)m1-X1-(CH2CH2O)n3-(CHR)m2-C(O)-、任选取代的-(CHR)m1-X1-X2-(CH2CH2O)n3-(CHR)m2-C(O)-，任选取代的-X1-(CHROCHR)m2-C(O)-、任选取代的-(CHR)p1-C(O)-、任选取代的-(CHR)m1-X1-(CHR)m2-C(O)-、任选取代的-(CHR)m1-X1-(CHR)n3-X2-(CHR)m2-C(O)-、任选取代的-X1-(CHR)m1-X2-(CHR)m2-C(O)-、任选取代的-(CH2CH2O)n3-C(O)-；
X1和X2各自独立地选自以下组：-O-、-C(O)-、-C(O)-NR-、任选取代的C6-C10芳基、任选取代的5-9元杂芳基、任选取代的3-8元杂脂环基和任选取代的C3-C6脂环基；
其中，所述的R各自独立地选自以下组：H、D、(CH2)n4OH、(CH2)n4NH2、(CH2O)n4(CH2CH2O)n5H、(CH2O)n4(CH2CH2O)n5CH3、(CH2)n4OCH3、(CH2CH2O)n5CH3、CH2C(O)NH(CH2O)n4(CH2CH2O)n5H、CH2C(O)NH(CH2O)n4(CH2CH2O)n5CH3；
其中，m1、m2、n3、n4和n5各自独立地选自0、1、2、3、4、5、6、7、8、9、10、11、12；p1选自0、1、2、3、4、5、6、7或8；
所述L3为肽残基；且所述的L3可以被一个或多个选自下组的取代基取代： CH2C(O)Rc；所述的Rc选自下组： 其中，n1和n2各自独立地为0、1、2、3、4、5、6、7、8、9、10、11、12；
所述L4为任选取代的-L4a-(NRb)n6-R12-L4b-，其中，L4a不存在，或L4a为任选取代的 其中n6为0或1；R12为化学键、CH2、或CD2；
L4b不存在，或L4b为任选取代的其中，Ra和Rb各自独立地选自以下组：氢、任选取代的C1-C4烷基、和任选取代的C1-C4氘代烷基；
所述L5不存在，或为任选取代的其中，Y选自下组：O、S或NH；v选自0、1、2、3、4、5、6、7、8、9、10；R10和R11各自独立地选自以下组：氢、氘、任选取代的C1-C4烷基、任选取代的C1-C4卤代烷基、任选取代的C3-C6环烷基和任选取代的C4-C8环烷基烷基，或R10和R11与其相连接的原子一起形成任选取代的3-6元环烷基，R10和R11各自独立地选自下组：氢原子、氘原子、卤素、任选取代的C1-C8烷基、任选取代的C1-C8卤代烷基和任选取代的C1-C8氘代烷基。
在另一优选例中，所述的L1为
在另一优选例中，X1和X2各自独立地选自以下组：-O-、-C(O)-、-C(O)-NR-、任选取代的苯基、任选取代的吡啶基、任选取代的C3-C6环烷基、任选取代的或任选取代的
在另一优选例中，所述的L2为选自下组的基团：任选取代的-(CH2)m1-X1-(CH2CH2O)n3-(CH2)m2-C(O)-；其中，X1为-C(O)-NH-；较佳地，m1和m2各自独立地选自1、2或3；n3选自0、1、2、3、4、5、6、7、8、9、10、11、12。
在另一优选例中，所述的L2为选自下组的基团：任选取代的-(CHR)m1-X1-X2-(CH2CH2O)n3-(CHR)m2-C(O)-；其中，X1为任选取代的或任选取代的X2为-C(O)-NR-；较佳地，m1和m2各自独立地选自0、1或2；n3选自1、2、3、4、5、6、7、8、9、10、11、12。
在另一优选例中，所述的L2为选自下组的基团：任选取代的-X1-(CHROCHR)m2-C(O)-；其中，X1为任选取代的芳基、任选取代的杂芳基；较佳地，m2选自0、1、2或3。
在另一优选例中，所述的L2为选自下组的基团：任选取代的(CHR)p1-C(O)-；p1选自0、1或2；R选自下组：H、(CH2)n4OH、(CH2O)n4(CH2CH2O)n5H；较佳地，n4和n5各自独立地选自0、1、2或3。
在另一优选例中，所述的L2为选自下组的基团：任选取代的-(CH2)m1-X1-(CH2CH2O)n3-(CHR)m2-C(O)-；其中，X1为-C(O)-；较佳地，m1和m2各自独立地选自0、1、2或3；n3选自0、1或2。
在另一优选例中，所述的L2为选自下组的基团：任选取代的-X1-(CH2)m1-X2-(CHR)m2-C(O)-；其中，X1为任选取代的芳基或任选取代的杂芳基；X2为-C(O)-；较佳地，m1、m2各自独立地选自0、1或2。
在另一优选例中，所述的L2为选自下组的基团：-(CHR)m1-X1-(CHR)m2-C(O)-；其中X1为任选取代的3-8元杂脂环基或选取代的C3-C6脂环基；较佳地，m1为0、1或2，m2为0。
在另一优选例中，所述的L2为选自下组的基团：任选取代的-(CHR)m1-X1-(CH2CH2O)n3-(CHR)m2- C(O)-；其中，X1为O；较佳地，m1，n3和m2各自独立地为0、1或2。在另一优选例中，所述的L2为选自下组的基团：任选取代的-(CHR)m1-X1-(CHR)n3-X2-(CHR)m2-C(O)-；其中X1任选取代的-C(O)-NR-，X2为O；较佳地，m1，n3和m2各自独立地为1、2或3；R如上文中所述。
在另一优选例中，所述L2为任选取代的选自下组的结构：
在一个优选的实施方式下，选择上述的L2结构，能够使所得到的配体偶联物的马来酰亚胺基团形成开环结构，从而抑制Retro-Michael反应，提高配体偶联物的稳定性，减少小分子部分的脱落，从而改善配体偶联物药物的安全性。
在另一优选例中，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的氨基酸构成的肽残基：苯丙氨酸、异亮氨酸、亮氨酸、色氨酸、缬氨酸、甲硫氨酸、酪氨酸、丙氨酸、苏氨酸、组氨酸、丝氨酸、谷氨酰胺、精氨酸、赖氨酸、天冬酰胺、谷氨酸、脯氨酸、瓜氨酸、天冬氨酸和甘氨酸。
在另一优选例中，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的氨基酸构成的肽残基：甘氨酸、丙氨酸、赖氨酸、苯丙氨酸、缬氨酸和瓜氨酸。
在另一优选例中，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的肽残基：-甘氨酸-苯丙氨酸-甘氨酸-(-Gly-Phe-Gly-)、-甘氨酸-甘氨酸-苯丙氨酸-甘氨酸-(-Gly-Gly-Phe-Gly-)、-缬氨酸-瓜氨酸-(-Val-Cit-)、-瓜氨酸-缬氨酸-(-Cit-Val-)、-瓜氨酸-丙氨酸-(-Cit-Ala-)、-缬氨酸-丙氨酸-(-Val-Ala-)、-缬氨酸-精氨酸-(-Val-Arg-)、-缬氨酸-赖氨酸-(-Val-Lys-)、-缬氨酸-赖氨酸(Ac)-(-Val-Lys(Ac)-)、-赖氨酸-缬氨酸-(-Lys-Val-)、-亮氨酸-瓜氨酸-(-Leu-Cit-)、-异亮氨酸-瓜氨酸-(-Ile-Cit-)、-色氨酸-瓜氨酸-(-Trp-Cit-)、-苯丙氨酸-赖氨酸-(-Phe-Lys-)、-苯丙氨酸-赖氨酸(Ac)-(-Phe-Lys(Ac)-)、-苯丙氨酸-瓜氨酸-(-Phe-Cit-)、-苯丙氨酸-丙氨酸-(-Phe-Ala-)、-苯丙氨酸-精氨酸-(-Phe-Arg-)、-丙氨酸-赖氨酸-(-Ala-Lys-)、-丙氨酸-丙氨酸-(-Ala-Ala-)、-丙氨酸-丙氨酸-丙氨酸-(-Ala-Ala-Ala-)、-丙氨酸-丙氨酸-天冬酰胺-(-Ala-Ala-Asn-)、-丙氨酸-丙氨酸-天冬氨酸-(Ala-Ala-Asp-)、-赖氨酸-丙氨酸-丙氨酸-天冬酰胺-(-Lys-Ala-Ala-Asn-)、-赖氨酸-丙氨酸-丙氨酸-天冬氨酸-(-Lys-Ala-Ala-Asp-)、-(D)-缬氨酸-亮氨酸-赖氨酸-(-D-Val-Leu-Lys-)、-甘氨酸-甘氨酸-精氨酸-(-Gly-Gly-Arg-)、-甘氨酸-甘氨酸-天冬酰胺-(-Gly-Gly-Asn-)、-甘氨酸-甘氨酸-苯丙氨酸-(-Gly-Gly-Phe-)、-缬氨酸-赖氨酸-甘氨酸-(-Val-Lys-Gly-)、-谷氨酸-丙氨酸-丙氨酸-(-Glu-Ala-Ala-)、-天冬氨酸-丙氨酸-丙氨酸-(-Asp-Ala-Ala-)、-缬氨酸-赖氨酸-甘氨酸-甘氨酸-(-Val-Lys-Gly-Gly-)和-赖氨酸-丙氨酸-天冬酰胺-(-Lys-Ala-Asn-)。
在另一优选例中，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的结构：

在另一优选例中，所述L4为化学键，或为任选取代的选自下组的基团： 其中，所述Ra和Rb各自独立地选自以下组：氢、任选取代的C1-C4烷基、任选取代的C1-C4氘代烷基。
在另一优选例中，所述L4为化学键，或为任选取代的选自下组的结构：
在另一优选例中，所述L5为化学键，或为选自以下组的结构：任选取代的 任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的和任选取代的
在另一优选例中，所述的式II化合物选自下组：
在另一优选例中，所述的式II化合物选自下组：
在另一优选例中，所述的式II化合物选自下组：
在另一优选例中，所述R4选自下组：氢原子、氘原子、卤素、羟基、氰基、NH2、NO2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基、取代或未取代的C1-C8烷硫基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C8环烷基)、-(CH2)m(3-12元杂环基)、-(CH2)mN(R7)2、-(CH2)mS(O)(CH2)pR7、- (CH2)mS(O)2(CH2)pR7、-(CH2)mNH(CH2)pR7；其中，m和p各自独立地为0、1或2，R7的定义如上文中所述；
R5选自下组：氢原子、氘原子、卤素、NH2、OH、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基；
或者，R4和R5与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱和或不饱和的5-6元碳环、未取代或被一个或多个Re取代的饱和或不饱和的5-6元杂环；其中，Re的定义如上文中所述。
在另一优选例中，R2和R3各自独立地选自下组：氢原子、氘原子、卤素、NH2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C6环烷基)、-(CH2)m(3-6元杂环基)、-(CH2)mN(R7)2、-(CH2)mOC(O)R7；其中，m为0、1、2、3或4，R7的定义如上文中所述；
或者，R2和R3与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱和或不饱和的5-6元环、未取代或被一个或多个Re取代的饱和或不饱和的5-6元杂环；其中，Re的定义如上文中所述。
在另一优选例中，R1和R6各自独立地为氢原子。
在另一优选例中，所述R4和R5各自独立地选自下组：氢原子、氘原子、卤素、羟基、NH2、取代或未取代的C1-C4烷基；
或者，R4和R5与其相连接的碳原子共同形成未取代或被一个或多个Re取代的氧杂5-6元杂环；其中，Re的定义如上文中所述。
在另一优选例中，R2选自下组：氘原子、卤素、NH2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C6环烷基)、-(CH2)m(3-6元杂环基)、-(CH2)mN(R7)2、-(CH2)mOC(O)R7；其中，m为0、1、2、3或4；
R3各选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C6环烷基)、-(CH2)m(3-6元杂环基)、-(CH2)mN(R7)2、-(CH2)mOC(O)R7；其中，m为0、1、2、3或4；
或者，R2和R3与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱和或不饱和的5-6元环、未取代或被一个或多个Re取代的饱和或不饱和的5-6元杂环；
R4选自下组：氢原子、氘原子、卤素、羟基、氰基、NH2、NO2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基；
R5选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基；
或者，R4和R5与其相连接的碳原子共同形成未取代或被一个或多个Re取代的选自下组的基团：-OCH2O-或-O(CH2)2O-；
R7选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基、羟基、氨基、氰基、硝基、巯基；
其中，Re的定义如上文中所述。
在另一优选例中，所述的式II化合物选自下组：








在一种优选的实施方式中，上述的配体偶联物选自下组：


在以上所示的结构中，“-L1-”选自以下结构：
在一种优选的实施方式中，所述的配体偶联物选自下组：

在以上所示的结构中，“-L1-”选自以下结构： 优选为 更优选为
在另一优选例中，所述配体偶联物包含式(I-a)所示的结构：
其中，R4、R5和L如本发明第一方面中的定义，a为大于0的数，a是小数或整数。
在另一优选例中，所述配体偶联物为选自以下组的结构：


其中a为大于0的数，a是小数或整数。
在另一优选例中，a为0至8的非零整数或小数，优选为1-8之间的整数或小数；更优选为2至8，可以为整数，也可以为小数；最优选为3至8，可以为整数，如：4.0，也可以为小数，如：3.9。
在另一优选例中，所述Ab为抗体或其抗原结合片段。
在另一优选例中，所述抗体选自以下组：鼠源抗体、嵌合抗体、人源化抗体和全人源抗体。
在另一优选例中，所述抗体为单克隆抗体。
在另一优选例中，所述抗原结合片段选自以下组：Fab，Fab′，Fv片段，F(ab')2，F(ab)2，scFv，di-scFv，VHH和dAb。
在另一优选例中，所述的抗体选自下组：Her-2特异性抗体(如Trastuzumab)、Trop2特异性抗体(如US7238785B2的Humanized RS7或Sacituzumab)、PSMA特异性抗体(如WO2003034903A2的PSMA特异性单抗AB-PG1-XG1-006)、FR-α特异性抗体(如US5952484的人源化LK26抗体(Farletuzumab,MORAb-003)、B7H3抗体(如WO2021244590A1中的抗体P7-C05-H4L3)，或IGF-1R特异性抗体。
在另一优选例中，所述的抗体为IGF-1R特异性抗体。
在另一优选例中，所述IGF-1R包含来源于灵长类动物的IGF-1R。
在另一优选例中，所述的抗体为IgG1或其突变。
在另一优选例中，所述抗体包含HCDR3，所述HCDR3包含SEQ ID NO：3所示的氨基酸序列。
在另一优选例中，所述抗体包含HCDR2，所述HCDR2包含SEQ ID NO：2所示的氨基酸序列。
在另一优选例中，所述抗体包含HCDR1，所述HCDR1包含SEQ ID NO：1所示的氨基酸序列。
在另一优选例中，所述抗体包含重链可变区VH，所述VH包含所述HCDR1、HCDR2和HCDR3，所述HCDR3包含SEQ ID NO：3所示的氨基酸序列；所述HCDR2包含SEQ ID NO：2所示的氨基酸序列；且所述HCDR1包含SEQ ID NO：1所示的氨基酸序列。
在另一优选例中，所述抗体包含重链可变区VH，所述VH包含SEQ ID NO：4所示的氨基酸序列。
在另一优选例中，所述的抗体具有如SEQ ID No.5所示的全长序列。
在另一优选例中，所述的抗体为上述任一抗体的变体，且所述变体包括所述CDR区域。
在另一优选例中，所述的变体为所述抗体的氨基酸序列经过取代、缺失和/或添加一个或多个氨基酸(例如1-30个、1-20个或1-10个，又例如1个、2个、3个、4个、5个、6个、7个、8个或9个氨基酸取代、缺失和/或插入)所形成的序列。
在另一优选例中，所述的变体为所述抗体的氨基酸序列的同源物，所述同源物可以为与所述CDR的氨基酸序列具有至少约85％(例如，具有至少约85％、约90％、约91％、约92％、约93％、约94％、约95％、约96％、约97％、约98％、约99％或更高的)序列同源性的氨基酸序列。
在另一优选例中，所述的CDR通过Kabat编号方案确定。
本发明的第二方面，提供了一种配体偶联物前体，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体，或其可药用的盐或水合物，其中所述配体偶联物前体包含式IA所示的结构：
LA-P(IA)，
其中，L为L1A-L2-L3-L4-L5-；其中，L1A为其中，Rd、L2、L3、L4、L5和P定义如本发明第一方面中所述。
在另一优选例中，所述的配体偶联物前体选自如下结构：



在以上所示的结构中，L1A选自
本发明的第三方面，提供了一种如式(L)所示的连接体，其将药物单元与配体连接而成的配体-药物偶联物：
L1-L2-L3-L4-L5(L)，
其中，其中，所述L1,L2,L3,L4,L5的定义如本发明第一方面中所述。
在另一优选例中，所述的连接体选自下组：




在另一优选例中，所述的连接体通过L1段与配体相连，通过L5段与P1相连，形成配体药物偶联物；且所述的P1选自下组：糖肽类抗生素，例如博来霉素或平阳霉素；DNA拓扑异构酶抑制剂，例如拓扑异构酶I抑制剂(例如喜树碱、羟基喜树碱、9‐氨基喜树碱、SN‐38、伊立替康、伊喜替康、拓扑替康、贝洛替康或卢比替康、DXd等)，拓扑异构酶II抑制剂(例如放线菌素D、多柔比星、多卡米星，柔红霉素、米托蒽醌、鬼臼毒素或依托泊苷)；干扰DNA合成药物，例如甲氨蝶呤、5‐氟尿嘧啶、阿糖胞苷、吉西他滨、巯嘌呤、喷司他丁、氟达拉滨、克拉屈滨或奈拉滨；作用于结构蛋白的药物，例如微管蛋白抑制剂，长春花生物碱类、长春新碱、长春碱、紫杉醇、多西他赛或卡巴他赛；肿瘤信号通路抑制剂，例如丝氨酸/苏氨酸激酶抑制剂、酪氨酸激酶抑制剂、天冬氨酸激酶抑制剂或组氨酸激酶抑制剂；蛋白酶体抑制剂；组蛋白去乙酰化酶抑制剂；肿瘤新生血管生成抑制剂；细胞周期蛋白抑制剂；美登素衍生物(例如DM1、DM4等)；卡里奇霉素衍生物；奥瑞他汀衍生物(例如单甲基澳瑞他汀E(MMAE)、单甲基澳瑞他汀F(MMAF)、澳瑞他汀E、澳瑞他汀F等)；Pyrrolobenzodiazepine dimers(PBD)衍生物；鹅膏毒素类衍生物(如α-Amanitin等)；蒽环类；杜卡霉素；艾日布林(eribulin)；美法仑；丝裂霉素C；苯丁酸氮芥；TLR激动剂；STING激动剂；糖皮质激素类以及其它抑制肿瘤细胞生长、促进肿瘤细胞凋亡或坏死的活性物质脱氢形成的基团。
本发明的第四方面，提供了一种如式(L-1)所示的连接体前体，其用于得到将药物单元与配体连接而成的配体-药物偶联物：
其用于得到将药物单元与配体连接而成的配体-药物偶联物：
LA-Rg(L-1)，
其中，Rg为H、OH、O(C1-C6烷基)；其中LA的定义如本发明第三方面中所述。
在另一优选例中，所述的连接体前体选自下组：



同时，本发明还提供了(L-1)另一优选例的合成方案，描述如下：
方案1：
Pg1选自等；
Pg2选自Boc、Fmoc、Cbz等；
Pg3选自Boc、Fmoc、Cbz等；
方案2：
Pg1选自等；
Pg2选自Boc、Fmoc、Cbz等；
Pg4选自Me、Et、iPr、Allyl、tBu、Bn、4-Methybenzyl、4-Methoxybenzyl、2,4-Dimethoxybenzyl,2,6-Dimethoxybenzyl、Trimethylsilyl、tert-Butyldimethylsilyl、Pentafluorophenyl等。
本发明的第五方面，提供了一种药物组合物，其含有本发明第一方面所述的配体偶联物，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其药学上可接受的盐、前药或溶剂合物，以及任选地药学上可接受的载体。
本发明的第六方面，提供了一种本发明第一方面所述的配体偶联物，或其互变异构体、内消旋体、 外消旋体、对映异构体、非对映异构体、或其混合物形式，或其药学上可接受的盐、前药或溶剂合物，和/或本发明的第五方面所述的药物组合物在制备用于治疗和/或预防与所述的配体的靶点表达相关和/或异常表达相关的疾病或病症的药物中的用途。
在另一优选例中，所述与所述配体的靶点表达相关和/或异常表达相关的疾病或病症为肿瘤/癌症、自身免疫疾病或者感染性疾病；较佳地，所述肿瘤/癌症为所述配体的靶点高表达、中表达、低表达的肿瘤/癌症。
在另一优选例中，所述肿瘤选自与以下组靶点表达相关的肿瘤：Her-2、Trop2、PSMA、FR-α、B7H3，或IGF-1R。
在另一优选例中，所述肿瘤包含实体肿瘤和/或血液肿瘤。
在另一优选例中，所述肿瘤是与IGF-1R靶点表达相关的肿瘤。
在另一优选例中，所述肿瘤选自下组：乳腺癌、卵巢癌、宫颈癌、子宫内膜癌、尿路上皮癌、肺癌、前列腺癌、结直肠癌、胃癌、食管癌、膀胱癌、肾癌、胰腺癌、甲状腺癌和头颈癌。星形细胞瘤、基底或鳞状细胞癌、脑癌、神经母细胞瘤、胶质母细胞瘤、脂肪肉瘤、膀胱癌、结肠直肠癌、结肠癌、软骨肉瘤、肾癌、绒毛膜癌、白血病、多发性骨髓瘤、尤因肉瘤、胃肠癌、头颈癌、肝癌、胶质细胞瘤、肝细胞癌、平滑肌瘤、黑素瘤、非小细胞肺癌、神经系统癌症、胰腺癌、肾细胞癌、横纹肌肉瘤、小细胞肺癌、胸腺瘤、甲状腺癌、睾丸癌和骨肉瘤。
本发明的另一方面，提供了一种如式(L-1)所示的连接体前体的制备方法，其特征在于，包括步骤：
用与反应，得到
其中，L1A为较佳地，L1A为更佳地，L1A为
L2如上述任一方面中所述；较佳地，L2选自下组： 更佳地，L2选自
较佳地，选自氨基酸或者二肽片段；较佳地，为甘氨酸或甘氨酸-甘氨酸片段较佳地，为甘氨酸-甘氨酸片段
较佳地，选自氨基酸或者二肽片段；较佳地，为甘氨酸或甘氨酸-甘氨酸片段较佳地，为甘氨酸-甘氨酸片段
较佳地，为二肽或三肽片段；较佳地，为甘氨酸-苯丙氨酸-甘氨酸片段苯丙氨酸-甘氨酸片段较佳地，为苯丙氨酸-甘氨酸片段
较佳地，为二肽或三肽片段；较佳地，为甘氨酸-苯丙氨酸-甘氨酸片段苯丙氨酸-甘氨酸片段较佳地， 为苯丙氨酸-甘氨酸片段
Pg1选自较佳地，所述Pg1选自 较佳地，所述Pg1选自较佳地，所述Pg1选自较佳地，所述Pg1选自
较佳地，所述的是通过以下方法制备的：
(1)以L1A-L2-OPg5与反应，得到较佳地，在无碱或者有碱参与下反应；较佳地，在无碱参与下反应；较佳地，所述碱选自三乙胺，N,N-二异丙基乙胺，2,4,6-三甲基吡啶，DMAP，DBU，NMM，NaHCO3；较佳地，所述的碱为NaHCO3；
Pg5选自较佳地，所述Pg5选自 较佳地，所述Pg5选自较佳地，所述Pg5选自较佳地，所述Pg5选自
(2)用Pg1OH与反应，得到
较佳地，所述Pg1OH选自较佳地，所述Pg1OH选自较佳地，所述Pg1OH选自较佳地，所述Pg1OH选自较佳地，所述Pg1OH选自
较佳地，所述的是通过以下方法制备的：
(i)由式反应得到
(ii)用与反应，得到
且所述的方法还包括：通过以下(iii)或(iv)的方法得到
(iii)先进行脱保护基Pg4，得到然后进行脱保护基Pg2，得到
较佳地，所述脱保护在碱存在下进行；较佳地，所述碱为有机碱；更佳地，所述碱为DBU；较佳地，所述脱保护在还原剂存在下进行；较佳地，所述的还原剂为H2；较佳地，所述脱保护在催化剂存在下进行；较佳地，所述催化剂为钯碳Pd/C；
(iv)先脱保护基Pg2，得到然后进行脱保护基Pg4，得到
较佳地，所述脱保护在碱存在下进行；较佳地，所述碱为有机碱；更佳地，所述碱为DBU；较佳地，所述脱保护在还原剂存在下进行；较佳地，所述的还原剂为H2；较佳地，所述脱保护在催化剂存在下进行；较佳地，所述催化剂为钯碳Pd/C；
其中Pg2选自Boc、Fmoc、Cbz；
Pg4选自Me、Et、iPr、Allyl、tBu、Bn、4-甲基苄基、4-甲氧基苄基、2,4-二甲氧基苄基、2,6-二甲氧基苄基、三甲基硅基、叔丁基二甲基硅基、五氟苯基。
在另一优选例中，所述的连接体前体为
本发明的另一方面，提供了一种如下式4所述化合物的制备方法：
其特征在于，所述方法包括步骤：
在惰性溶剂中，用如下式15h所述化合物与式1d所述化合物发生缩合反应得到式4所述化合物：
在另一优选例中，所述的惰性溶剂选自下组：二氯甲烷、四氢呋喃、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、HMPA，或其组合；优选为N,N-二甲基甲酰胺；
在另一优选例中，反应在缩合剂存在下进行；更优选地，所述的缩合剂选自下组：HATU、HBTU、TBTU、EDCI、HOAt、HOBt、CDI、TCFH、TFFH、DCC、DIC、BOP、AOP、PyAOP、BrOP、PyClOP、PyBrOP、DMTMM，或其组合，更优选地，所述缩合剂为HATU；
在另一优选例中，所反应在碱存在下反应；更优选地，所述的碱选自下组：TEA，DIPEA，DBU，DMAP，吡啶，2,6-二甲基吡啶，2,4,6-三甲基吡啶，咪唑，N-甲基咪唑，或其组合；更优选地，所述碱为2,4,6-三甲基吡啶。
本发明的另一方面，提供了一种如下式15h所述化合物的制备方法，
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用如下式15f所述化合物与式8e所述化合物反应得到式15g所述化合物；
在另一优选例中，所述的惰性溶剂选自下组：乙腈、水、四氢呋喃，2-甲基四氢呋喃，二氯甲烷，或其组合；进一步优选为乙腈、水，或其组合；进一步优选为乙腈和水体积比为10:1至1:10的组合；更优选地，所述惰性溶剂为乙腈和水体积比为2:1至4:1的组合；更优选地，所述惰性溶剂为乙腈和水体积比为3:1的组合；
在另一优选例中，所述的反应可以在碱存在下进行；较佳地，所述碱选自TEA，DIPEA，NMM，碳酸氢钠，DBU，或其组合；更优选地，所述碱为DIPEA；
(2)在惰性溶剂中，如下式15g所述化合物经硅基脱除试剂脱除保护基，得到式15h所述化合物；
在另一优选例中，所述的硅基脱除试剂选自下组：酸、氟化试剂(含氟试剂)；优选地，所述硅基脱除试剂选自氟化氢、氟化氢水溶液、三乙胺三氢氟酸盐、吡啶氢氟酸盐、甲酸、乙酸、三氟乙酸、二氯乙酸、甲磺酸、三氟甲磺酸；优选地，所述的硅基脱除试剂为甲酸；
在另一优选例中，所述的惰性溶剂选自下组：四氢呋喃、N,N-二甲基甲酰胺、乙腈、水，或其组合；进一步优选为乙腈、水，或其组合；进一步优选为乙腈和水体积比为10:1至1:10，进一步优选为乙腈：水体积比为1:4至4:1，进一步优选为乙腈：水体积比为1:1.5。
本发明的另一方面，本发明还提供了一种如下式8e所述化合物的制备方法，
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用如下式8c所述化合物在碱性条件下脱除Fmoc保护基，得到式15b所述化合物；
在另一优选例中，所述惰性溶剂选自二氯甲烷、四氢呋喃、2-甲基四氢呋喃，或其组合；更优选地，所述惰性溶剂为二氯甲烷；
在另一优选例中，所述碱为有机碱；更优选地，所述碱为二甲胺，二乙胺，DBU，哌啶；更优选地，所述碱为DBU。
(2)在惰性溶剂中，用如下式15b所述化合物脱除苄基保护基，得到式8e所述化合物；
在另一优选例中，所述惰性溶剂选自四氢呋喃、水，或其组合；更优选地，所述惰性溶剂为水；更优选地，所述惰性溶剂为体积比为比1：5至5：1的四氢呋喃和水的组合。
在另一优选例中，所述脱保护在碱存在下进行；较佳地，所述碱为有机碱；更佳地，所述碱为DBU；
在另一优选例中，所述脱保护在还原剂存在下进行；更佳地，所述的还原剂为氢气H2；更佳地，所述脱保护在催化剂存在下进行；更佳地，所述催化剂为钯碳Pd/C；
本发明的另一方面，本发明还提供了一种如下式8c所述化合物的制备方法；
其特征在于，所述方法包括步骤：
在惰性溶剂中，用如式8b所述化合物与乙醇酸苄酯反应，得到式8c所述化合物；
在另一优选例中，所述惰性溶剂选自二氯甲烷、四氢呋喃、2-甲基四氢呋喃，二氧六环，或其组合；更优选地，所述惰性溶剂为四氢呋喃。
在另一优选例中，反应在酸或碱存在下进行；更优选地，所述酸为对甲苯磺酸、对甲苯磺酸一水合物；更优选地，所述碱为氢氧化锂、氢氧化锂一水合物、叔丁醇钾、叔丁醇钠、氢氧化钠；更优选地，所述碱为氢氧化锂；更优选地，所述碱为氢氧化锂一水合物；
本发明的另一方面，本发明还提供了一种如下式8b所述化合物的制备方法：
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用下式15a所述化合物与双甘肽反应，得到式8a所述化合物；
在另一优选例中，反应在碱存在下进行；更优选地，所述碱为碳酸氢钠；
在另一优选例中，所述惰性溶剂选自乙二醇二甲醚、水，或其组合；更优选地，所述惰性溶剂为乙二醇二甲醚和水的组合；更优选地，所述惰性溶剂为乙二醇二甲醚和水体积比为1:5至5:1 的组合；更优选地，所述惰性溶剂为乙二醇二甲醚和水体积比为1:2至2:1的组合；
(2)在惰性溶剂中，用下式8a所述化合物反应，得到式8b所述化合物；
在另一优选例中，所述惰性溶剂选自N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、HMPA；更优选地，所述惰性溶剂为N,N-二甲基甲酰胺。
在另一优选例中，反应在四乙酸铅存在下进行；
在另一优选例中，反应在乙酸铜存在下进行；
在另一优选例中，反应在乙酸存在下进行；
在另一优选例中，反应在乙酸、四乙酸铅、乙酸铜同时存在下进行；
在另一优选例中，反应在乙酸、四乙酸铅同时存在下进行；
本发明的另一方面，本发明还提供了一种如下式15f所述化合物的制备方法：
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用下式15c所述化合物与四氟苯酚发生缩合反应，得到式15d所述化合物；
在另一优选例中，所述惰性溶剂选自二氯甲烷、四氢呋喃、2-甲基四氢呋喃；更优选地，所述惰性溶剂为二氯甲烷；
在另一优选例中，反应在缩合剂存在下进行；更优选地，所述的缩合剂选自下组：HATU、HBTU、TBTU、EDCI、HOAt、HOBt、CDI、TCFH、TFFH、DCC、DIC、BOP、AOP、PyAOP、BrOP、PyClOP、PyBrOP、DMTMM，或其组合；更优选地，所述缩合剂为DCC。
(2)在惰性溶剂中，用下式15d所述化合物与双甘肽反应，得到式15e所述化合物；
在另一优选例中，所述惰性溶剂选自乙二醇二甲醚、水，或其组合；更优选地，所述惰性溶剂为乙二醇二甲醚和水的组合；更优选地，所述惰性溶剂为乙二醇二甲醚和水体积比为1:5至5:1的组合；更优选地，所述惰性溶剂为乙二醇二甲醚和水体积比为1:2至2:1的组合；
在另一优选例中，反应在无碱或者有碱参与下反应；更优选地，所述碱选自三乙胺，N,N-二异丙基乙胺，2,4,6-三甲基吡啶，DMAP，DBU，NMM，NaHCO3；更优选地，所述的碱为NaHCO3；
(3)在惰性溶剂中，用下式15e所述化合物与四氟苯酚发生缩合反应，得到式15f所述化合 物；
在另一优选例中，所述惰性溶剂选自二氯甲烷、四氢呋喃、2-甲基四氢呋喃；更优选地，所述惰性溶剂为二氯甲烷；
在另一优选例中，反应在缩合剂存在下进行；更优选地，所述的缩合剂选自下组：HATU、HBTU、TBTU、EDCI、HOAt、HOBt、CDI、TCFH、TFFH、DCC、DIC、BOP、AOP、PyAOP、BrOP、PyClOP、PyBrOP、DMTMM，或其组合；更优选地，所述缩合剂为DCC。
在另一优选例中，反应在有碱或无碱存在下进行；更优选地，所述反应无需碱的参与；
本发明的另一方面，本发明还提供了一种如下式15c所述化合物的制备方法：
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用下式4a所述化合物与硅基试剂反应，得到式4b所述化合物；
在另一优选例中，所述惰性溶剂选自组：乙腈、DMF、DMA、THF、二氯甲烷；更优选地，所述惰性溶剂为乙腈；
在另一优选例中，反应在碱存在下进行；更优选地，所述碱选自DBU、咪唑、DIPEA、TEA；更优选地，所述碱为DBU；
在另一优选例中，所述硅基试剂为TBSCl、TBSOTf；更优选地，所述硅基试剂为TBSCl；
(2)在惰性溶剂中，用下式4b所述化合物在碱存在下与N-甲氧基羰基顺丁烯二酰亚胺反应，得到15c所述化合物；
在另一优选例中，所述惰性溶剂选自组：水、THF、DMF，或其组合；更优选地，所述惰性四氢呋喃和水体积比为1:1的组合；
在另一优选例中，所述碱选自组：碳酸氢钠、碳酸钠、三乙胺、二异丙基乙胺；更优选地，所述碱为碳酸氢钠。
本发明的另一方面，本发明还提供了一种如下式1d所述化合物的制备方法，
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用下式14g所述化合物与14d所述化合物在添加剂存在下发生缩合环化反应，得到式14k所述化合物；
在另一优选例中，所述惰性溶剂优选自甲苯、乙酸、氯苯，或其组合；更优选地，所述惰性溶剂为甲苯和乙酸的组合；更优选地，所述惰性溶剂为甲苯和乙酸体积比为1:5至5:1的组合；更优选地，所述惰性溶剂为甲苯和乙酸体积比为1:2至2:1的组合；更优选地，所述惰性溶剂为甲苯和乙酸体积比为1:1的组合；
在另一优选例中，反应可以在添加剂存在下进行；更优选地，所述添加剂可以选自组对甲苯磺酸，对甲苯磺酸一水合物，对甲苯磺酸吡啶盐；更优选地，所述添加剂为对甲苯磺酸吡啶盐。
(2)在惰性溶剂中，用下式14k所述化合物在有机碱条件下脱Fmoc保护基，得到式1d和式1d’的混合物；
在另一优选例中，所述有机碱选自二级胺、三级胺；更优选地，所述有机碱选自哌啶、二甲胺、二乙胺，更优选地，所述有机碱为哌啶；
在另一优选例中，所述惰性溶剂选自四氢呋喃、2-甲基四氢呋喃；更优选地，所述惰性溶剂为四氢呋喃。
(3)对所得到的1d和1d’的混合物进行手性拆分，得到1d；
本发明的另一方面，本发明还提供了一种如下式14g所述化合物的制备方法，
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用如式14e所述化合物脱乙酰基保护，得到式14f所述化合物。
在另一优选例中，所述惰性溶剂选自无溶剂、水、四氢呋喃，或其组合；更优选地，所述惰性溶剂为水；更优选地，所述惰性溶剂为无溶剂；
在另一优选例中，反应在酸存在下进行；更优选地，所述酸为盐酸；更优选地，所述盐酸浓度为3-9N；更优选地，所述盐酸浓度为6N；
(2)在碱存在下，用如式14f所述化合物与FmocCl反应，得到式14g所述化合物；
在另一优选例中，所述碱选自有机碱和无机碱；更优选地，所述碱选自三乙胺、二异丙基乙胺、DBU、碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾；更优选地，所述碱为碳酸钾；
在另一优选例中，所述惰性溶剂选自乙腈、DMF、DMA、二氯甲烷、水、四氢呋喃，或其组合；更优选地，所述惰性溶剂为水和四氢呋喃体积比为1:5至5:1的组合；更优选地，所述惰性溶剂为水和四氢呋喃体积比为3:4的组合；
本发明的另一方面，本发明还提供了一种如下式14b所述化合物的制备方法，
其特征在于，所述方法包括步骤：
在碱存在下，在惰性溶剂中，用如式14a所述化合物与2种不同硅基试剂反应进行硅基保护，得到式14b所述化合物；
在另一优选例中，所述硅基试剂为TESCl、TESOTf、TIPSCl、TIPSOTf；更优选地，所述硅基试剂选自TESCl、TIPSCl；
在另一优选例中，所述惰性溶剂选自N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、HPMA、四氢呋喃、二氯甲烷；更优选地，所述惰性溶剂选自N,N-二甲基甲酰胺；
在另一优选例中，所述碱选自优选自TEA，DIPEA，NMM，吡啶，2,6-二甲基吡啶，2，4，6-三甲基吡啶，咪唑，DMAP；更优选地，所述碱为咪唑。
本发明的另一方面，本发明还提供了一种如下式14c所述化合物的制备方法，
其特征在于，所述方法包括步骤：
在惰性溶剂中，用如式14b所述化合物与劳森试剂反应，得到式14c所述化合物；
在另一优选例中，所述惰性溶剂选自四氢呋喃、二氧六环、2-甲基四氢呋喃、甲苯；更优选地，所述惰性溶剂为甲苯；
在另一优选例中，反应可以在有碱或者无碱存在下进行；所述碱优选自三乙胺，DIPEA，NMM，吡啶，2,6-二甲基吡啶，2,4,6-三甲基吡啶，DMAP，碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾，叔丁醇钾，叔丁醇钠；更优选地，所述碱选自碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾；更优选地，所述碱为碳酸钠。
本发明的另一方面，本发明还提供了一种如下式14d所述化合物的制备方法，
其特征在于，所述方法包括步骤：
在惰性溶剂中，用如式14c所述化合物经硅基脱除试剂作用下脱除TIPS和TES硅基保护基，得到式14d所述化合物。
在另一优选例中，所述硅基脱除试剂选自下组：酸、氟化试剂(含氟试剂)；更优选地，所述硅基脱除试剂选自甲酸，乙酸，三氟乙酸，甲磺酸，三氟甲磺酸，二氯乙酸，氟化氢、氟化氢水溶液、三乙胺三氢氟酸盐、氟化氢吡啶盐；更优选地，所述硅基脱除试剂为氟化氢水溶液。
在另一优选例中，所述惰性溶剂选自四氢呋喃、2-甲基四氢呋喃，甲苯；更优选地，所述惰性溶剂为四氢呋喃。
本发明的另一方面，提供了一种如下式7所示的分子的制备方法：
其特征在于，所述方法包括步骤：
在惰性溶剂中，用如下式7i所述化合物和下式1d所述化合物发生缩合反应，生成式7化合物：
在另一优选例中，所述的惰性溶剂选自下组：二氯甲烷、四氢呋喃、N,N-二甲基甲酰胺、N,N- 二甲基乙酰胺、HMPA，或其组合；优选为N,N-二甲基甲酰胺。
在另一优选例中，所述的缩合剂选自下组：HATU、HBTU、TBTU、EDCI、HOAt、HOBt、CDI、TCFH、TFFH、DCC、DIC、BOP、AOP、PyAOP、BrOP、PyClOP、PyBrOP、DMTMM。或其组合，优选为EDCI。
在另一优选例中，所述的碱选自下组：TEA，DIPEA，NMM，DBU，DMAP，吡啶，2,6-二甲基吡啶，2,4,6-三甲基吡啶，咪唑，N-甲基咪唑，或其组合，优选为2,4,6-三甲基吡啶。
本发明的另一方面，提供了一种如下式7i所示的分子的制备方法，
其特征在于，所述方法包括步骤：
在惰性溶剂中，用如下式14j所述化合物与下式8e所述化合物反应，得到式7i化合物；
在另一优选例中，所述的惰性溶剂选自下组：乙腈、水、四氢呋喃，2-甲基四氢呋喃，二氯甲烷，或其组合；进一步优选为四氢呋喃。
在另一优选例中，反应在无碱或者有碱参与下反应；优选地，所述碱选自三乙胺，N,N-二异丙基乙胺，2,6-二甲基吡啶，2,4,6-三甲基吡啶，DBU，NMM；更优选地，所述反应无需碱的参与；
本发明的另一方面，本发明还提供了一种如下式14j所示的分子的制备方法：
其特征在于，所述方法包括步骤：
(1)在惰性溶剂中，用下式7g所述化合物的与14h所述化合物发生缩合反应，得到式14i化合物；
在另一优选例中，所述的惰性溶剂选自下组：乙腈、水、四氢呋喃，2-甲基四氢呋喃，二氯甲烷，乙酸乙酯，或其组合；进一步优选为乙酸乙酯。
在另一优选例中，反应在无碱或者有碱参与下反应；优选地，所述碱选自三乙胺，N,N-二异丙基乙胺，2,6-二甲基吡啶，2,4,6-三甲基吡啶，DBU，NMM；更优选地，所述反应无需碱的参与；
(2)在惰性溶剂中，用下式14i所述化合物在酸性条件下脱叔丁基保护，得到式8g化合物；
在另一优选例中，所述的惰性溶剂选自下组：二氯甲烷、四氢呋喃、二氧六环、乙酸乙酯、 甲苯，或其组合；进一步优选为甲苯。
在另一优选例中，所述的酸选自下组：盐酸，硫酸，氯化氢乙酸乙酯溶液，氯化氢四氢呋喃溶液，氯化氢二氧六环溶液，三氟乙酸，三氟甲磺酸，甲磺酸，二氯乙酸；优选地，所述酸选自三氟乙酸；
(3)在惰性溶剂中，用下式8g所述化合物与五氟苯酚在缩合剂存在下发生缩合反应，得到式14j化合物；
在另一优选例中，所述的缩合剂选自下组：HATU、HBTU、TBTU、EDCI、HOAt、HOBt、CDI、TCFH、TFFH、DCC、DIC、BOP、AOP、PyAOP、BrOP、PyClOP、PyBrOP、DMTMM。或其组合，优选为EDCI。
所述的惰性溶剂选自下组：二氯甲烷、四氢呋喃、2-甲基四氢呋喃、甲苯，或其组合；进一步优选为二氯甲烷。
本发明的另一方面，提供了一种如下式14b所示化合物：
本发明的另一方面，提供了一种如下式14c所示化合物：
本发明的另一方面，提供了一种如下式14g所示化合物：
本发明的另一方面，提供了一种如下式14i所示化合物：
本发明的另一方面，提供了一种如下式14j所示化合物：
本发明的另一方面，提供了一种如下式14k所示化合物：
本发明的另一方面，提供了一种如下式15c所示化合物：
本发明的另一方面，提供了一种如下式15d所示化合物：
本发明的另一方面，提供了一种如下式15f所示化合物：
本发明的另一方面，提供了一种如下式15g所示化合物：
本发明的另一方面，提供了一种如下式7c所示化合物：
本发明的另一方面，提供了一种如下式7e所示化合物：
本发明的另一方面，提供了一种如下式7h所示化合物：
本发明的另一方面，提供了一种如下式8b所示化合物：
本发明的另一方面，提供了一种如下式8e所示化合物：
本发明的另一方面，提供了一种如下式8g所示化合物:
本发明的另一方面，提供了一种如下式9b所示化合物：
本发明的另一方面，提供了一种如下式9c所示化合物：
本发明的另一方面，提供了一种如下式9e所示化合物：
本发明的另一方面，提供了一种如下式9f所示化合物：
本发明的另一方面，提供了一种如下式9g所示化合物：
本发明的另一方面，提供了一种如下式9h所示化合物：
本发明的另一方面，提供了一种如下式9i所示化合物：
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
具体实施方式
本发明人基于长期而深入的研究，制备得到了一类结构新颖的配体偶联药物、适用于配体偶联物的药物分子(毒素)、适用于配体偶联物的连接体前体、适用于配体偶联物的配体偶联物前体，所述的药物稳定性更好、疗效好、安全性更高。基于上述发现，发明人完成了本发明。
术语
如本文所用，术语“烷基”包括直链或支链的烷基。例如C1-C8烷基表示具有1-8个碳原子的直链或支链的烷基，例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基等。
如本文所用，术语“烯基”包括直链或支链的烯基。例如C2-C6烯基指具有2-6个碳原子的直链或支链的烯基，例如乙烯基、烯丙基、1-丙烯基、异丙烯基、1-丁烯基、2-丁烯基、或类似基团。
如本文所用，术语“炔基”包括直链或支链的炔基。例如C2-C6炔基是指具有2-6个碳原子的直链或支链的炔基，例如乙炔基、丙炔基、丁炔基、或类似基团。
如本文所用，术语“C3-C10环烷基”指具有3-10个碳原子的环烷基。其可以是单环，例如环丙基、环丁基、环戊基、环己基、或类似基团。也可以是双环形式，例如桥环或螺环形式。
如本文所用，术语“C1-C8烷胺基”是指被C1-C8烷基所取代的胺基，可以是单取代或双取代的；例如，甲胺基、乙胺基、丙胺基、异丙胺基、丁胺基、异丁胺基、叔丁胺基、二甲胺基、二乙胺基、二丙胺基、二异丙胺基、二丁胺基、二异丁胺基、二叔丁胺基等。
如本文所用，术语“C1-C8烷氧基”是指具有1-8个碳原子的直链或支链的烷氧基；例如，甲氧基、 乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔丁氧基等。
如本文所用，术语“具有1-3个选自下组N、S和O的杂原子的3-10元杂环烷基”是指具有3-10个原子的且其中1-3个原子为选自下组N、S和O的杂原子的饱和或部分饱和的环状基团。其可以是单环，也可以是双环形式，例如桥环或螺环形式。具体的实例可以为氧杂环丁烷、氮杂环丁烷、四氢-2H-吡喃基、哌啶基、四氢呋喃基、吗啉基和吡咯烷基等。
如本文所用，术语“C6-C10芳基”是指具有6-10个碳原子的芳基，例如，苯基或萘基等类似基团。
如本文所用，术语“具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基”指具有5-10个原子的且其中1-3个原子为选自下组N、S和O的杂原子的环状芳香基团。其可以是单环，也可以是稠环形式。具体的实例可以为吡啶基、哒嗪基、嘧啶基、吡嗪基、三嗪基、吡咯基、吡唑基、咪唑基、(1,2,3)-三唑基以及(1,2,4)-三唑基、四唑基、呋喃基、噻吩基、异恶唑基、噻唑基、恶唑基等。
当未特别说明时，本文中的链状基团(如烷基、卤代烷基或氘代烷基)具有1-10个碳原子，优选具有1-6个碳原子，或1-4个碳原子；本文中的非芳香性环状基团(如环烷基、杂环烷基、脂环基、脂杂环基等)为3-12元，优选为3-8元，3-6元；本文中的芳香性环状基团(如芳基、杂芳基等)为5-15元，如6-10元芳基、5-7元杂芳基、5-10元杂芳基等。
本发明所述的基团除非特别说明是“取代的或未取代的”，否则本发明的基团均可被选自下组的取代基所取代：卤素、腈基、硝基、羟基、氨基、C1-C6烷基-胺基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、卤代C1-C6烷基、卤代C2-C6烯基、卤代C2-C6炔基、卤代C1-C6烷氧基、烯丙基、苄基、C6-C12芳基、C1-C6烷氧基-C1-C6烷基、C1-C6烷氧基-羰基、苯氧羰基、C2-C6炔基-羰基、C2-C6烯基-羰基、C3-C6环烷基-羰基、C1-C6烷基-磺酰基等。
如本文所用，“卤素”或“卤原子”指F、Cl、Br、和I。更佳地，卤素或卤原子选自F、Cl和Br。“卤代的”是指被选自F、Cl、Br、和I的原子所取代。
除非特别说明，本发明所描述的结构式意在包括所有的同分异构形式(如对映异构，非对映异构和几何异构体(或构象异构体))：例如含有不对称中心的R、S构型，双键的(Z)、(E)异构体等。因此，本发明化合物的单个立体化学异构体或其对映异构体、非对映异构体或几何异构体(或构象异构体)的混合物都属于本发明的范围。
如本文所用，术语“互变异构体”表示具有不同能量的结构同分异构体可以超过低能垒，从而互相转化。比如，质子互变异构体(即质子移变)包括通过质子迁移进行互变，如1H-吲唑与2H-吲唑。化合价互变异构体包括通过一些成键电子重组而进行互变。
如本文所用，术语“水合物”是指本发明化合物与水进行配位形成的配合物。
本申请的化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、具体实施方式与其他化学合成方法的结合所形成的实施方式、以及本领域技术人员所熟知的等同替换方式，优选的实施方式包括但不限于本申请的实施例。
本申请所使用的溶剂可以经市售获得，化合物经人工或者软件命名，市售化合物采用供应商目录名称。
在本申请中，术语“配体”通常指能识别和结合目标细胞相关的抗原或受体的大分子化合物。配体的作用可以是将药物呈递给与配体结合的目标细胞群，这些配体包括但不限于蛋白类激素、凝集素、生长因子、抗体或其他能与细胞、受体和/或抗原结合的分子。在本申请中，配体可以表示为Ab，配体抗原通过配体上的杂原子与连接单元形成连接键，可以为抗体或其抗原结合片段，所述抗体可以选自嵌合抗体、人源化抗体、全人抗体或鼠源抗体；所述抗体可以是单克隆抗体。例如所述抗体可以是，靶向选自以下组的靶点的抗体或其抗原结合片段：HER2、TROP2、PSMA、FR-α或B7H3和IGF-1R。
在本申请中，术语“Trop2”、“TROP2”通常是指单程跨膜I型细胞膜蛋白。在本申请中，术语“Trop2”还可涵盖Trop 2的同源物、变体和同工型，包括剪接同工型。术语“Trop”还包括具有Trop 2同源物、变体和同工型中的一个或多个序列的蛋白，以及该序列的片段，只要是该变体蛋白(包括同工型)。Trop2可以是人Trop2。例如，Uniprot登录号P09758提供了Trop2和序列的描述。
在本申请中，术语“HER2”通常是指人表皮生长因子受体2(HER2)。例如，术语“HER2”指来自任何人来源的任何天然HER2。该术语还涵盖“全长”和未加工的HER2以及源自细胞中加工的任何形式的HER2(例如成熟蛋白)。该术语还涵盖HER2的天然发生变体和同等型，例如剪接变体或等位变体。例如，Uniprot登录号P04626提供了HER2和序列的描述。
在本申请中，术语“PSMA”指谷氨酸羧基肽酶II。在本申请中，术语“PSMA”还可涵盖PSMA的同源物、变体和同工型。术语“PSMA”还包括具有各种不同来源(如人源)的PSMA同源物、 变体和同工型中的一个或多个序列的蛋白，以及该序列的片段。例如，Uniprot登录号Q04609提供了PSMA和序列的描述。
在本申请中，术语“FR-α”指叶酸受体α，由FOLR1编码。在本申请中，术语“FR-α”还可涵盖FR-α的同源物、变体和同工型。术语“FR-α”还包括具有各种不同来源(如人源)的FR-α同源物、变体和同工型中的一个或多个序列的蛋白，以及该序列的片段。例如，Uniprot登录号P15328提供了FR-α和序列的描述。
在本申请中，术语“B7H3”指CD276。在本申请中，术语“B7H3”可以涵盖其任意同源物、变体和同工型，也可以包括其在人类中可能的任意表达形式(如2Ig和4Ig)。术语“B7H3”还包括具有各种不同来源(如人源)的B7H3同源物、变体和同工型中的一个或多个序列的蛋白，以及该序列的片段。例如，Uniprot登录号Q5ZPR3提供了B7H3(CD276)和序列的描述。
在本申请中，术语“IGF-1R”指胰岛素样生长因子I受体。在本申请中，术语“IGF-1R”还可涵盖其同源物、变体和同工型。术语“IGF-1R”还包括具有各种不同来源(如人源)的IGF-1R同源物、变体和同工型中的一个或多个序列的蛋白，以及该序列的片段。例如，Uniprot登录号P08069提供了IGF-1R和序列的描述。
在本申请中，术语“肽残基”通常是指包含一个或多个氨基酸残基连接而成的残基。例如，多肽残基中的一个或多个氨基酸可以是任选取代的。例如，本申请的多肽残基可以包含甘氨酸-甘氨酸-苯丙氨酸-甘氨酸(Gly-Gly-Phe-Gly)。
在本申请中，术语“药物单元”通常是指直接或间接缀合抗体或抗原结合片段以形成免疫缀合物的化学部分。例如，“药物单元”包括但不限于文中描述的抗肿瘤活性的化合物。例如药物单元包括拓扑异构酶抑制剂。
在本申请中，术语“抗肿瘤活性的化合物”通常是指具有使肿瘤细胞的增殖速率、存活力或转移活性的降低的能力的化合物。例如，抗肿瘤活性可以由治疗期间出现的异常细胞的生长速率减少或肿瘤尺寸稳定或缩减显示的，或与在无治疗情况下对照相比因治疗所致的存活期更长显示的。抗肿瘤活性可使用公认的体外或体内肿瘤模型评估，例如异种移植模型。
在本申请中，术语“包含”通常是指包括明确指定的特征，但不排除其他要素。术语“以上”、“以下”通常是指包含本数的情况。
在本申请中，术语“约”通常是指在指定数值以上或以下0.5％-10％的范围内变动，例如在指定数值以上或以下0.5％、1％、1.5％、2％、2.5％、3％、3.5％、4％、4.5％、5％、5.5％、6％、6.5％、7％、7.5％、8％、8.5％、9％、9.5％、或10％的范围内变动。
在本申请中，本申请的化合物包含化合物的其互变异构体、内消旋体、外消旋体、对映异构体、和/或非对映异构体。
在本申请中，本申请的化合物的某些原子可能以一种以上的同位素形式出现。例如，氢可能以氕(1H)、氘(2H)和氚(3H)的形式存在，碳可能以三种不同的同位素(12C、13C和14C)自然存在。可并入本申请化合物中的同位素示例还包括但不限于15N、18O、17O、18F、32P、33P、129I、131I、123I、124I、125I，或者类似的同位素。因此，相对于这些同位素的自然丰度，本申请的化合物可以是一种或多种这些同位素富集的形式。如本领域技术人员所知，此类同位素富集化合物可用于多种用途。例如，用重同位素如氘(2H)替代可能会提供某些治疗优势，这可以是由于更高的代谢稳定性。
在本申请中，术语“药物组合物”通常是指含有一种或多种本申请所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物，以及其他组分例如生理学/可药用的载体和赋形剂。药物组合物可以是促进对生物体的给药，利于活性成分的吸收进而发挥生物活性。常规的药物组合物的制备可以见本领域常用技术。
在本申请中，术语“药学上可接受的盐”或“可药用的盐”通常是指本申请化合物或配体-药物偶联物的盐，或本申请中所述的化合物的盐，这类盐用于哺乳动物体内时可以具有安全性和/或有效性，且可以具有应有的生物活性，本申请抗体-抗体药物偶联化合物可以与酸形成盐，药学上可接受的盐的非限制性实例包括：盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、硫酸氢盐、柠檬酸盐、乙酸盐、琥珀酸盐、抗坏血酸盐、草酸盐、硝酸盐、梨酸盐、磷酸氢盐、磷酸二氢盐、水杨酸盐、柠檬酸氢盐、酒石酸盐、马来酸盐、富马酸盐、甲酸盐、苯甲酸盐、甲磺酸盐、乙磺酸盐、苯磺酸盐、或对甲苯磺酸盐。
在本申请中，术语“偶联物”通常是指本申请的化合物通过一个或多个化学反应而制备的化合物，或者通过诸如桥接(bridge)，间隔物(spacer)，或连接部分等的一个或多个连接结构彼此连接。
在本申请中，术语“药学上可接受的载体”通常是指给予治疗剂，例如抗体或多肽、基因和其它治疗剂的载体。该术语指本身不诱导对接受组合物的个体有害的抗体产生并且可以给予而不产生过度毒性的任何药物载体。例如，药学上可接受的载体(carrier)可以与基因工程中用于包含目标基因的核酸载体(vector)相区分。合适的载体可以是大的、代谢缓慢的大分子，例如蛋白质、多糖、聚乳酸、聚乙醇酸、多聚氨基酸、氨基酸共聚物、脂质聚集物和灭活的病毒颗粒。本领域技术人员熟知这些载体。治疗组合物中药学上可接受的载体可包括液体，例如水、盐水、甘油和乙醇。这些载体中也可存在辅助物质，例如润湿剂或乳化剂、pH缓冲物质等。
在本申请中，“抗体”通常可以覆盖单克隆抗体、多克隆抗体、二聚体、多聚体、多特异性抗体(例如双特异性抗体)和抗体片段，只要它们表现出所需的生物活性。抗体可以为鼠、人、人源化、嵌合的抗体或来源于其它物种。抗体为由能够识别和结合特异性抗原的免疫系统产生的蛋白质。靶抗原一般具有由多种抗体的CDRs识别的大量结合位点，也称作表位。特异性结合不同表位的各抗体具有不同的结构。因此，一种抗原可以具有一种以上相应的抗体。抗体包括全-长免疫球蛋白分子或全-长免疫球蛋白分子的免疫活性部分，即含有特异性结合所关注靶标的抗原或其部分的分子，这类靶标包括，但不限于癌细胞或产生与自身免疫性疾病相关的自身免疫抗体的细胞。本申请描述的免疫球蛋白可以具有免疫球蛋白分子的任意类型(例如IgG、IgE、IgM、IgD和IgA)、类别(例如IgG1、IgG2、IgG3、IgG4、IgA1和IgA2，或其任意突变)或亚类。免疫球蛋白可以来源于任意的物种。然而，在一个方面中，免疫球蛋白来源于人、鼠或兔。“抗体片段”可以包含全长抗体的一部分，一般为其抗原结合区或可变区。抗体片段的实例包括：Fab、Fab’、F(ab’)2和Fv片段；双抗体；线性抗体；微抗体(minibody)；Fab表达文库制备的片段；抗-独特型(抗-Id)抗体；CDR(互补决定区)；和以免疫特异性方式结合癌细胞抗原、病毒抗原或微生物抗原的上述任意的表位-结合片段；单链抗体分子；和由抗体片段形成的多特异性抗体。本申请中组成抗体药物偶联物的抗体可以保持其原有野生状态时的抗原结合能力。因此，本申请中的抗体可以，例如可以专一性地，与抗原结合。涉及的抗原包括，例如，肿瘤相关抗原(TAA)，细胞表面受体蛋白和其他细胞表面分子，细胞存活调节因子，细胞增殖调节因子，与组织生长与分化相关的分子(如已知或预知的具有功能性的)，淋巴因子，细胞因子，参与细胞循环调节的分子，参与血管生成的分子，以及与血管生成有关的分子(如已知抗体结合的抗原可以是上述分类中一个或一个子集，而其它的子集则包含其它的具有特殊性质的分子/抗原(与目标抗原相比)。应用在抗体药物偶联物中的抗体包括，但不局限于，针对细胞表面受体和肿瘤相关抗原的抗体。这样的肿瘤相关抗原是业内所熟知的，可以通过业内熟知的抗体制备方法和信息来制备。这些目标物能够特异性地表达在一种或多种癌症细胞表面，而在一种或多种非癌细胞表面表达很少或不表达。通常，相对于非癌细胞表面而言,这样的肿瘤相关多肽在癌细胞表面可以更加过度表达。
在本申请中，术语“嵌合抗体(chimeric antibody)”通常是指鼠源性抗体的可变区与人抗体的恒定区融合而成的抗体，可以减轻鼠源性抗体诱发的免疫应答反应。建立嵌合抗体，可以建立分泌鼠源性特异性单抗的杂交瘤，然后从鼠杂交瘤细胞中克隆可变区基因，可以根据需要克隆人抗体的恒定区基因，将鼠可变区基因与人恒定区基因连接成嵌合基因后插入表达载体中，可以在真核系统或原核系统中表达嵌合抗体分子。
在本申请中，术语“人源化抗体(humanized antibody)”，也称为CDR移植抗体(CDR-grafted antibody)，通常是指将鼠的CDR序列移植到人的抗体可变区框架，即不同类型的人种系抗体框架序列中产生的抗体。可以克服嵌合抗体由于携带大量鼠蛋白成分，从而诱导的异源性反应。此类构架序列可以从包括种系抗体基因序列的公共DNA数据库或公开的参考文献获得。如人重链和轻链可变区基因的种系DNA序列可以在“VBase”人种系序列数据库。
在本申请中，术语“全人源抗体”、“全人抗体”或“完全人源抗体”，也称“全人源单克隆抗体”，其抗体的可变区和恒定区可以都是人源的，去除免疫原性和毒副作用。单克隆抗体的发展经历了四个阶段，分别为：鼠源性单克隆抗体、嵌合性单克隆抗体、人源化单克隆抗体和全人源单克隆抗体。本申请所述抗体或配体可以为全人源单克隆抗体。全人抗体制备的相关技术可以为：人杂交瘤技术、EBV转化B淋巴细胞技术、噬菌体显示技术(phage display)、转基因小鼠抗体制备技术(transgenic mouse)和单个B细胞抗体制备技术等。
在本申请中，术语“CDR”通常是指抗体的可变结构域内主要促成抗原结合的6个高变区之一。所述6个CDR的最常用的定义之一由Kabat E.A.等人，或Chothia等人和MacCallum等人提供。如本申请中使用的，CDR的Kabat定义可以应用于轻链可变结构域的CDR1、CDR2和CDR3(LCDR1、LCDR 2、LCDR 3或L1、L2、L3)，以及重链可变结构域的CDR1、CDR2和CDR3(HCDR 1、HCDR 2、HCDR 3或H1、H2、H3)。
在本申请中，术语“能够与巯基偶联的基团”通常是指所述化合物A具有巯基，所述化合物B具有能够与巯基偶联的基团，化合物B通过能够与巯基偶联的基团与化合物A的巯基反应，可以以此实现化合物A与化合物B的连接。
在本申请中，术语“连接体”通常是指一端与一个基团连接而另一端与另一个基团相连的化学结构片段或键，也可以连接其他连接体后再与药物和/或配体相连。所述直接或间接连接配体可以是指所述基团通过共价键直接连接配体，也可以是通过连接体连接配体。例如，连接体可以是本申请所述连接体的所示的结构。例如，可以使用包含酸不稳定接头结构(例如腙)、蛋白酶敏感(例如肽酶敏感)接头结构、光不稳定接头结构、二甲基接头结构、或含二硫化物接头结构的化学结构片段或键作为连接体。
在本申请中，术语“连接基团”通常是指具有与另一个基团相连的能力的基团。例如，具有连接基团的化合物，可以通过该连接基团与另一个基团的偶联反应，实现该化合物与另一个基团的连接。例如，马来酰亚胺基团可以作为连接基团。
在本申请中，术语与某靶点“表达相关”的疾病通常是指该疾病的发生和/或进展与该靶点的表达水平有关联。例如，相对于来自组织或器官的正常细胞的表达水平，来自疾病区如患者的特定组织或器官内的细胞中某个靶点的表达水平提高，即高表达的。或者例如，相对于来自组织或器官的正常细胞的表达水平，来自疾病区如患者的特定组织或器官内的细胞中某个靶点的表达水平降低，即低表达的。或者例如，来自疾病区如患者的特定组织或器官内的细胞表达某个靶点，即阳性的。或者例如，来自疾病区如患者的特定组织或器官内的细胞不表达某个靶点，即阴性的。例如，靶点表达的特征可以由本领域已知的标准测定确定。
在本申请中，术语“有效量”通常是指治疗剂治疗、缓解或预防目标疾病或状况的量，或是表现出可检测的治疗或预防效果的量。对于某一对象的精确有效量取决于该对象的体型和健康状况、病症的性质和程度、以及选择给予的治疗剂和/或治疗剂的组合。因此，预先指定准确的有效量是没用的。然而，对于某给定的状况而言，可以用常规实验来确定该有效量，临床医师是能够判断出来的。
除非特别说明，本申请中，所有出现的化合物均意在包括所有可能的光学异构体，如单一手性的化合物，或各种不同手性化合物的混合物(即外消旋体)。本申请的所有化合物之中，各手性碳原子可以任选地为R构型或S构型，或R构型和S构型的混合物。
在本申请中，术语“本申请化合物”通常是指指本申请的化合物。该术语还包括本申请化合物的各种晶型形式、药学上可接受的盐、水合物或溶剂合物。
当本文中使用商品名时，该商品名意在包括商品名产品制剂、其相应的仿制药，以及商品名产品的活性药物组分。
药物组合物和施用方法
由于本发明化合物具有优异的肿瘤细胞增殖的抑制活性，因此本发明化合物及其各种晶型，药学上可接受的无机或有机盐，水合物或溶剂合物，以及含有本发明化合物为主要活性成分的药物组合物可用于预防和/或治疗(稳定、减轻或治愈)治疗与肿瘤细胞增殖相关的疾病。
本发明的药物组合物包含安全有效量范围内的本发明化合物及药学上可以接受的赋形剂或载体。其中“安全有效量”指的是：化合物的量足以明显改善病情，而不至于产生严重的副作用。通常，药物组合物含有1-2000mg本发明化合物/剂，更佳地，含有1-200mg本发明化合物/剂。较佳地，所述的“一剂”为一个胶囊或药片，或者为单位剂量的注射制剂。
“药学上可接受的载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合于人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明化合物以及它们之间相互掺和，而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制，代表性的施用方式包括(但并不限于)：口服、肠胃外(静脉内、肌肉内或皮下)。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中，活性化合物与至少一种常规惰性赋形剂(或载体)混合，如柠檬酸钠或磷酸二钙，或与下述成分混合：(a)填料或增容剂，例如，淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；(b)粘合剂，例如，羟甲基纤维素、藻 酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；(c)保湿剂，例如，甘油；(d)崩解剂，例如，琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠；(e)缓溶剂，例如石蜡；(f)吸收加速剂，例如，季胺化合物；(g)润湿剂，例如鲸蜡醇和单硬脂酸甘油酯；(h)吸附剂，例如，高岭土；和(i)润滑剂，例如，滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠，或其混合物。胶囊剂、片剂和丸剂中，剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备，如肠衣和其它本领域公知的材料。它们可包含不透明剂，并且，这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时，活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，例知，乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外，悬浮液可包含悬浮剂，例如，乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液，和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
本发明化合物可以单独给药，或者与其他药学上可接受的治疗剂联合给药。
联合给药时，所述药物组合物还包括与一种或多种(2种，3种，4种，或更多种)其他药学上可接受的治疗剂。该其他药学上可接受的治疗剂中的一种或多种(2种，3种，4种，或更多种)可与本发明的化合物同时、分开或顺序地用于预防和/或治疗肿瘤细胞增殖相关的疾病。
使用药物组合物时，是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人)，其中施用时剂量为药学上认为的有效给药剂量，对于60kg体重的人而言，日给药剂量通常为1～2000mg，优选1～500mg。当然，具体剂量还应考虑给药途径、病人健康状况等因素，这些都是熟练医师技能范围之内的。
一种毒素分子中间体的制备工艺
本发明中，还提供了一种毒素分子1d的合成中间体14d(WO 2022262789 A1中化合物1k)的全新制备工艺，其具体的制备工艺如上文中所述。现有技术中公开的合成路线(WO 2022262789 A1)如下：
相比于上式现有技术，本发明的制备工艺使用TIPS硅基保护基替换现有技术中的2个TES硅基保护基中1个，主要优势体现在：
1、本申请合成路线中间体14b和14c相比于上式现有技术中间体1i和1j稳定性更好，易于放大生产、长期保存；
2、本申请合成路线中间体14b和14c实现均可以分离纯化，易于质量控制。而上式现有技术中间体1i和1j均以粗品用于下一步反应。
3、本申请合成路线收率相较于上式现有技术(WO 2022262789 A1)中的收率从49％提高至73％。
一种毒素分子的制备工艺
本发明还提供了一种毒素分子1d(WO 2022262789 A1中化合物1n-P1)的新制备工艺，在现有 技术中的合成路线(WO 2022262789 A1)如下：
相比于上式现有技术，本发明的制备工艺使用Fmoc保护基替换现有技术中乙酰基Ac保护基，主要优势体现在：
1、本申请合成路线中将上式现有技术合成路线中1l的乙酰基保护基替换为Fmoc保护基，得到化合物14g，使化合物1d(WO 2022262789 A1中化合物1n-P1)的合成收率，从7.9％提高到15.6％；
2、上式现有技术(WO 2022262789 A1)合成路线中化合物1m的脱乙酰基保护基步骤，反应条件剧烈，重复性差，放大保护基脱除不完全；本申请方法14k脱除Fmoc保护基步骤反应条件更为温和，更适合放大生产。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
缩写定义


实施例
实施例1.1
第一步
将化合物1b(342mg,0.81mmol)与1a(500mg,0.85mmol)溶于乙腈(3.42mL)和水(6.84mL)的混合溶剂中，混合体系冷却至0℃，搅拌下逐滴加入N,N-二异丙基乙胺(83mg,0.64mmol)，加毕继续搅拌反应3h。反应液直接用制备色谱分离纯化得1c(283mg)，收率：39％。
MS-ESI计算值[M+Na]+＝1020，实测值为1020。
第二步
将化合物1c(85mg,0.19mmol)溶于N,N-二甲基甲酰胺(1.70mL)中，加入三氟乙酸(22mg,0.19mmol)，混合体系冷却至0℃，依次加入1d(226mg,0.23mmol)，1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(72mg,0.38mmol)和2,4,6-三甲基吡啶(23mg,0.19mmol)，加料完全后反应体系保持0℃～10℃继续搅拌反应1h。反应液用HClaq(0.05M)调至pH至6～7后用制备液相分离纯化得化合物1(134mg)，收率：49％。
1H NMR(400MHz,DMSO-d6)δ8.66(t,J＝6.4Hz,1H),8.60(d,J＝8.8Hz,1H),8.28(t,J＝6.0Hz,1H),8.15(t,J＝5.6Hz,1H),8.09(d,J＝8.0Hz,1H),8.04-7.95(m,2H),7.84-7.77(m,2H),7.28-7.14(m,5H),6.99(s,2H),6.69(s,1H),5.91(d,J＝16.8Hz,1H),5.70-5.62(m,1H),5.56-5.45(m,2H),5.35(d,J＝18.8Hz,1H),4.68(d,J＝6.8Hz,2H),4.51-4.42(m,1H),4.17-4.04(m,2H),3.80-3.55(m,12H),3.55-3.42(m,32H),3.17-3.10(m,2H),3.06-2.98(m,1H),2.80-2.71(m,1H),2.41-2.28(m,7H),2.27-2.15(m,2H),1.94-1.82(m,2H),0.86(t,J＝7.2Hz,3H).
实施例1.2
第一步
将2a(14.72g,150.16mmol)溶于丙酮(118mL)中，冰浴下加入2b(20.00g,150.16mmol)，混合体系搅拌5min后TLC监测反应完全。反应液浓缩得固体粗产品。粗产品用醋酸酐(28mL)溶解，加入乙酸钠(24.63g,300.32mmol)，反应体系升温至90℃回流反应2h。反应液过滤除去不溶性固体，滤饼用甲苯淋洗，滤液减压浓缩得粗品，粗品经硅胶柱层析(EA：Hexanes＝0-100％)分离得2c(17.43g)，收率：43％。
MS-ESI计算值[M+Na]+＝236，实测值为236。
第二步
将2c(12.95g,60.74mmol)与2d(9.00g,60.74mmol)溶于甲苯(180mL)中，加入对甲苯磺酸(2.10g,12.15mmol)，混合体系升温至90℃回流反应2h。反应液冷却至室温，减压浓缩得残余物，残余物溶解在乙酸乙酯中，有机相依次用饱和碳酸氢钠和饱和食盐水(200mL x 1)洗，无水硫酸钠干燥，过滤，滤液减压浓缩得粗品，粗品经硅胶柱层析(EA：Hexanes＝0-100％)分离得2e(5.53g)，收率：33％。
MS-ESI计算值[M+H]+＝270，实测值为270。
第三步
将2e(3.87g,14.37mmol)溶解于THF(77.4mL)中，将氢氧化锂(1.37g,57.49mmol)溶于H2O(38.7mL)中并加入上述溶液中，混合体系室温下搅拌反应30min。反应液加入乙酸乙酯(15mL)，用HClaq(1N)调节pH至2左右，水相用乙酸乙酯(38mL x 3)萃取，合并有机相，有机相经饱和食盐水(15mL)后用无水硫酸钠干燥，过滤，滤液减压浓缩得粗产品2f(3.06g)。
MS-ESI计算值[M+H]+＝260，实测值为260。
第四步
将N-羟基丁二酰亚胺(6.49g,56.37mmol)溶于N,N-二甲基甲酰胺(36.5mL)中，冰浴下滴加三氟乙酸酐(11.84g,56.37mmol)，搅拌30min后滴加2,4,6-三甲基吡啶(6.83g,56.37mmol)，加料完全后混合体系继续搅拌40min，反应液记为A，待用。将粗产品2f(3.06g)溶于N,N-二甲基甲酰胺(36.5mL)中，冰浴下滴加2,4,6-三甲基吡啶(3.41g,28.15mmol)，保持冰浴下搅拌30min后逐滴加入上述A反应液，反应体系自然升温至室温下搅拌反应24h。向反应液中加入二氯甲烷(180mL)，加入HClaq(0.7N,140mL)后继续搅拌30min，分液，水相用二氯甲烷(70mL)萃取，合并有机相，有机相经水洗至pH＝5～7，饱和食盐水洗1次，无水硫酸钠干燥，过滤，滤液减压浓缩得粗品，粗品经硅胶柱层析(EA：Hexanes＝0-100％)分离得2g(3.54g)，收率：78％。
MS-ESI计算值[M+H]+＝339，实测值为339。
1H NMR(400MHz,CDCl3)δ6.77(s,2H),4.79(t,J＝4.8Hz,1H),4.49-4.40(m,2H),3.91(t,J＝11.6Hz,2H),3.79-3.70(m,2H),3.45-3.34(m,1H),2.86(s,4H).
第五步
将2h(850mg,3.38mmol)与2g(1.20g,3.55mmol)溶于N,N-二甲基甲酰胺(8.5mL)中，冰浴下逐滴加入N,N-二异丙基乙胺(437mg,3.38mmol)，混合体系继续控温0℃～10℃搅拌反应2h。反应液经制备液相分离纯化得2i(740mg),收率：46％。
MS-ESI计算值[M+H]+475，实测值为475。
第六步
将2j(10.00g,13.59mmol)溶于THF(450mL)中，加入湿Pd/C(2g,20％w/w)，混合体系氢气氛下搅拌反应66h。反应液过滤，用DCM/MeOH混合溶剂淋洗滤饼，滤液经无水硫酸钠干燥，过滤，浓缩得粗产品。粗产品经硅胶柱层析(MeOH：DCM＝0-100％)分离得2k(6.10g)，收率：69％。
MS-ESI计算值[M+H]+＝668，实测值为668。
第七步
氮气氛下，将1d(2.70g,5.97mmol)和三氟乙酸(680mg,5.97mmol)溶于N,N-二甲基甲酰胺(54mL)中，冰浴下搅拌10min，然后向反应液中加入2k(5.40g,8.36mmol)，1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(2.30g,11.94mmol)和2,4,6-三甲基吡啶(722mg,5.97mmol)，继续控温0℃～10℃搅拌反应2h。冰浴下向反应液中滴加HClaq(0.05N,54mL)，有固体析出，2-甲基四氢呋喃(100mL)稀释悬浊液，搅拌至溶解后分液，水相用2-甲基四氢呋喃(100mL x 2)萃取，合并有机相，有机相用饱和食盐水(50mL x 1)洗，无水硫酸钠干燥后过滤，滤液减压浓缩得粗品。粗品经硅胶柱层析(MeOH：DCM＝0-100％)分离得2l(6.00g)，收率：84％。
MS-ESI计算值[M+H]+＝1079，实测值为1079。
第八步
将2l(6.00g,5.56mmol)溶于DCM/MeOH(120mL/12mL)的混合溶剂中，冰浴下逐滴加入二乙胺(24mL)，加料完全后自然升温至室温下搅拌反应4h。将反应液直接浓缩得褐色固体粗品，加入甲基叔丁基醚打浆，过滤，滤饼用甲基叔丁基醚淋洗3次，滤液浓缩得黄色固体粗品。取1g粗产品经制备液相分离得到2m(150mg),剩余粗品经硅胶柱层析(MeOH：DCM＝0-100％)分离得2m(800mg)，合并收率：59％。
MS-ESI计算值[M+H]+＝857，实测值为857。
第九步
将2i(74mg,0.16mmol)溶于N,N-二甲基甲酰胺(1.30mL)中，氮气置换3次，冰浴下加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(88mg,0.23mmol)，搅拌10min后加入2m(132mg,0.16mmol)，搅拌至溶解后加入2,4,6-三甲基吡啶(54mg,0.45mmol)，继续控温0℃～10℃反应2h。将反应液用HClaq(0.05N)调节pH＝6～7，制备液相分离纯化得2(71mg)，收率：34％。
MS-ESI计算值[M+H]+＝1313，实测值为1313。
实施例1.3
第一步
氮气氛下，将3a(5.00g,26.74mmol)溶于N,N-二甲基甲酰胺(50mL)中，降温至0～5℃后加入NaH(1.28g,32.09mmol),搅拌10min后加入溴乙酸叔丁酯(6.23g,32.09mmol)，混合体系保持0～5℃搅拌反应2h。向反应液中加入水(200mL)，水相用乙酸乙酯(200mL)萃取，有机相用饱和食盐水(200mL x 2)洗后经无水硫酸钠干燥，过滤，滤液减压浓缩得3b(4.60g)，收率：43％。
MS-ESI计算值[M+H]+＝302,304，实测值为302,304。
1H NMR(400MHz,CDCl3)δ8.60(d,J＝2.0Hz,1H),7.84(dd,J＝8.4,2.4Hz,1H),7.45(d,J＝8.4Hz,1H),4.69(s,2H),4.10(s,2H),1.49(s,9H).
第二步
氮气氛下，将3b(5.00g,16.60mmol)，3c(3.61g,19.93mmol)，Pd2(dba)3(0.76g,0.83mmol)，BINAP(1.03g,1.66mmol)，碳酸铯(13.53g,41.52mmol)溶于无水甲苯(50mL)中，混合体系升温至内温80℃搅拌反应16h。反应液过滤，滤液减压浓缩得粗产品，粗产品经硅胶柱层析(EA：hexanes＝0-100％)分离得3d(4.50g)，收率：67％。
MS-ESI计算值[M+H]+＝403，实测值为403。
第三步
将3d(2.81g,6.98mmol)溶于THF(28mL)和HClaq(1N,28mL)混合溶剂中，混合体系室温下搅拌反应3h。向反应液中加入水(100mL)，水相用乙酸乙酯(100mL x 2)洗，弃去有机相。水相用氨水调pH＝8-9后用乙酸乙酯(100mL x 2)萃取，合并有机相，无水硫酸钠干燥，过滤，滤液减压浓缩得3e(1.43g)，收率：86％。
MS-ESI计算值[M+H]+＝239，实测值为239。
第四步
将3e(1.83g,7.68mmol)，马来酸酐(0.75g,7.68mmol)溶于乙腈(18.3mL)中，室温下搅拌反应2h。反应液直接旋干得2.45g白色固体中间体。将2.45g白色固体中间体加入到反应瓶中，依次加入乙酸酐(5mL),乙酸钠(2.09g,15.36mmol),混合体系室温下搅拌反应2h。向反应液中加入水(50mL)，水相用乙酸乙酯(50mL)萃取，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得残余物，残余物经硅胶柱层析(EA：hexanes＝0-100％)分离得3f(1.97g)，收率：80％。
MS-ESI计算值[M+H]+＝319，实测值为319。
1H NMR(400MHz,DMSO-d6)δ8.51(d,J＝2.0Hz,1H),7.83(dd,J＝8.4,2.4Hz,1H),7.6(d,J＝8.4Hz,1H),7.24(s,2H),4.67(s,2H),4.15(s,2H),1.44(s,9H).
第五步
将3f(0.90g,2.83mmol)溶于二氯甲烷(9mL)中，加入三氟乙酸(1.8mL),室温下搅拌反应5h。将反应液直接旋干，二氯甲烷(45mL x 5)带蒸，油泵浓缩至无明显油状物，得粗产物3g(0.93g)。
MS-ESI计算值[M+H]+＝263，实测值为263。
第六步
向反应瓶内依次加入3g(0.06g)，2m(0.20g,0.23mmol)和N,N-二甲基甲酰胺(4mL),搅拌溶解后置于冰浴中，加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(0.13g,0.35mmol)和2,4,6-三甲基吡啶(0.26g,2.15mmol)，混合体系保持0～5℃下搅拌反应1h。反应液用HClaq(0.5N)调节pH＝4-5后送制备液相中性纯水体系制备分离得3(70mg)，收率：27％。
MS-ESI计算值[M+H]+＝1101，实测值为1101。
1H NMR(400MHz,DMSO-d6)δ8.65(t,J＝6.8Hz,1H),8.60(d,J＝8.8Hz,1H),8.34-8.24(m,2H),8.09(d,J＝8.0Hz,1H),7.99(t,J＝5.6Hz,1H),7.81(d,J＝11.2Hz,1H),7.79(s,1H),7.30-7.14(m,5H),7.04(s,2H),6.68(s,1H),5.91(d,J＝16.8Hz,1H),5.70-5.61(m,1H),5.56-5.45(m,2H),5.36(d,J＝19.6Hz,1H),5.05(t,J＝6.0Hz,1H),4.68(d,J＝6.4Hz,2H),4.59(dd,J＝9.2,6.0Hz,1H),4.52-4.42(m,1H),4.17-4.05(m,2H),4.00-3.92(m,1H),3.89-3.79(m,1H),3.78-3.68(m,5H),3.64-3.54(m,2H),3.01(dd,J＝8.8,4.4Hz,1H),2.74(dd,J＝13.6,9.6Hz,1H),2.39(s,3H),2.26-2.18(m,2H),1.94-1.82(m,2H),0.86(t,J＝7.6Hz,3H).
实施例1.4
第一步
将4a(10.00g,95.20mmol)溶于乙腈(100mL)中，加入叔丁基二甲基氯硅烷(15.06g,99.92mmol)，混合体系降温至0℃，逐滴加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(13.73g,90.21mmol)，加料完全后反应体系恢复至室温搅拌反应16h。产物逐渐析出。将反应液直接过滤，收集滤饼得4b(11.50g)，收率：55％。
MS-ESI计算值[M+H]+＝220，实测值为220。
第二步
向反应瓶内依次加入4b(5.55g，25.33mmol),丙酮(55.5mL)和马来酸酐(2.48g，25.33mmol),加完室温搅拌反应2h。反应液直接旋干得8.25g黄色油状物。将上述黄色油状物溶于甲苯(82mL)中，加入三乙胺(5.12g,50.66mmol)，混合体系升温至120℃回流反应2h。将反应液直接减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得4c(1.53g)，收率：33％。
MS-ESI计算值[M-H]-＝184，实测值为184。
1H NMR(400MHz,DMSO-d6)δ7.00(s,2H),6.05(s,1H),4.30(dd,J＝9.6,5.6Hz,1H),3.98(dd,J＝10.8,5.6Hz,1H),3.84(dd,J＝10.8,10.8Hz,1H).
第三步
向反应瓶内依次加入4c(65mg,0.234mmol)，2m(0.20g,0.23mmol)和N,N-二甲基甲酰胺(4mL)，搅拌溶解后置于冰浴中，加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(0.13g,0.35mmol)和2,4,6-三甲基吡啶(85mg,0.70mmol)，混合体系保持0～5℃下搅拌反应1h。反应液用HClaq(0.5N)调节pH＝4-5后用制备液相中性纯水体系制备分离得4(70mg)，收 率：14％。
MS-ESI计算值[M+H]+＝1024，实测值为1024。
1H NMR(400MHz,DMSO-d6)δ8.65(t,J＝6.8Hz,1H),8.60(d,J＝8.8Hz,1H),8.29(q,J＝5.6Hz,2H),8.09(d,J＝8.0Hz,1H),7.99(t,J＝5.6Hz,1H),7.81(d,J＝11.2Hz,1H),7.80(s,1H),7.29-7.14(m,5H),7.04(s,2H),6.68(s,1H),5.91(d,J＝16.8Hz,1H),5.71-5.60(m,1H),5.56-5.45(m,2H),5.36(d,J＝19.6Hz,1H),5.05(t,J＝5.6Hz,1H),4.68(d,J＝6.4Hz,2H),4.59(dd,J＝9.2,6.0Hz,1H),4.52-4.43(m,1H),4.17-4.04(m,2H),4.00-3.92(m,1H),3.98-3.80(m,1H),3.78-3.68(m,5H),3.64-3.54(m,2H),3.20-3.09(m,1H),3.00(dd,J＝14.0,4.4Hz,1H),2.73(dd,J＝13.6,9.6Hz,1H),2.39(s,3H),2.26-2.17(m,2H),1.94-1.83(m,2H),0.86(t,J＝7.2Hz,3H).
实施例1.5
第一步
将5a(650mg,1.70mmol)和5b(699mg,1.70mmol)溶于无水二氯甲烷(6mL)中，冰浴下依次加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(771mg,2.03mmol)和N,N-二异丙基乙胺(440mg,2.40mmol)，加料完全后反应体系恢复至室温搅拌反应1h。反应液直接浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得5c(1.10g)，收率：83％。
MS-ESI计算值[M+H]+＝777，实测值为777。
第二步
将5c(1.10g,1.42mmol)溶于无水二氯甲烷(2.6mL)中，冰浴下逐滴加入三氟乙酸(2mL)，加料完全后反应体系恢复至室温搅拌反应2h。反应液直接浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得粗产品5d(1.16g)。
MS-ESI计算值[M+H]+＝721，实测值为721。
第三步
将5f(800mg,1.69mmol)溶于无水乙腈(12mL)中，冰浴下逐滴加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(129mg,0.85mmol)，加料完全后反应体系恢复至室温搅拌反应1h。将5e(750mg,1.69mmol)加入到上述反应液，冰浴下依次加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(771mg,2.03mmol)和N,N-二异丙基乙胺(654mg,5.07mmol)，加料完全后反应体系恢复至室温搅拌反应2h。反应液用乙酸乙酯(200mL)稀释，有机相经饱和食盐水(50mL x3)洗，无水硫酸钠干燥后过滤，滤液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得粗产品5g(440mg)，收率：38％。
MS-ESI计算值[M+Na]+＝701，实测值为701。
第四步
将5g(420mg,0.62mmol)溶于无水乙腈(10mL)中，冰浴下逐滴加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(94mg,0.62mmol)，加料完全后反应体系恢复至室温搅拌反应2h。将5d(446mg,0.62mmol)加入到上述反应液，冰浴下依次加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(353mg,0.93mmol)和N,N-二异丙基乙胺(240mg,1.86mmol)，加料完全后反应体系恢复至室温搅拌反应1h。反应液用乙酸乙酯(100mL)稀释，有机相经饱和食盐水(25mL x3)洗，无水硫酸钠干燥后过滤，滤液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得5h(600mg)，收率：83％。
MS-ESI计算值[M+Na]+＝1181，实测值为1181。
第五步
将5h(600mg,0.52mmol)溶于四氢呋喃/水(8mL/2mL)混合溶剂中，加入Pd/C(60mg,10％W/W)，混合体系氢气氛下搅拌反应5h。反应液过滤除去不溶物，滤液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得5i(360mg)，收率：65％。
MS-ESI计算值[M+Na]+＝1091.5，实测值为1091.8。
第六步
向反应瓶内依次加入1d(50mg,0.11mmol)，5i(140mg,0.13mmol)和N,N-二甲基甲酰胺(2mL),搅拌溶解后置于冰浴中，加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(65mg,0.17mmol)和N,N-二异丙基乙胺(44mg,0.34mmol)，混合体系保持0～5℃下搅拌反应1h。反应液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得粗产品5j(140mg)，收率：85％。
MS-ESI计算值[M+H]+＝1502.6，实测值为1503。
第七步
将5j(55mg,0.037mmol)溶于无水乙腈(2mL)中，冰浴下逐滴加入二乙胺(27mg,0.37mmol)，加料完全后反应体系恢复至室温搅拌反应过夜。反应液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得5k(30mg)，收率：63％。
MS-ESI计算值[M+H]+＝1280.6，实测值为1281。
第八步
将5k(30mg,0.023mmol)和5l(20mg,0.12mmol)溶于无水二氯甲烷(1mL)中，冰浴下依次加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(35mg,0.092mmol)和N,N-二异丙基乙胺(16mg,0.12mmol)，混合体系室温下搅拌反应1h。反应液用HClaq(0.5N)调节pH＝4-5后用制备液相中性纯水体系制备分离得5(15mg)，收率：45％。
MS-ESI计算值[M+H]+＝1431.6，实测值为1432。
实施例1.6
第一步
将6a(4.00g,21.03mmol)溶于无水二氯甲烷(64mL)中，加入戴斯-马丁氧化剂(11.15g,26.30mmol)，加料完全后混合体系室温搅拌反应2h。反应液加二氯甲烷(100mL)稀释，有机相依次用饱和硫代硫酸钠溶液(50mL x 1)和饱和食盐水(50mL x 2)洗，无水硫酸钠干燥，过滤，滤液减压浓缩粗产品6b(5.30g)。
第二步
将粗产品6b(500mg)和6c(1.20g,3.19mmol)溶于无水甲醇(25mL)中，加入乙酸(7.56g,126.00mmol)和氰基硼氢化钠(418mg,6.65mmol)，加料完全后混合体系室温搅拌反应3h。反应液加二氯甲烷(150mL)稀释，饱和碳酸氢钠(50mL)淬灭过量的乙酸，分液，有机相用饱和食盐水(50mL x 2)洗，无水硫酸钠干燥，过滤，滤液减压浓缩粗产品6d(1.38g)。
MS-ESI计算值[M+H]+＝556，实测值为556。
第三步
将粗产品6d(1.38g)溶于无水四氢呋喃(30mL)中，加入N,N-二异丙基乙胺(482mg,3.73mmol)和氯甲酸-9-芴基甲酯(1.29g,4.97mmol)，加料完全后混合体系室温搅拌反应3h。反应液加二氯甲烷(150mL)稀释，有机相用饱和食盐水(50mL x 2)洗，无水硫酸钠干燥，过滤，滤液减压浓缩残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得6e(1.00g)，收率：65％。
MS-ESI计算值[M+H]+＝778，实测值为778。
第四步
将6e(1.00g,1.28mmol)溶于无水二氯甲烷(4mL)中，加入三氟乙酸(1.46g,12.85mmol)混合体系室温搅拌反应1h后补加三氟乙酸(1.46g,12.85mmol)，反应液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得6f(500mg)，收率：54％。
MS-ESI计算值[M+H]+＝722.4，实测值为722.9。
第五步
将2j(500mg,0.68mmol)溶于无水乙腈(5mL)中，冰浴下逐滴加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(134mg,0.88mmol)，加料完全后反应体系恢复至室温搅拌反应2h。将6f(490mg,0.68mmol)加入到上述反应液，冰浴下依次加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(388mg,1.02mmol)和N,N-二异丙基乙胺(220mg,1.70mmol)，加料完全后反应体系恢复至室温搅拌反应1h。反应液用二氯甲烷(100mL)稀释，有机相经饱和食盐水(25mL x3)洗，无水硫酸钠干燥后过滤，滤液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得6g(470mg)，收率：57％。
MS-ESI计算值[M+Na]+＝1239.6，实测值为1239.9。
1H NMR(400MHz,DMSO-d6)δ7.84(d,J＝7.6Hz,2H),7.82-7.74(m,1H),7.63(d,J＝7.6Hz,2H),7.61-7.52(m,2H),7.50-7.44(m,2H),7.44-7.24(m,15H),4.90-4.81(m,2H),4.73-4.62(m,1H),4.59(m,J＝5.6Hz,2H),4.30(s,2H),4.29-4.25(m,1H),4.15-4.02(m,1H),4.00-3.89(m,2H),3.86(d,J＝5.2Hz,2H),3.80-3.45(m,34H),3.43(s,3H),3.41-3.38(m,1H),3.11(dd,J＝14.0,10.0Hz,1H).
第六步
将6g(470mg,0.39mmol)溶于四氢呋喃/水(4mL/1mL)混合溶剂中，加入湿Pd/C(62mg,13％W/W)，混合体系氢气氛下搅拌反应2h。反应液过滤除去不溶物，滤液减压浓缩得粗产品6h(360mg)。
MS-ESI计算值[M+Na]+＝1149.5，实测值为1149.9。
参照参考实施例5中由化合物5i与化合物1d经过三步反应合成化合物5，化合物6h与化合物1d经三步反应合成化合物6。
MS-ESI计算值[M+H]+＝1489.6，实测值为1490。
实施例1.7
合成路线1
第一步
氮气氛下，将7a(10.60g,30.00mmol)溶于四氢呋喃/甲苯(200mL/50mL)混合溶剂中，加入四醋酸铅(17.30g,39.00mmol)和吡啶(3.08g,39.00mmol)，混合体系升温至75℃搅拌反应4h。反应液过滤除去不溶物，滤液减压浓缩除去大部分溶剂，残余物用乙酸乙酯(400mL)溶解，有机相依次经水(100mL x 2)，饱和碳酸氢钠水溶液(100mL)，稀盐酸(0.5N,100mL x 2)，饱和食盐水(100mL x 2)洗，无水硫酸钠干燥，过滤。滤液减压浓缩，残余物经硅胶柱层析(EA：hexanes＝0-100％)分离得7b(9.70g)，收率：88％。
MS-ESI计算值[M+Na]+＝391，实测值为391。
第二步
氮气氛下，将7b(8.00g,21.74mmol)溶于无水四氢呋喃(40mL)中，冰浴下依次加入对甲苯磺酸(374mg,2.18mmol)和羟乙酸叔丁酯(8.60g,65.14mmol)，加料完全后混合体系恢复至室温下搅拌反应1h。反应液用乙酸乙酯(200mL)稀释，有机相依次经水(50mL x 2)，饱和碳酸氢钠水溶液(50mL)，饱和食盐水(100mL x 2)洗，无水硫酸钠干燥后过滤。滤液减压浓缩，残余物经硅胶柱层析(EA：hexanes＝0-100％)分离得7c(5.90g)，收率：62％。
MS-ESI计算值[M+Na]+＝463，实测值为463。
第三步
氮气氛下，将7c(4.90g,11.14mmol)溶于无水乙腈(40mL)中，冰浴下加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(847mg,5.57mmol)，加料完全后混合体系恢复至室温下搅拌反应3h。将7d(6.13g,11.14mmol)加入到上述反应液，冰浴下依次加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(6.34mg,16.68mmol)和N,N-二异丙基乙胺(2.88g,22.32mmol)，加料完全后反应体系恢复至室温搅拌反应1h。反应液用乙酸乙酯(200mL)稀释，有机相经饱和食盐水(25mL x 3)洗，无水硫酸钠干燥后过滤，滤液减压浓缩得残余物，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得7e(5.8g)，收率：74％。
MS-ESI计算值[M+Na]+＝724，实测值为724。
第四步
氮气氛下，将7e(2.80g,3.99mmol)溶于无水乙腈(30mL)中，冰浴下加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(606mg,3.99mmol)，加料完全后混合体系恢复至室温下搅拌反应5h。将反应液冷却至0℃，分批加入1-羟基苯并三唑(1.08g,7.98mmol)，反应体系析出固体(呈果冻状)，保持冰浴下继续搅拌1h后过滤，上层滤饼用异丙醚/正己烷(10mL/40mL)打浆后再过滤，收集滤饼得7f(2.0g)。
MS-ESI计算值[M+H]+＝480，实测值为480。
第五步
将7g(0.99g,3.20mmol)和7f(2.40g,3.20mmol)溶于乙腈/水(15mL/15mL)混合溶剂中，冰浴下加入2,4,6-三甲基吡啶(387mg,3.20mmol)，加料完全后混合体系恢复至室温下搅拌反应2h。反应液用乙酸乙酯(200mL)稀释，有机相依次经水(30mL x 2)，稀盐酸(0.5N,50mL x 2)，饱和食盐水(50mL x 3)洗，无水硫酸钠干燥后过滤。滤液减压浓缩，残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得7h(1.25g)，收率：58％。
MS-ESI计算值[M+Na]+＝697，实测值为697。
第六步
氮气氛下，将溴化锌(8.00g,35.60mmol)称入反应瓶内，加入硝基甲烷(15mL)，室温下搅拌10min，体系呈乳浊液状。将反应瓶置于冰浴下，逐滴加入7h(1.20g,1.78mmol)的硝基甲烷(20mL)溶液，加料完全后混合体系保持在冰浴下继续搅拌反应4h。反应液加水(50mL)稀释，水相用氨水(2％w/w)调节pH至5-6，分液。水相用二氯甲烷(50mL x 3)洗后冻干，冻干所得残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得7i(450mg)，收率：41％。
MS-ESI计算值[M+Na]+＝641，实测值为641。
1H NMR(400MHz,DMSO-d6)δ7.28-7.14(m,5H),6.97(s,2H),4.66-4.54(m,2H),4.43(dd,J＝9.2,4.4Hz,1H),3.81(s,2H),3.77-3.52(m,12H),3.07(dd,J＝14.0,4.8Hz,1H),2.81(dd,J＝13.6,9.6Hz,1H),2.33(t,J＝6.0Hz,2H).
第七步
向10mL单口瓶中依次加入化合物1d(50mg，0.11mmol)，7i(74mg，0.12mmol)，1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(31mg，0.16mmol)和N,N-二甲基甲酰胺(2mL)，冰浴下向混合体系逐滴加入2,4,6-三甲基吡啶(60mg，0.49mmol)。滴加完毕后恢复室温搅拌反应3小时。将反应液逐滴滴入甲基叔丁基醚(60mL)中，固体析出，过滤收集固体，固体用二氯甲烷/甲醇混合溶剂(24mL/4mL)溶解，浓缩得到粗品，粗品经液相制备液相分离纯化得到化合物7(16mg)，收率：17％。
MS-ESI计算值[M+H]+＝1052，实测值：1052。
1H NMR(400MHz,DMSO-d6)δ8.65(t,J＝6.8Hz,1H),8.61(d,J＝9.2Hz,1H),8.28(t,J＝4.4Hz,1H),8.14-8.06(m,2H),8.06(t,J＝5.6Hz,1H),7.82(d,J＝11.2Hz,1H),7.79(s,1H),7.28-7.13(m,5H),6.99(s,2H),5.92(d,J＝16.8Hz,1H),5.70-5,60(m,1H),5.53(d,J＝8.0Hz,1H),5.48(d,J＝4.8Hz,1H),5.37(d,J＝19.6Hz,1H),4.68(d,J＝6.4Hz,1H),4.51-4.41(m,1H),4.17-4.04(m,2H),3.72-3.68(m,2H),3.68-3.63(m,2H),3.62-3.58(m,1H),3.58-3.54(m,3H),3.54-3.39(m,3H),3.48-3.43(m,2H),3.19-3.08(m,1H),3.06-2.97(m,1H),2.80-2.70(m,1H),2.70-2.65(m,1H),2.39(s,3H),2.35-2.28(m,3H),2.27-2.18(m,2H),1.94-1.82(m,2H),0.85(t,J＝7.2Hz,3H).
合成路线2
第一步
氮气氛下，将8a(4.50g,8.98mmol)溶于无水N,N-二甲基甲酰胺(25mL)中，加入醋酸(1.19g,19.76mmol)，四醋酸铅(7.96g,17.96mmol)和醋酸铜(1.10g,8.98mmol)，混合体系升温至50℃搅拌反应0.5h。反应液加水(50mL)淬灭，水相用乙酸乙酯(500mL)萃取，分液，有机相依次用饱和碳酸氢钠水溶液(100mL x 1)，水(100mL)和饱和食盐水(50mL x 4)洗，无水硫酸钠干燥后过滤。滤液减压浓缩得粗产品8b(4.70g)。
MS-ESI计算值[M+Na]+＝538，实测值为538。
第二步
氮气氛下，将8b(4.70g,9.13mmol)溶于无水四氢呋喃(40mL)中，冰浴下依次加入对甲苯磺酸(235mg,1.37mmol)和羟乙酸苄酯(5.30g,31.96mmol)，加料完全后混合体系恢复至室温下搅拌反应4h。反应液用乙酸乙酯(200mL)稀释，有机相依次经水(50mL x 1)，饱和碳酸氢钠水溶液(50mL x 1)，饱和食盐水(50mL x 2)洗，无水硫酸钠干燥后过滤。滤液减压浓缩，残余物经硅胶柱层析(EA：hexanes＝0-100％)分离得8c(4.50g)，收率：79％。
MS-ESI计算值[M+Na]+＝644，实测值为644。
第三步
将8c(4.50g,7.25mmol)溶于四氢呋喃/水(50mL/15mL)混合溶剂中，加入湿Pd/C(380mg,8％W/W)，混合体系氢气氛下搅拌反应过夜。反应液过滤除去不溶物，滤液减压浓缩得粗产品8d(2.65g)。
MS-ESI计算值[M+Na]+＝554，实测值为554。
第四步
氮气氛下，将8d(2.65g,4.99mmol)溶于无水乙腈(30mL)中，冰浴下加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.52g,9.98mmol)，加料完全后混合体系恢复至室温下搅拌反应5h。将反应液冷却至0℃，分批加入1-羟基苯并三唑(1.35g,9.98mmol)，反应体系析出固体，保持冰浴下继续搅拌2h后过滤，收集滤饼抽干得粗产品8e(1.85g)。
MS-ESI计算值[M+H]+＝310，实测值为310。
第五步
将7g(3.10g,10.00mmol)和8f(1.45g,11.00mmol)溶于乙腈/水(25mL/8mL)混合溶剂中，冰浴下加入三乙胺(1.51g,15.00mmol)，加料完全后混合体系恢复至室温下搅拌反应2h。反应液旋去大部分乙腈，残余物用二氯甲烷/水(100mL/50mL)稀释，分液，水相用二氯甲烷(50mL x 2)洗后冻干，冻干后残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得粗产品8g(4.25g)。
MS-ESI计算值[M+H]+＝328，实测值为328。
第六步
将8g(1.03g)和N-羟基琥珀酰亚胺(552mg,4.80mmol)溶于无水二氯甲烷(10mL)中，冰浴下加入二环己基碳二亚胺(0.99g,4.80mmol)，加料完全后混合体系恢复至室温下搅拌反应1.5h。反应液过滤除去不溶固体，母液待用。冰浴下向母液中加入8e(0.52g)和2,4,6-三甲基吡啶(203mg,1.68mmol)，混合体系恢复至室温下搅拌反应4h。反应液加水(50mL)稀释，水相用二氯甲烷(50mL x 2)洗后冻干，冻干后残余物经硅胶柱层析(MeOH：DCM＝0-100％)分离得7i(630mg)。
MS-ESI计算值[M+Na]+＝641,实测值为641。
第七步
将化合物1d(110mg，0.24mmol)，7i(195mg，0.32mmol)依次加入单口瓶(10mL)中，再加入无水N,N-二甲基甲酰胺(3mL)，混合体系降温至0℃后，依次逐滴滴加三氟乙酸(29mg，0.25mmol)，2,4,6-三甲基吡啶(133mg，1.10mmol)和1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(68mg，0.35mmol)，加料完全后，混合体系恢复至室温搅拌反应3小时。反应液直接经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物7(86mg)，收率：34％。
MS-ESI计算值[M+H]+＝1052，实测值为1052。
合成路线3
第一步
氮气氛围下，将9a(5.10g,11.48mmol)溶于无水二氯甲烷(100mL)中，依次加入2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(6.54g，17.22mmol)，N,N-二异丙基乙胺(4.44g，34.44mmol)和甘氨酸叔丁酯(1.80g，13.78mmol)。加料完全室温搅拌反应2小时。反应液加入二氯甲烷(100mL)稀释，有机相依次经稀盐酸(2N，50mL x 1)，水(50mL x 1)和饱和食盐水(50mL x 2)洗后干燥，过滤，滤液减压浓缩得到白色固体粗产品9b(6.80g)。
MS-ESI计算值[M+H]+＝558，实测值为558。
第二步
氮气氛围下，将上一步粗产品9b(6.30g)溶于无水乙腈(100mL)中，冰浴下加入1,8-二氮杂环[5,4,0]十一烯-7(3.44g，22.62mmol)，混合体系恢复至室温搅拌反应5h。将上述反应瓶再次置于冰浴中，依次加入Fmoc-甘氨酸(4.03g，13.57mmol)、2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(5.16g，13.57mmol)和N,N-二异丙基乙胺(2.19g，16.97mmol)，加料完全室温继续搅拌反应1小时。反应液加入乙酸乙酯(200mL)稀释，有机相依次经稀盐酸(2N，50mL x 1)，水(50mL x 2)和饱和食盐水(50mL x 2)洗后干燥，过滤，滤液减压浓缩得残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)分离得粗产物9c(8.5g)。
MS-ESI计算值[M+H]+＝615，实测值为615。
第三步
氮气氛围下，将9c(8.50g,13.83mmol)溶于无二氯甲烷(20mL)中，冰水浴降温到0℃，逐滴滴加三氟乙酸(20mL,0.261mol)，混合体系自然升温到室温搅拌反应4小时。减压浓缩，向残余物中加入乙酸乙酯(100mL)和水(100mL)，溶液体系经饱和碳酸氢钠调节pH至4-5之间(有固体析出和水相形成乳浊液)，分液，收集水相乳浊液，水相经乙酸乙酯(50mL X 2)洗涤，水相经1N盐酸水溶液调节pH至1-2，加入二氯甲烷(200mL)，分液，水相经二氯甲烷(150mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得白色固体粗产品9d(4.10g)。
MS-ESI计算值[M+H]+＝559，实测值为559。
第四步
氮气氛围下，反应瓶中依次加入9d(4.10g，7.34mmol)、醋酸(1.78g，29.35mmol)四醋酸铅(13.00g,17.96mmol)和醋酸铜(1.80g,14.68mmol)，混合体系升温至50℃搅拌反应0.5h。向反应液加入水(50mL)淬灭，水相经二氯甲烷(500mL)萃取，分液，有机相依次饱和碳酸氢钠水溶液(100mL x 1)，水(100mL)和饱和食盐水(50mL x 4)洗，无水硫酸钠干燥后过滤。滤液减压浓缩得粗产品9e(3.84g)。
MS-ESI计算值[M+Na]+＝595，实测值为595。
第五步
氮气氛围下，将9e(3.80g,6.60mmol)溶于无水四氢呋喃(40mL)中，冰浴下，依次加入对甲苯磺酸(171mg,1.00mmol)和羟乙酸苄酯(3.86g,25.20mmol)，加料完全后混合体系恢复至室温下搅拌反应4h。反应液经乙酸乙酯(200mL)稀释，有机相依次经水(50mL x 1)，饱和碳酸氢钠水溶液(50mL x 1)，饱和食盐水(50mL x 2)洗涤，无水硫酸钠干燥后过滤。滤液减压浓缩，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)分离得9f(2.14g)，收率：48％。
MS-ESI计算值[M+Na]+＝701，实测值为701。
第六步
将9f(2.10g,3.09mmol)溶于四氢呋喃/水(50mL/15mL)混合溶剂中，加入湿Pd/C(168mg,8％W/W)，混合体系氢气氛围下搅拌反应5小时。反应液过滤除去不溶物，滤液减压浓缩得粗产品9g(2.40g)。
MS-ESI计算值[M+Na]+＝611，实测值为611。
第七步
氮气氛围下，将9g(2.18g,3.70mmol)溶于无水乙腈(30mL)中，冰浴下，加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.13g,7.41mmol)，加料完全后混合体系恢复至室温下搅拌反应5h。将反应液冷却至0℃，分批加入1-羟基苯并三唑(1.35g,9.98mmol)，反应体系析出固体，加入乙腈(30mL)，室温打浆2小时，过滤，滤饼经乙腈(20mL X 2)洗涤，收集滤饼抽干得白色粉末粗产品9h(1.83g)。
MS-ESI计算值[M+H]+＝367，实测值为367。
第八步
将9i(500mg，1.43mmol，9i：2,4,6-三甲基吡啶＝1：0.655)、2,4,6-三甲基吡啶(494mg,4.08mmol)和N-羟基琥珀酰亚胺(206mg,1.79mmol)溶于无水二氯甲烷(25mL)中，冰浴下，加入二环己基碳二亚胺(443mg,2.15mmol)，加料完全毕，混合体系在0℃下搅拌反应3h。冰浴下，向上述反应液中加入9h(600mg，1.60mmol)，混合体系恢复至室温并搅拌过夜。反应液加水(100mL)稀释，水相经二氯甲烷(100mL x 3)洗涤，水相冻干，冻干后残余物经硅胶柱层析(MeOH：DCM＝0-50％)分离得7i(550mg)，收率：62％。
MS-ESI计算值[M+Na]+＝641,实测值为641。
第九步
将化合物1d(110mg，0.24mmol)，7i(195mg，0.32mmol)依次加入单口瓶(10mL)中，再加入无水N,N-二甲基甲酰胺(3mL)，混合体系降温至0℃后，依次逐滴滴加三氟乙酸(29mg，0.25mmol)，2,4,6-三甲基吡啶(133mg，1.10mmol)和1-乙基-(3-二甲基氨基丙基)碳二亚胺盐酸盐(68mg，0.35mmol)，加料完全后，混合体系恢复至室温搅拌反应3小时。反应液直接经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物7(90mg)，收率：35％。
MS-ESI计算值[M+H]+＝1052，实测值为1052。
实施例1.8

第一步
氮气保护下，将10a(10g，22.91mmol)，N6-Boc-L-赖氨酸叔丁酯盐酸盐(9.32g，27.50mmol)溶于四氢呋喃/水混合溶剂(V四氢呋喃：V水＝4：1，100mL)中，混合体系降温至0℃搅拌10分钟后加入碳酸氢钠(3.85g，45.83mmol)，混合体系保持0℃搅拌反应2小时。反应液加水(100mL)和乙酸乙酯(100mL)，分液，水相经乙酸乙酯(100mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，减压浓缩得到残余物，残余物经硅胶柱层析(乙酸乙酯：石油醚＝0-100％)纯化得到化合物10b(12.50g)，收率：87％。
MS-ESI计算值[M+Na]+646，实测值为646。
第二步
将10b(12.50g，20.04mmol)溶于氯化氢二氧六环溶液(63mL，4M)中，混合体系室温下搅拌反应3小时。反应液减压浓缩得到残余物，残余物经甲基叔丁基醚(150mL)打浆纯化得到粗品10c(11.40g)。
MS-ESI计算值[M+H]+＝468，实测值为468。
第三步
将10c(11.40g)溶于无水二氯甲烷(190mL)中，加入正丙醛(7.01g，120.70mmol)，混合体系室温下搅拌反应15分钟后分批次加入三乙酰氧基硼氢化钠(21.33g，100.64mmol)，加料完成后混合体系室温下继续搅拌反应1小时。反应体系用饱和氯化铵水溶液(10mL)淬灭，混合体系室温下搅拌1小时，加水(200mL)和乙酸乙酯(100mL)，分液，水相经乙酸乙酯(100mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物10d(9.40g)，两步收率：85％。
MS-ESI计算值[M+H]+＝552，实测值为552。
第四步
氮气保护下，将10e(2.5g，5.27mmol)溶于无水二氯甲烷(35mL)中，再加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.20g，7.88mmol)，混合体系降温至0℃搅拌反应10分钟后恢复至室温继续搅拌反应1小时。混合体系再次降温至0℃，加入10d(3.49g，6.33mmol)，N,N-二异丙基乙胺(1.02g，7.89mmol)，2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(3.01g，7.92mmol)，加料完全后保持0℃反应1小时。反应液加水(50mL)和乙酸乙酯(50mL)，分液，水相经乙酸乙酯(100mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物10f(2.00g)，收率：48％。
MS-ESI计算值[M+H]+＝786，实测值为786。
第五步
将10f(2.00g，2.54mmol)溶于四氢呋喃/水混合溶剂(V四氢呋喃：V水＝3：1，40mL)中，再加入10％湿钯碳(200mg)，混合体系保持氢气气氛下室温搅拌反应3小时。反应体系过滤除去不溶物，滤饼用乙酸乙酯淋洗，滤液减压浓缩得到残余水相，水相经乙酸乙酯(20mL x 3)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物10g(930mg)，收率：53％。
MS-ESI计算值[M+H]+＝696，实测值为696。
第六步
氮气气氛下，将10g(652mg，0.94mmol)，1d(330mg，0.73mmol)溶于无水二氯甲烷(5mL)中，混合体系降温至0℃，加入N,N-二异丙基乙胺(189mg，1.46mmol)，2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(330mg，0.87mmol)，混合体系保持0℃下搅拌反应1小时。反应液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物10h(730mg)，收率：88％。
MS-ESI计算值[M+H]+＝1129，实测值为1129。
第七步
氮气保护下，将10h(720mg，0.64mmol)溶于无水四氢呋喃(7mL)中，降温至0℃，再加入哌啶(272mg，3.19mmol)，混合体系保持0℃搅拌反应1小时。反应液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物10i(350mg)，收率：61％。
MS-ESI计算值[M+H]+＝907，实测值为907。
1H NMR(400MHz,DMSO-d6)δ7.78(s,1H),7.72(d,J＝10.8Hz,1H),5.91(d,J＝16.4Hz,1H),5.70-5.60(m,1H),5.49(d,J＝16.4Hz,1H),4.74-4.62(m,2H),4.24-4.15(m,1H),4.13(d,J＝6.0Hz,2H),3.81-3.61(m,2H),3.34-3.20(m,1H),3.18(s,2H),3.16-3.07(m,1H),3.00(d,J＝4.8Hz,1H),2.93-2.81(m,2H),2.37(s,3H),2.31-2.21(m,5H),1.99-1.83(m,3H),1.67-1.46(m,4H),1.39-1.22(m,8H),0.91-0.82(m,6H),0.82(t,J＝7.2Hz,6H),0.76(d,J＝6.8Hz,3H).
第八步
将10i(150mg，0.17mmol)溶于无水N,N-二甲基甲酰胺(2mL)中，再加入2,4,6-三甲基吡啶(60mg，0.50mmol)，2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(94mg，0.25mmol)，混合体系保持0℃搅拌反应5分钟后加入4c(57mg，0.20mmol)，加料完全后保持0℃继续搅拌反应1小时。反应液加水(5mL)和乙酸乙酯(10mL)，分液，水相经乙酸乙酯(10mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经制备HPLC纯化得到化合物10(125mg)，收率：67％。
MS-ESI计算值[M+H]+＝1074，实测值为1074。
实施例1.9

第一步
氮气保护下，将11a(5.00g，12.18mmol)，对氨基苯甲醇(2.25g，18.27mmol)溶于无水二氯甲烷(100mL)中，混合体系降温至0℃后加入N,N-二异丙基乙胺(3.94g，30.49mmol)，2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(5.56g，14.62mmol)，加料完全后，继续保持0℃搅拌反应1小时。反应液加水(200mL)和二氯甲烷/甲醇混合溶剂(V二氯甲烷：V甲醇＝10：1，300mL)，分液，水相经二氯甲烷/甲醇混合溶剂(V二氯甲烷：V甲醇＝10：1，300mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物11b(6.68g)，收率：100％。
MS-ESI计算值[M-OH]+＝498，实测值为498。
第二步
氮气保护下，将11b(3.23g，6.26mmol)，双(4-硝基苯基)碳酸酯(2.86g，9.40mmol)溶于无水二氯甲烷/N,N-二甲基甲酰胺混合溶剂(V二氯甲烷：VN,N-二甲基甲酰胺＝2:1，48mL)中，加入N,N-二异丙基乙胺(2.43g，18.80mmol)，加料完全后，混合体系室温下搅拌反应12小时。反应液加水(100mL)淬灭，再加入乙酸乙酯(100mL)，分液，水相经乙酸乙酯(100mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，加入甲基叔丁基醚(10mL)打浆纯化得到化合物11c(2.00g)，收率：47％。
MS-ESI计算值[M+Na]+＝703，实测值为703。
第三步
氮气保护下，将11c(1.27g，1.87mmol)，1d(430mg，0.95mmol)溶于无水N,N-二甲基甲酰胺(12mL)中，混合体系降温至0℃后加入三滴三乙胺，保持0℃搅拌15分钟后加入1-羟基苯并三唑(299mg，2.21mmol)，吡啶(2.15g，27.18mmol)，加料完全后，混合体系保持0℃搅拌15min后恢复至室温搅拌反应2小时。反应液加水(20mL)和乙酸乙酯(30mL)，分液，水相经乙酸乙酯(30mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物11d(550mg)，收率：58％。
MS-ESI计算值[M+H]+＝993，实测值为993。
第四步
将11d(500mg，0.50mmol)溶于1,4-二氧六环(5mL)，加入哌啶(5mL)，混合体系室温下搅拌反应2小时。向反应液中滴加石油醚(5mL)，大量固体析出，过滤，收集滤饼干燥得到11e(386mg)收率：94％。
MS-ESI计算值[M+H]+＝771，实测值为771。
1H NMR(400MHz,DMSO-d6)δ7.76(s,1H),7.66(d,J＝10.4Hz,1H),7.60(d,J＝8.0Hz,2H),7.43(d,J＝8.4Hz,2H),5.91(d,J＝16.4Hz,1H),5.49(d,J＝16.4Hz,1H),5.29(q,J＝4.8Hz,1H),5.20-5.02(m,2H),4.50-4.39(m,1H),3.30-3.14(m,1H),3.14-3.02(m,1H),2.99(d,J＝5.2Hz,1H),2.31(s,3H),2.30-2.21(m,1H),2.13-1.98(m,1H),1.98-1.80(m,3H),1.30(d,J＝7.2Hz,3H),0.88(d,J＝6.8Hz,3H),0.84(t,J＝7.2Hz,3H),0.78(d,J＝6.8Hz,3H).
第五步
将11e(150mg，0.20mmol)溶于无水N,N-二甲基甲酰胺(2mL)，再加入2,4,6-三甲基吡啶(71mg，0.59mmol)，2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(111mg，0.29mmol)，保持0℃下搅拌5分钟后加入4c(67mg，0.23mmol)，加料完全后，混合体系保持0℃搅拌反应1小时。反应液加水(5mL)和乙酸乙酯(10mL)，分液，水相经乙酸乙酯(10mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经制备HPLC纯化得到化合物11(38mg)，收率：21％。
MS-ESI计算值[M+H]+＝938，实测值为938。
1H NMR(400MHz,DMSO-d6)δ8.56–8.00(m,3H),7.78(s,1H),7.72(d,J＝10.8Hz,1H),7.59(d,J＝8.0Hz,2H),7.42(d,J＝8.0Hz,2H),7.02(s,2H),5.92(d,J＝16.4Hz,1H),5.65-5.42(m,2H),5.42-5.26(m,2H),5.23-4.97(m,2H),4.68-4.51(m,1H),4.41-4.27(m,1H),4.23-4.11(m,1H),4.04-3.94(m,1H),3.92-3.77(m,1H),3.31-3.18(m,1H),3.16-2.92(m,1H),2.35(s,3H),2.30-2.20(m,1H),2.15-2.02(m,1H),2.03-1.91(m,1H),1.92-1.82(m,2H),1.31-1.26m,3H),0.86(t,J＝6.8Hz,3H),0.83-0.78(m,3H),0.77(d,J＝6.8Hz,3H).
实施例1.10
第一步
将12a(4.00g，6.65mmol)，双(4-硝基苯基)碳酸酯(10.08g，33.14mmol)溶于无水N,N-二甲基甲酰胺(80mL)中，加入N,N-二异丙基乙胺(2.40g,18.57mmol)，加料完全后，混合体系室温下搅拌反应2小时。向反应液中依次逐滴滴加乙酸乙酯(120mL)，石油醚(240mL)，滴加完毕，混合体系室温下搅拌10分钟后过滤，收集滤饼干燥得到化合物12b(3.30g)，收率：65％。
MS-ESI计算值[M+H]+＝767，实测值为767。
第二步
氮气保护下，将12b(675mg，0.88mmol)，1d(270mg，0.60mmol)溶于无水N,N-二甲基甲酰胺(5mL)中，混合体系降温至0℃后，加入三滴三乙胺，搅拌15min后加入1-羟基苯并三唑(189mg，1.40mmol)和吡啶(1.36g，17.19mmol)，混合体系保持0℃搅拌15分钟恢复至室温继续搅拌反应2小时。反应液加水(20mL)和乙酸乙酯(30mL)，分液，水相经乙酸乙酯(30mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物12c(350mg)，收率：54％。
MS-ESI计算值[M+Na]+＝1101，实测值为1101。
第三步
将12c(570mg，0.53mmol)溶于无水四氢呋喃(10mL)中，加入哌啶(450mg，5.28mmol),混合体系室温下搅拌反应3小时。反应液加入甲基叔丁基醚(15mL)，析出固体，搅拌30分钟，过滤，滤饼干燥得到化合物12d(400mg)，收率：88％。
MS-ESI计算值[M+H]+＝857，实测值为857。
第四步
将12d(210mg，0.25mmol)溶于无水N,N-二甲基甲酰胺(3mL)，再加入2,4,6-三甲基吡啶(89mg，0.73mmol)和2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(140mg，0.37mmol)，保持0℃搅拌反应5分钟后加入4c(71mg，0.25mmol)，加料完全后，混合体系保持0℃搅拌反应1小时。反应液加水(5mL)和乙酸乙酯(10mL)，分液，水相经乙酸乙酯(10mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经制备HPLC纯化得到化合物12(30mg)，收率：12％。
MS-ESI计算值[M+H]+＝1024，实测值为1024。
1H NMR(500MHz,DMSO-d6)δ7.79(s,1H),7.75(d,J＝10.5Hz,1H),7.59(d,J＝7.5Hz,1H),7.42(d,J＝8.5Hz,1H),7.02(s,2H),5.92(d,J＝17.0Hz,1H),5.57(d,J＝20.0Hz,1H),5.51(d,J＝16.5Hz,1H),5.37(d,J＝19.5Hz,1H),5.33-5.28(m,1H),5.16(d,J＝12.5Hz,1H),5.08(d,J＝12.5Hz,1H),4.60-4.54(m,1H),4.37-4.30(m,1H),4.20-4.14(m,1H),4.00-3.93(m,1H),3.88-3.81(m,1H),3.30-3.21(m,1H),3.15-3.06(m,1H),3.05-2.89(m,2H),2.36(s,3H),2.31-2.23(m,1H),2.14-2.03(m,1H),2.02-1.93(m,1H),1.92-1.82(m,2H),1.74-1.64(m,1H),164-1.53(m,1H),1.48-1.31(m,2H),0.89-0.80(m,6H),0.76(d,J＝6.5Hz,3H).
实施例1.11

第一步
将12b(427mg，0.56mmol)，13a(270mg，0.38mmol)溶于无水N,N-二甲基甲酰胺(15mL)中，再加入1-羟基苯并三唑(51mg，0.38mmol)，吡啶(744mg，9.41mmol)，混合体系室温下搅拌反应12小时。反应体系加水(20mL)和乙酸乙酯(30mL)，分液，水相经乙酸乙酯(30mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物13b(220mg)，收率：43％。
MS-ESI计算值[(1/2M)+H]+＝673，实测值为673。
第二步
将13b(200mg，0.15mmol)溶于无水四氢呋喃/无水N,N-二甲基甲酰胺混合溶剂(V四氢呋喃：VN,N-二甲基甲酰胺＝2：1，5.4mL)中，加入哌啶(66mg，0.78mmol),混合体系室温下搅拌反应1小时。反应液直接经硅胶柱层析(甲醇：二氯甲烷＝0-100％)纯化得到化合物13c(110mg)，收率：66％。
MS-ESI计算值[M+H]+＝1123.7，实测值为1123.4。
第三步
将13c(110mg，0.10mmol)溶于无水N,N-二甲基甲酰胺(3mL)，再加入2,4,6-三甲基吡啶(25mg，0.21mmol)和2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(59mg，0.16mmol)，混合体系保持0℃搅拌反应5分钟后加入4c(55mg，0.19mmol)，加料完全后继续保持0℃搅拌反应1小时。反应液加水(5mL)和乙酸乙酯(10mL)，分液，水相经乙酸乙酯(10mL x 2)萃取，合并有机相，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经制备HPLC纯化得到化合物13(54mg)，收率：43％。
MS-ESI计算值[M+H]+＝1290.7，实测值为1290.4。
1H NMR(500MHz,DMSO-d6)δ8.05(d,J＝8.5Hz,1H),7.58-7.52(m,2H),7.36-7.21(m,5H),7.21-7.10(m,1H),7.02(s,2H),5.14-4.91(m,2H),4.60-4.52(m,1H),4.51-4.44(m,1H),4.44-4.36(m,1H),4.36-4.30(m,1H),4.28-4.20(m,1H),4.20-4.14(m,1H),4.05-3.90(m,3H),3.85(dd,J＝11.0,9.0Hz,1H),3.59-3.51(m,1H),3.25–3.20(m,3H),3.21–3.15(m,3H),3.10(s,1H),3.07-2.90(m,3H),2.88-2.80(m,2H),2.43-2.34(m,1H),2.30-2.20(m,1H),2.16-1.88(m,4H),1.85-1.63(m,4H),1.62-1.22(m,6H),1.06-0.96(m,6H),0.89-0.86(m,2H),0.85-0.80(m,10H),0.80-0.70(m,12H).
实施例1.12

第一步
氮气保护下，将咪唑(161.60g，2373.68mmol)溶于无水N,N-二甲基甲酰胺(1.25L)中，混合体系降温至0±5℃，滴加三异丙基氯硅烷(458.20g，2376.56mmol)，混合体系保持0±5℃搅拌反应30分钟，向反应体系中滴加14a(250.00g，949.67mmol)的N,N-二甲基甲酰胺(1250mL)溶液，滴加完毕后，混合体系保持0±5℃搅拌反应18小时。加入咪唑(129.30g，1899.24mmol)，搅拌10分钟后，滴加三乙基氯硅烷(286.50g，1900.86mmol)，滴加完毕后，混合体系保持0±5℃搅拌反应18小时。向反应体系滴加甲醇(250mL)，混合体系保持0℃搅拌1小时。恢复至室温，反应液用水(5000mL)稀释，水相用甲基叔丁基醚(5000mL x 2)萃取，合并有机相。有机相经氯化钠水溶液(2500mL x 2，5％)洗涤，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(正庚烷：乙酸乙酯＝0-100％)纯化得到14b(479.10g)，纯度：99.95％，含量：93.5％，折含量收率：88％。
MS-ESI计算值[M+H]+＝534，实测值为534。
1H NMR(400MHz,CDCl3)δ6.70(s,1H),6.14(d,J＝16.4Hz,1H),5.69-5.66(m,1H),5.59(d,J＝16.4Hz,1H),5.16(d,J＝16.0Hz,1H),4.53(d,J＝2.4Hz,2H),1.87-1.75(m,2H),1.37-1.23(m,3H),1.13(d,J＝7.6Hz,18H),0.95-0.87(m,12H),0.67(q,J＝7.6Hz,6H).
第二步
氮气保护下将14b(450.0g，含量：93.5％，788.13mmol)溶于甲苯(4.5L)，加入碳酸钠(25.10g，236.81mmol)，劳森试剂(382.50g，945.68mmol)，混合体系升温至110℃搅拌反应3小时。反应体系降温至50-60℃，向反应体系中滴加正庚烷(4500mL)，搅拌1小时后过滤，滤饼用正庚烷(900mL)淋洗，合并有机相，滤液减压浓缩得到残余物，残余物经硅胶柱层析(正庚烷：乙酸乙酯＝0-100％)纯化得到化合物14c(517.0g)，直接用于下一步。
MS-ESI计算值[M+H]+＝550，实测值为550。
1H NMR(400MHz,CDCl3)δ7.20(s,1H),6.14(d,J＝16.4Hz,1H),5.87(t,J＝2.0Hz,1H),5.26(d,J＝16.8Hz,1H),4.82(d,J＝2.0Hz,1H),1.90-1.75(m,2H),1.41-1.27(m,3H),1.18-1.11(m,18H),0.97-0.85(m,12H),0.77-0.66(m,6H).
第三步
氮气保护下，将上一步粗品14c(517.0g)溶于无水四氢呋喃(4.5L)中，室温下加入氢氟酸(295.50g，48wt.％，7092.00mmol)，加料完全后，室温搅拌反应36小时。反应液加水(4500mL)稀释，水相经乙酸乙酯(4500mL x 2)萃取，合并有机相。有机相经饱和食盐水(2250mL x 2)洗涤，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(二氯甲烷：乙酸乙酯＝0-100％)纯化后得到粗品，粗品中加入甲基叔丁基醚(2250mL)打浆1小时，过滤得到化合物14d(194.60g)，含量：94％，两步收率：83％。
MS-ESI计算值[M+H]+＝280，实测值为280。
1H NMR(400MHz,CDCl3)δ6.63(s,1H),5.82(d,J＝17.2Hz,1H),5.41(d,J＝17.2Hz,1H),4.45-4.30(m,2H),2.99-2.92(m,2H),1.80(q,J＝7.2Hz,2H),0.78(t,J＝7.2Hz,3H).
第四步
氮气保护下，将水(8.0L)和HCl(aq)(8.0L,6N)加入反应釜(50L)中，再加入14e(800.00g，3196.55mmol)，混合体系升温至100±5℃搅拌反应4小时。反应体系降温至30℃，向反应体系中缓慢滴加氨水(3500mL，25％～28％)调节pH至4～5(滴加过程中，控制反应体系温度＜40℃)。滴加完毕后，混合体系搅拌30分钟，过滤，滤饼用水(2500mL x 1)淋洗。滤饼经乙醇(8L)室温下打浆1小时，过滤，滤饼用乙醇(1000mL x 1)淋洗。收集滤饼，滤饼在50±5℃下鼓风干燥得14f(709.00g)，收率：91％。
MS-ESI计算值[M+H]+＝209，实测值为209。
第五步
将四氢呋喃(10200mL)，水(10200mL)和14f(680.00g，2779.03mmol)加入反应釜(50L)，混合体系降温至0～10℃后加入碳酸钾(653.00g，4724.69mmol)，再缓慢滴加氯甲酸-9-芴基甲酯(733.31g，2834.60mmol)的四氢呋喃(3400mL)溶液(滴加过程中控制反应液温度在0～10℃)，混合体系保持0～10℃搅拌反应1小时。反应液用2-甲基四氢呋喃(10200mL x 2)萃取，有机相再依次用水(10200mL x 1)，饱和食盐水(10000mL x 1)洗涤。有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物。向残余物中加入甲基叔丁基醚(6800mL)，室温下搅拌4小时，过滤，滤饼用甲基叔丁基醚(680mL x 1)淋洗，收集滤饼，滤饼在50±5℃下鼓风干燥得14g(1090.00g)，收率：91％。
MS-ESI计算值[M+H]+＝431，实测值为431。
1H NMR(400MHz,DMSO-d6)δ7.90(d,J＝7.2Hz,2H),7.80-7.73(m,2H),7.53-7.28(m,6H),6.39(d,J＝12.8Hz,1H),4.40-4.15(m,4H),3.03-2.75(m,2H),2.20-2.07(m,1H),2.04-1.87(m,1H),1.98(s,3H).
第六步
氮气保护下，将7g(150.00g，483.47mmol)加入三口瓶(3L)中，再加入乙酸乙酯(1200mL)，滴加14h(111.20g，含量：90％，531.69mmol)的乙酸乙酯(300mL)溶液，加料完全后，混合体系保持室温搅拌反应2-6小时。向反应体系中加入饱和食盐水(450mL)，室温下搅拌10分钟后，分液，保留有机相。有机相经饱和食盐水(450mL x 1)洗涤，无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(乙酸乙酯：石油醚＝0-100％)纯化得到化合物14i(134.00g)，收率：73％。
MS-ESI计算值[M+H]+＝384，实测值为384。
1H NMR(400MHz,DMSO-d6)δ8.13-8.05(m,2H),7.01(s,2H),3.71(d,J＝6.0Hz,2H),3.70(d,J＝6.0Hz,2H),3.61-3.52(m,4H),3.50-3.44(m,2H),2.33(t,J＝6.4Hz,2H),1.40(s,9H).
第七步
氮气保护下，将14i(184.30g，480.70mmol)加入三口瓶(3L)中，再加入甲苯(1.84L)，滴加三氟乙酸(823.27g，7220.21mmol)，加料完全后，混合体系保持室温搅拌反应4.5小时。反应液减压浓缩得到残余物，向残余物中加入甲苯(600mL)，继续减压浓缩，连续操作三次，直至固体析出。向固体中加入乙酸乙酯(1.7L)，打浆2小时后过滤得到化合物8g(150.20g)，收率：96％。
MS-ESI计算值[M-H]-＝326，实测值为326。
1H NMR(400MHz,DMSO-d6)δ8.12-8.05(m,2H),7.01(s,2H),3.75(d,J＝6.0Hz,2H),3.70(d,J＝5.6Hz,2H),3.60-3.52(m,4H),3.50-3.44(m,2H),2.33(t,J＝6.4Hz,2H).
第八步
氮气保护下，将8g(20.00g，61.11mmol)溶于二氯甲烷(200mL)中，降温至0±5℃后，加入五氟苯酚(16.90g，91.82mmol)，搅拌反应10分钟，加入1-(3-二甲基氨基丙基)-3-乙基碳二亚胺盐酸盐(17.60g，91.82mmol)，混合体系保持0±5℃搅拌反应4-16小时。反应液加水(200mL)稀释，搅拌10分钟，分液，有机相经饱和食盐水(100mL x 1)洗涤，无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经硅胶柱层析(丙酮：二氯甲烷＝0-100％)纯化得粗品，向粗品中加入甲基叔丁基醚(150mL)，室温搅拌1小时，过滤，滤饼于35℃下干燥，得到化合物14j(23.00g)，收率：76％。
MS-ESI计算值[M+H]+＝494，实测值为494。
1H NMR(400MHz,CDCl3)δ7.12(d,J＝5.6Hz,1H),6.96(t,J＝5.6Hz,1H),6.70(s,1H),4.42(d,J＝6.0Hz,2H),4.03(d,J＝6.0Hz,1H),3.72(t,J＝5.2Hz,2H),3.69(t,J＝5.6Hz,2H),3.59(t,J＝5.2Hz,2H),2.49(t,J＝5.6Hz,2H).
第九步
氮气保护下，将8e(7.50g，24.25mmol)溶于四氢呋喃(400mL)中，室温搅拌1小时，再加入14j(10.00g，20.27mmol)，加料完全后，混合体系保持室温下搅拌反应16小时。向反应液中加入乙酸乙酯(400mL)，搅拌1小时，过滤，干燥滤饼，滤饼经二氯甲烷/甲醇(v:v＝20:1,100mL)混合溶剂溶解，混合溶液经硅胶柱层析(甲醇:二氯甲烷＝0-100％)纯化得到粗品(14.51g)，粗品经甲醇(30mL)溶解，向甲醇溶液中滴加乙酸乙酯(450mL)，保持室温下搅拌24小时，过滤，干燥滤饼得到化合物7i(10.20g)，收率：81％。
MS-ESI计算值[M+Na]+＝641，实测值为641。
第十步
氮气保护下，依次将甲苯(3200mL)，乙酸(3200mL)，14d(320.00g，1145.68mmol)，14g(592.00g，1375.21mmol)和对甲苯磺酸吡啶盐(144.00g，573.02mmol)加入到反应瓶(10L)中，混合体系加热至110℃搅拌反应24小时。反应液冷却至30±10℃，转移至萃取釜(80L)中，依次加入2-甲基四氢呋喃(6400mL)和水(6400mL)，搅拌10-20分钟，分液，保留上层有机相。有机相依次经水(4800mL x 3)和饱和氯化钠水溶液(4800mL x 1)洗涤，无水硫酸钠干燥后过滤，滤液经减压浓缩(50±5℃)至基本无液滴滴出，残余物用甲基叔丁基醚带蒸两遍(640mL×2)，所得粗品1加入甲基叔丁醚(3200mL)打浆2～2.5小时，过滤，滤饼经甲叔醚淋洗(640mL×2)两次，收集滤饼，干燥得到粗品2。将粗品2溶于N,N-二甲基甲酰胺(6400mL)，滴加甲基叔丁醚(25600mL)，滴加完毕后保持20～30℃下搅拌析晶16～18小时，过滤，滤饼再用甲基叔丁醚(3200mL)打浆2～2.5小时后过滤，滤饼经甲基叔丁醚淋洗两遍(640mL×2)，收集滤饼，滤饼鼓风干燥(50±5℃)得14k(490g)，收率：63％。
MS-ESI计算值[M+H]+＝674，实测值为674。
1H NMR(400MHz,DMSO-d6)δ8.16-8.06(m,1H),7.85(d,J＝7.2Hz,2H),7.82-7.74(m,2H),7.74-7.64(m,2H),7.42-7.33(m,2H),7.33-7.23(m,2H),6.76-6.64(m,2H),5.97-5.81(m,1H),5.58-5.40(m,2H),5.38-5.20(m,2H),4.68-4.52(m,1H),4.34(s,2H),3.28-3.14(m,1H),3.12-2.96(m,1H),2.32(s,3H),2.28-2.18(m,1H),2.18-2.04(m,1H),2.00-1.82(m,2H),0.94-0.82(m,3H).
第十一步
氮气氛下，将四氢呋喃(19200mL)，14k(480g，712.42mmol)依次加入到反应釜中，混合体系降温至0～5℃，向反应瓶中缓慢滴加哌啶(546g，6412.21mmol)，(滴加时控温0～5℃)，滴毕，反应体系保持0～5℃搅拌反应22-24小时。向反应釜中缓慢滴加盐酸水溶液(1440mL，6N) (滴加时控温0～10℃)，混合体系继续搅拌10-15分钟，减压浓缩得到残余物，残余物经水(9600mL)打浆2-2.5小时，过滤，滤饼经乙腈(480mL x 2)淋洗，收集滤饼，滤饼经干燥后送制备分离纯化(制备仪器：汉邦工业级制备型液相色谱仪，规格型号：DAC150，制备柱填料：Welch Ultimate XB-C18,150*250mm,10μm)，制备液使用5％氨水调节pH至7～8，搅拌30～35分钟后过滤，滤饼用水(1000mL x 1)淋洗，收集滤饼，滤饼鼓风干燥(60℃)24±2小时得1d(97g)，收率：30％。
MS-ESI计算值[M+H]+＝452，实测值为452。
第十二步
氮气保护下，将N,N-二甲基甲酰胺(1200mL)加入到反应瓶中，将1d(60.00g，132.89mmol)和三氟乙酸(15.20g，133.31mmol)加入到反应瓶中，混合体系降温至0～10℃，搅拌十分钟后加入7i(115.10g，186.07mmol)、1-(3-二甲基氨基丙基)-3-乙基碳二亚胺盐酸盐(51.00g，266.04mmol)和2,4,6-三甲基吡啶(16.10g，132.86mmol)，反应体系在0～10℃搅拌反应1小时。向反应瓶中滴加盐酸水溶液(1200mL，0.05N)，继续滴加水(1800mL)，搅拌10～20分钟，过滤，滤饼经水(300mL x 2)洗涤，收集滤饼，滤饼经二氯甲烷/甲醇(V/V＝30/1，1800mL)溶解，溶液经无水硫酸钠干燥后过滤，滤液经硅胶柱层析纯化(甲醇：二氯甲烷＝0-100％)得粗品。粗品使用甲基叔丁基醚(600mL)打浆1～1.5小时，过滤，滤饼经甲基叔丁基醚(300mL x 2)淋洗，收集滤饼用旋转蒸发仪抽干5±1小时得化合物7(90.0g)，收率：64％。
MS-ESI计算值[M+H]+＝1052，实测值为1052。
实施例1.13

第一步
氮气保护下，将15a(438.00g，904.0mmol)溶解于乙二醇二甲醚(4380mL)中，加入水(2630mL)，反应体系温度降至0-5℃，依次加入双甘肽(238.87g，1808.0mmol)和碳酸氢钠(151.87g，1808.0mmol)，加料完全后，反应体系温度升至20-25℃搅拌反应1小时。反应液降至-5-0℃，加入稀盐酸(0.5M，4380mL)，搅拌10分钟，水相依次经2-甲基四氢呋喃(8760mL x 1)和2-甲基四氢呋喃(4380mL x 1)萃取，合并上述有机相。有机相经饱和食盐水(4380mL x 1)洗涤，无水硫酸钠干燥后过滤，滤液旋干得到粗品，粗品用丙酮(8760mL)打浆16小时后过滤，滤饼经干燥后得到8a(375.00g)，收率：83％。
MS-ESI计算值[M+H]+＝502，实测值为502。
第二步
将8a(375.00g，747.69mmol)溶解于N,N-二甲基甲酰胺(4000mL)中，向反应瓶内依次加入四乙酸铅(730.11g，1646.70mmol)、乙酸铜(135.95g，748.50mmol)和乙酸(98.80g，1646.70mol)，混合体系升温至45～50℃搅拌反应0.5小时。将反应液加入到2-甲基四氢呋喃(7500mL)和水(7500mL)中，分液，水相经2-甲基四氢呋喃(3750mL x 1)萃取，合并上述有机相，有机相依次经饱和碳酸氢钠水溶液(3750mL x 1)、水(3750mL x 1)和饱和食盐水(3750mL x 1)洗涤，无水硫酸钠干燥，过滤，滤液浓缩得到粗品，粗品经甲基叔丁基醚(3750mL)打浆 16小时后过滤，滤饼经鼓风干燥16小时后得到8b(345.00g)，收率：89％。
MS-ESI计算值[M-CH3COO]+＝456，实测值为456。
1H NMR(400MHz,DMSO-d6)δ8.67(t,J＝6.8Hz,1H),8.34(t,J＝5.6Hz,1H),7.87(d,J＝7.6Hz,1H),7.71-7.58(m,3H),7.50-7.10(m,9H),5.18-5.04(m,2H),4.40-4.00(m,4H),3.78(d,J＝5.6Hz,2H),3.83-3.69(m,2H),3.05(dd,J＝13.6,4.0Hz,1H),2.80(dd,J＝13.2,10.8Hz,1H),1.98(s,3H).
第三步
氮气保护下，将8b(345.00g，669.17mmol)溶于四氢呋喃(3450mL)中，反应体系冷却至0-5℃，向反应体系依次加入乙醇酸苄酯(244.47g，1472.17mmol)和对甲苯磺酸(17.20g，100.37mmol)，加毕，反应体系升温至20～25℃搅拌反应1小时。向反应体系中加入乙酸乙酯(3450mL)和水(3450mL)，分液，水相经乙酸乙酯(3450mL x 1)萃取，合并上述有机相，有机相依次经水(3450mL x 1)和食盐水(3450mL x 1)洗涤，经无水硫酸钠干燥后过滤，滤液浓缩得粗品，粗品经硅胶柱层析(乙酸乙酯：石油醚＝0-100％)纯化得到8c(178.00g),收率：42％。
MS-ESI计算值[M+Na]+＝644，实测值为644。
1H NMR(400MHz,DMSO-d6)δ8.63(t,J＝6.8Hz,1H),8.35(t,J＝5.6Hz,1H),7.87(d,J＝7.6Hz,1H),7.71-7.60(m,3H),7.45-7.13(m,14H),5.13(s,2H),4.67-4.61(m,2H),4.32-4.24(m,1H),4.22-4.09(m,5H),3.83-3.69(m,2H),3.06(dd,J＝13.6,4.0Hz,1H),2.80(dd,J＝13.6,10.4Hz,1H).
第四步
氮气保护下，将8c(102.00g，164.07mmol)溶解于二氯甲烷(1020mL)中，反应体系降温至-5～0℃，加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(24.97g，164.07mmol)，加料完全后，混合体系在0～5℃搅拌反应1小时。反应液直接经硅胶柱层析(二氯甲烷：异丙醇＝0-100％)纯化得15b(43.50g)，收率：66％。
MS-ESI计算值[M+H]+＝400，实测值为400。
1H NMR(400MHz,DMSO-d6)δ8.64(t,J＝6.4Hz,1H),8.26-8.14(m,1H),7.45-7.15(m,10H),5.15(s,2H),4.64(d,J＝6.8Hz,2H),4.15(s,2H),3.81-3.65(m,2H),3.44(dd,J＝8.4,4.4Hz,1H),2.98(dd,J＝13.6,4.8Hz,1H),2.59(dd,J＝13.6,8.8Hz,1H).
第五步
氮气保护下，将15b(43.00g，107.65mmol)溶解于四氢呋喃(430mL)和水(430mL)混合溶剂中，反应体系降温至0～10℃，加入湿Pd/C(6.50g)，氢气置换三次，0～10℃保持氢气氛下搅拌反应24小时。反应液过滤，滤饼依次经四氢呋喃(43mL)和水(43mL)洗涤，滤液减压浓缩除去四氢呋喃，残余水相经2-甲基四氢呋喃(430mL x 2)洗涤后冻干得8e(31.50g)，收率：95％。
MS-ESI计算值[M-H]-＝308，实测值为308。
1H NMR(400MHz,DMSO-d6)δ9.07(s,1H),8.67(s,1H),7.33-7.26(m,2H),7.25-7.18(m,3H),4.68-4.56(m,2H),3.92-3.71(m,4H),3.52(dd,J＝16.4,4.0Hz,1H),3.01(dd,J＝13.6,6.4Hz,1H),2.79(dd,J＝13.2,7.6Hz,1H).
第六步
依次将4a(1000.00g，9515.65mmol)、乙腈(10.00L)加入到反应瓶(20L)中，向反应瓶中加入叔丁基二甲基氯硅烷(1505.92g，9991.42mmol)，反应体系降温至0～10℃后缓慢加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1376.18g，9039.84mmol)，加料完全后，反应体系恢复至室温继续搅拌反应40小时。将反应液直接过滤，所得滤饼经甲醇(18.00L)溶解，过滤，滤液中加入乙腈(54.00L)，搅拌2小时析出固体，过滤收集滤饼干燥得4b(1481.60g)，收率：71％。
MS-ESI计算值[M-H]-＝218，实测值为218。
第七步
将4b(500.00g，2279.36mmol)和四氢呋喃(3.75L)加入到反应瓶中，反应体系降温至0～5℃，加入N-甲氧基羰基顺丁烯二酰亚胺(395.00g，含量：85％，2164.59mmol)，加料完全后恢复至室温搅拌反应16小时。将反应液再次降温至0～5℃，加入10％碳酸氢钠水溶液(3.75L)(加料过程控温＜20℃)，加毕，反应体系升温至30℃搅拌反应88小时。将反应液降温至0～5℃，滴加5％柠檬酸水溶液调节pH至5～6，加入乙酸乙酯(3.75L)，搅拌分液，水相经乙酸乙酯(1.50 L)萃取。合并有机相，有机相依次经水(3.75L x 1)和饱和食盐水(3.75L x 1)洗涤，无水硫酸钠干燥后过滤，滤液减压浓缩得残余物，残余物经硅胶柱层析(乙酸乙酯：石油醚＝0-100％)纯化得15c(350.00g)，含量：88％，收率：45％。
MS-ESI计算值[M+H]+＝300，实测值为300。
1H NMR(400MHz,DMSO-d6)δ13.35(br s,1H),7.14(s,2H),4.69-4.81(m,1H),4.13-3.97(m,2H),0.77(m,9H),0.00(s,3H),-0.06(s,3H).
第八步
将二氯甲烷(1260mL)和15c(210.00g，701.40mmol)加入到反应瓶中，反应体系冷却至0-5℃,依次加入N,N'-二环己基碳二亚胺(159.30g，772.56mmol)的二氯甲烷(420mL)溶液和四氟苯酚(122.46g，737.40mmol)的二氯甲烷(420mL)溶液，反应体系保持0-5℃搅拌反应1小时。将反应液过滤，滤饼经二氯甲烷(1050mL)洗涤，滤液旋干得残余物，向残余物中加入甲基叔丁基醚(2100mL)，搅拌10分钟后过滤，滤饼经甲基叔丁基醚(630mL)淋洗，滤液浓缩得残余物，残余物中加入正己烷(2100mL)打浆30分钟后过滤，滤饼经正己烷(630mL)洗涤，过滤，干燥得到15d(246.78g)，收率：79％。
MS-ESI计算值[M+H]+＝448，实测值为448。
1H NMR(400MHz,CD3OD)δ7.48-7.36(m,1H),6.98(s,2H),5.30(dd,J＝9.2,6.0Hz,1H),4.34-4.23(m,2H),0.84(s,9H),0.07(s,3H),0.02(s,3H).
第九步
将水(1470mL)和双甘肽(79.58g，602.91mmol)加入到反应瓶中，开启搅拌，再加入乙二醇二甲醚(2450mL)，反应体系降温至5-10℃，向反应体系中加入15d(245.00g，547.53mmol)和碳酸氢钠(92.09g，1096.18mmol)，混合体系搅拌反应40小时。反应液经甲基叔丁基醚(2450mL x 2)洗涤，水相加入2-甲基四氢呋喃(7350mL)，加入预先冷却的柠檬酸水溶液(3920mL，2.5％)调节pH至5-6(滴加时控制温度在0℃左右)，分液，水相经2-甲基四氢呋喃(2450mL x1)萃取，合并有机相，有机相依次经水(7350mL x 4)和饱和氯化钠水溶液(3680mL x 1)洗涤，有机相经无水硫酸钠干燥后过滤，滤液减压浓缩得到残余物，残余物经乙酸乙酯(2450mL)打浆10分钟后过滤，滤饼经乙酸乙酯(735mL)洗涤，所得滤液再次减压浓缩得到残余物，残余物经乙酸乙酯(1230mL)溶解，滴加正己烷(6125mL)析出固体，搅拌16小时后过滤，滤饼经正己烷(735mL)淋洗，干燥，得到15e(115.40g)，收率：51％。
MS-ESI计算值[M+H]+＝414，实测值为414。
1H NMR(400MHz,DMSO-d6)δ8.41(t,J＝5.6Hz,1H),8.05(t,J＝5.6Hz,1H),7.11(s,2H),4.73(dd,J＝10.4,5.2Hz,1H),4.11(dd,J＝10.4,5.6Hz,1H),4.00(t,J＝10.4Hz,1H),3.83-3.73(m,3H),3.57(dd,J＝16.8,5.6Hz,1H),0.76(s,9H),-0.01(s,3H),-0.07(s,3H).
第十步
将二氯甲烷(1150mL)和15e(115.00g，278.11mmol)加入到反应瓶中，将反应体系温度降至-40～-30℃，依次加入N,N'-二环己基碳二亚胺(86.10g，417.29mmol)的二氯甲烷(155mL)溶液和四氟苯酚(46.24g，278.44mmol)的二氯甲烷(155mL)溶液，保持-40～-30℃下搅拌反应5小时。反应液加水(2300mL)淬灭，反应液过滤除去不溶物，滤液搅拌后分液，水相经二氯甲烷(1150mL)萃取，合并有机相，有机相经饱和食盐水(1730mL x 1)洗涤，无水硫酸钠干燥后过滤，滤液减压浓缩得残余物，残余物经乙酸乙酯(1150mL)打浆30分钟后过滤，滤饼经乙酸乙酯(345mL)漂洗，收集滤液浓缩，残余物经(甲基叔丁基醚：正己烷＝2：13，1730mL)打浆3小时后过滤，滤饼经正己烷(345mL)淋洗，收集滤饼干燥得到15f(146.80g)，收率：94％。
MS-ESI计算值[M+H]+＝562，实测值为562。
1H NMR(400MHz,CDCl3)δ7.70-7.61(m,1H),7.14-7.06(m,1H),7.06-6.96(m,1H),6.75(s,2H),4.72(dd,J＝8.4,6.4Hz,1H),4.50-4.35(m,2H),4.35-4.24(m,1H),4.16-3.94(m,2H),3.87(dd,J＝10.4,6.4Hz,1H),0.87(s,9H),0.085(s,3H),0.078(s,3H).
第十一步
将乙腈(2628mL)，水(876mL)和15f(146.00g，260.00mmol)加入到反应瓶中，反应体系降温至-5-0℃，加入8e(96.60g，312.30mmol)和N,N-二异丙基乙胺(33.70g，260.65mmol)，反应体系保持-5-0℃下搅拌反应18小时。向反应液中加入甲基叔丁基醚(2920mL)和水(1460 mL)，搅拌后分液，有机相经水(1460mL x 1)萃取，合并水相，水相用甲基叔丁基醚(2190mL x 3)洗涤，收集水相，加入磷酸体系缓冲溶液(2190mL，配样比例：6.51g磷酸二氢钠和0.30g磷酸氢二钠溶解到100.0mL水中)，搅拌10～20分钟，混合溶液经2-甲基四氢呋喃(2190mL x 3)萃取，合并有机相，有机相经饱和食盐水(2190mL x 2)洗涤，经无水硫酸钠干燥后过滤，滤液减压浓缩得残余物经HPLC制备分离(制备仪器：汉邦工业级制备型液相色谱仪，规格型号：DAC150，制备柱填料：月旭Xtimate C18)，向制备液中加入约一半制备液体积的混合溶剂(乙酸乙酯：2-甲基四氢呋喃＝1：1)，搅拌分液，水相再用约一半制备液体积的乙酸乙酯萃取，合并两次有机相，有机相用约一半制备液体积的去离子水洗涤3次，减压浓缩，残余物经冻干得到15g(83.54g)，收率：46％。
MS-ESI计算值[M+Na]+＝727，实测值为727。
第十二步
依次将乙腈(664mL)、H2O(996mL)和15g(83.00g，117.8mmol)加入到反应瓶中，反应体系降温至5-10℃，加入甲酸(65.11g，1414.5mmol)，反应体系保持5-10℃下搅拌反应40小时。向反应液中加入甲基叔丁基醚(830mL)，分液，有机相经水(420mL x 2)萃取，合并水相，水相经冻干得粗品，粗品中加入二氯甲烷(1660mL)，减压浓缩，重复此操作5次(除去残留甲酸)后加水(830mL)溶解，水溶液再次冻干得到15h(65.30g)，收率：94％。
MS-ESI计算值[M+H]+＝591，实测值为591。
1H NMR(400MHz,DMSO-d6)δ8.54(t,J＝6.4Hz,1H),8.37-8.28(m,1H),8.12(d,J＝7.6Hz,1H),8.02(t,J＝6.4Hz,1H),7.29-7.15(m,5H),7.05(s,2H),4.65-4.57(m,3H),4.55-4.45(m,1H),4.02-3.94(m,3H),3.92-3.82(m,1H),3.80-3.68(m,4H),3.65-3.57(m,2H),3.04(dd,J＝13.6,4.4Hz,1H),2.78(dd,J＝14.0,10.0Hz,1H).
第十三步
氮气保护下，将1d(120.00g，265.77mmol)的N,N-二甲基甲酰胺(2400mL)溶液加入到反应釜中，混合体系降温至-10～-5℃，向反应釜中加入15h(157.20g，266.19mmol)和2-(7-偶氮苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(151.20g，397.64mmol)，向反应釜中缓慢滴入2,4,6-三甲基吡啶(64.80g，534.74mmol)(滴加期间温度保持在-10～-5℃)，滴毕，反应体系在-10～-5℃搅拌反应4小时。向反应釜中缓慢滴加2％柠檬酸水溶液(7200mL)，滴加完毕后继续搅拌10～15分钟后过滤，滤饼经水(1200mL x 3)洗涤，干燥，所得粗品化合物经反相色谱制备(制备仪器：汉邦工业级制备型液相色谱仪，规格型号：DAC150，制备柱填料：Kromasil100-10-C18(W))，制备液分批处理(每25.0±5.0kg作为一个批次)。将每一批次制备液转移至50L反应釜中，开启搅拌，缓慢加入乙腈使溶液澄清，然后加入乙酸乙酯(10000mL)，搅拌5～10分钟，静置5～10分钟，分层。有机相经水(10000mL x 3)洗，合并水相经乙酸乙酯(10000mL)反萃，合并上述两次有机相再经水(10000mL x 2)洗，有机相经旋转蒸发仪浓缩至无液体滴出，将旋转蒸发瓶中的物料转移至10L布氏漏斗中抽滤，滤饼抽滤至无液体滴出后，依次使用蒸馏水(1200mL x 2)淋洗旋转蒸发瓶，淋洗滤饼，抽滤至滤饼无液体滴出。合并上述多批次湿品，将湿品加入水(2400mL)，0～10℃下搅拌2～3小时后过滤，滤饼经水(480mL)淋洗，收集滤饼经真空烘箱(30～35℃)干燥40小时得到化合物4(152.00g)，收率：56％。
MS-ESI计算值[M+H]+＝1024，实测值为1024。
1H NMR(400MHz,DMSO-d6)δ8.70-8.62(m,1H),8.56(d,J＝8.8Hz,1H),8.35-8.24(m,2H),8.09(d,J＝8.0Hz,1H),8.04-7.95(m,1H),7.76(s,1H),7.69(d,J＝8.8Hz,1H),7.28-7.13(m,5H),7.05(s,2H),6.69(s,1H),5.90(d,J＝16.4Hz,1H),5.72-5.62(m,1H),5.48(d,J＝16.8Hz,1H),5.42(d,J＝20.0Hz,1H),5.17(d,J＝19.6Hz,1H),5.06(t,J＝5.6Hz,1H),4.68(d,J＝7.2Hz,2H),4.60(dd,J＝9.6,6.0Hz,1H),4.52-4.43(m,1H),4.18-4.04(m,2H),4.01-3.92(m,1H),3.90-3.81(m,1H),3.79-3.68(m,4H),3.65-3.55(m,2H),3.28-3.07(m,2H),3.01(dd,J＝13.6,4.0Hz,1H),2.73(dd,J＝13.6,9.6Hz,1H),2.35(s,3H),2.28-2.12(m,2H),1.88(q,J＝7.2Hz,2H),0.85(t,J＝7.2Hz,3H).
实施例1.14

第一步
将8a(200.00g，399.12mmol)溶解于N,N-二甲基甲酰胺(600mL)中，待用。向反应瓶内依次加入N,N-二甲基甲酰胺(400mL)、乙酸(119.80g，1996.67mmol)和四乙酸铅(260.00g，598.66mmol)，将上述8a的N,N-二甲基甲酰胺溶液缓慢滴入至反应瓶内，滴加完全后，混合体系升温至40℃搅拌反应4小时。向反应液中加入二氯甲烷(4000mL)和水(4000mL)，搅拌30分钟，过滤除去不溶物，滤液分液，水相经二氯甲烷(1000mL x 1)萃取，合并上述有机相，有机相经水(2000mL x 3)洗涤，经减压浓缩得到粗品，粗品经甲基叔丁基醚(1000mL)打浆1小时后过滤，收集滤饼干燥后得到8b(179.63g)，收率：87％。
MS-ESI计算值[M-CH3COO]+＝456，实测值为456。
第二步
氮气保护下，将8b(300.00g，582.29mmol)、四氢呋喃(1200mL)加入反应瓶中，反应体系冷却至0-5℃后加入乙醇酸苄酯(106.39g，640.50mmol)(残余乙醇酸苄酯用300mL四氢呋喃冲洗后加入反应瓶内)，随后滴加氢氧化锂(16.70g，698.74mmol)的水(300mL)溶液，滴加完毕后，反应体系保持0～5℃搅拌反应2小时。向反应体系中加入水(3000mL)和二氯甲烷(3000mL)稀释，搅拌后分液，有机相经食盐水(4000mL x 1)洗，有机相经减压浓缩至约450g，所得粗品溶液经硅胶柱层析(乙酸乙酯：石油醚＝0-100％)纯化得到8c(269.20g),收率：74％。
MS-ESI计算值[M+Na]+＝644，实测值为644。
第三步
氮气保护下，将8c(264.00g，424.98mmol)溶解于二氯甲烷(26440mL)中，反应体系降温至-5～0℃，加入1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(64.60g，424.72mmol)，加料完全后，混合体系在0～5℃搅拌反应2小时。反应液直接经硅胶柱层析(二氯甲烷：异丙醇＝0-100％)纯化得15b(111.00g)，收率：66％。
MS-ESI计算值[M+H]+＝400，实测值为400。
第四步
依次将15b(108.00g，270.60mmol)和水(2160mL)加入反应瓶中，加入湿Pd/C(10.80g)，氢气置换三次，保持氢气氛下搅拌反应3小时。反应液过滤除去不溶物，水相直接冻干得8e(82.16g)，收率：98％。
MS-ESI计算值[M-H]-＝308，实测值为308。
实施例2
抗体-药物偶联物制备方法
使用抗IGF-1R抗体序列进行制备，所述的抗体具有如下所示的CDR区(Kabat定义)：
CDR1：SFVMA(SEQ ID No.1)
CDR2：AISGSGSRARYADSVKG(SEQ ID No.2)
CDR3：NPRRATPDLTQYAY(SEQ ID No.3)
重链可变区：
全长序列如下：
将抗体透析至50mM PB缓冲液中，得到抗体中间体。取适量抗体中间体，依次加入10mM三(2-羧乙基)膦盐酸盐(TCEP)母液、10mM二乙烯三胺五乙酸(DTPA)母液，并补加50mM PB缓冲液，使反应体系抗体终浓度为20mg/mL，TCEP与抗体摩尔比为4，DTPA终浓度为1mM。充分混匀后置于恒温混匀仪中，还原反应温度25±2℃，转速400rpm，还原反应2小时。还原结束后，在冰水浴中依次向各反应体系中添加适量5mM连接子-药物(linker-payload)母液，连接子-药物与抗体摩尔比为4.5，补加DMSO至偶联反应DMSO终体积为20％。充分混匀后，置于恒温混匀仪中，偶联反应温度25±2℃，转速400rpm，偶联反应1小时。偶联结束后，将ADC样品采用超滤离心管透析至透析液(10mM His/His-HCl，pH6.0±0.2)中，得到ADC原液，分装后-80℃保存。
分别采用高效排阻液相色谱(SEC-HPLC)和高效液相疏水色谱(HIC-HPLC)检测ADC的分子大小变异体纯度及平均药物抗体偶联比(DAR,Drug-to-antibody ratio)，主要参数如表1及表2所示。制备得到的ADC的纯度和药物抗体偶联比结果如表3所示，检测结果表明，制备得到的ADC均具有较高纯度，且药物抗体偶联比分布均一。
表1.高效排阻液相色谱(SEC-HPLC)主要参数
表2.高效液相疏水色谱(HIC-HPLC)主要参数
表3.抗体药物偶联物的纯度、平均药物抗体偶联比及DAR4百分比
实施例3
ADC血浆稳定性研究
参考本申请的实施例1方法得到本申请的连接子-药物(linker-payload)，并参考本申请的实施例2的方法得到本申请的抗体-药物偶联物(ADC)。
将适量待测ADC原液加入8mL抗凝人血浆中，使血浆中ADC浓度为200μg/mL，置于生化培养箱中37℃孵育0h、24h、72h或168h后收取样品，经蛋白A层析纯化。取纯化后的ADC样品进行超滤离心浓缩，离心结束后加入5M三(2-羧乙基)膦盐酸盐(TCEP)母液5μL及适量超纯水至总样品体积200μL左右，置于56℃干式恒温仪中40min后取出，再次进行超滤离心(12000rpm,15min)，离心结束后加入100μL的超纯水混匀后，进行RP-MS分析。质谱设置为positive模式，流动相为A：0.1％甲酸水，B：0.1％甲酸乙腈，柱温为40℃，流速为0.4mL/min。
根据分子量大小，分析偶联不同数目小分子药物质量数，根据各峰面积百分比和偶联药物个 数计算平均偶联率(Drug-to-antibody ratio,DAR)，并通过不同孵育时间后的DAR值变化，研究ADC的血浆稳定性，检测结果如表4所示。其中平均偶联率值计算公式为：
实验结果表明，本申请制备得到的ADC均表现良好的血浆稳定性。
表4.抗体药物偶联物在人血浆中孵育不同时间后DAR值变化
实施例4
人源肿瘤细胞体外增殖抑制检测
参考本申请的实施例1方法得到本申请的linker-payload，并参考本申请的实施例2的方法得到本申请的ADC。
收取对数生长期的人源肿瘤细胞，消化后采用新鲜的完全培养液重悬并调整至合适浓度，加入96孔细胞培养板中，将细胞培养板放置于37℃、5％CO2培养箱中培养过夜。次日，向细胞培养板的相应孔内加入不同浓度的待测ADC样品(最高终浓度1μM、1:4或1:8梯度稀释)或者缓冲液对照，继续置于二氧化碳培养箱中培养168h后，将测试板平衡至室温，采用CellTiter Glo assay kit(Promega,G7558)、多功能酶标仪检测luminescence读值。按照以下公式计算细胞抑制率：抑制率(％)＝(1–(RLUADC–RLU空白)/(RLU缓冲液–RLU空白))×100％。利用Graphpad Prism软件绘制药效抑制率曲线并拟合EC50值，各ADC在不同人源肿瘤细胞中的EC50值如表5所示。
本申请制备得到的ADC表现优异的肿瘤细胞体外增殖抑制活性。
表5.ADC对人源肿瘤细胞体外增殖抑制活性
实施例5
体内抗肿瘤功效测定
参考本申请的实施例1方法得到本申请的linker-payload，并参考本申请的实施例2的方法得到本申请的ADC。
收取对数生长期的人源肿瘤细胞，计数后调整至相应浓度，在冰上重悬于无血清培养基与Matrigel(Corning 356234)1:1混合液中，接种至BALB/c裸鼠皮下，每只200μL。待肿瘤生长至可测量范围后，采用游标卡尺测量各肿瘤的长径及短径，并按照下述公式计算肿瘤体积：V＝(a×b2)/2，其中a代表肿瘤长径，b代表肿瘤短径。
待平均肿瘤体积达到100～200mm3时，将动物按照肿瘤体积进行随机区组法分组。按照预定给药方案对荷瘤裸鼠经尾静脉注射溶剂对照(生理盐水)或者不同剂量的ADC(3mg/kg或10mg/kg)。每周测量2次肿瘤长、短径，并记录动物体重。统计各组肿瘤体积，并按照下述公式计算肿瘤生长抑制率TGI：TGI＝100％×[1－(TVtT－TV0T)/(TVtC－TV0C)]。其中(TVtT代表给药组在测量当天的肿瘤体积，TV0T代表给药组在分组时的肿瘤体积；TVtC代表溶剂对照组在测量当天的肿瘤体积，TV0C代表溶剂对照组在分组时的肿瘤体积。
本申请制备得到的ADC表现优异的体内抗肿瘤活性。
实施例6
大鼠体内药代动力学检测
取一只6-8周健康成年的Sprague Dawley大鼠，尾静脉推注ADC约1min±10s，给药体积为 5mL/kg，给药浓度为20mg/kg，分别在给药结束后0.083h、lh、2h、8h、24h、48h、72h、96h、120h、144h和168h采集血液，于30-120分钟之内离心分离血清。通过常规的ELISA方法检测血样中总抗体(Tab)和ADC的浓度。
总抗体的检测方法简述如下，4℃包被Trop2-His过夜，浓度0.75ug/mL,37℃ 5％的脱脂奶粉封闭2h，加入标曲和质控点孵育2h，标曲检测范围为64ng/mL-0.5ng/mL,64ng/mL起始，2倍梯度稀释，质控浓度点设置为60ng/mL，6ng/mL，0.6ng/mL，质控点回收率需要在80％-120％之间，随后加入1:8000稀释加入山羊中生产的抗人K轻链过氧化物酶抗体，(厂家：sigma，货号：A7164-1ML)二抗，稃育1h，PBST洗8遍后，加入TMB显色，0.1M硫酸终止，OD450酶标仪读板，使用酶标检测仪分析软件SoftMaxPro，计算不同时间点血样浓度。
ADC的检测方法简述如下，4℃包被Trop2-His过夜，浓度0.75ug/mL,37℃ 5％的脱脂奶粉封闭2h，加入标曲和质控点孵育2h，标曲检测范围为64ng/mL-0.5ng/mL,64ng/mL起始，2倍梯度稀释，质控浓度点设置为60ng/mL，6ng/mL，0.6ng/mL，质控点回收率需要在80％-120％之间，随后加入1:8000稀释加入山羊中生产的抗人K轻链过氧化物酶抗体，(厂家：sigma，货号：A7164-1ML)二抗，稃育1h，PBST洗8遍后，加入TMB显色，0.1M硫酸终止，OD450酶标仪读板，使用酶标检测仪分析软件SoftMaxPro，计算不同时间点血样浓度。
使用ELISA绘制出血液中药物浓度变化曲线，ADC浓度与总抗体浓度基本重合，脱落极低，在血液中很稳定。
实施例7
细胞增殖抑制实验
取对数生长期的KPL-4肿瘤细胞，采用新鲜RPMI1640培养液重悬细胞，计数并将细胞悬液调至2×104个/mL。将细胞悬液接种至96孔细胞培养板中，100μL/孔，置于二氧化碳培养箱(37℃，5％CO2)中培养过夜。第二天取出其中一块接种细胞的96孔板，平衡至室温后向测试板各孔中加入预先平衡至室温并配制混匀的CellTiter-Glo试剂(Promega,USA)100μL，避光孵育30分钟后在酶标仪中读取luminescence数值(记为G0值)；取另一块平行板并在测试板的相应孔内加入不同浓度的待测化合物或者DMSO(终浓度0.5％)，于二氧化碳培养箱中培养72h后，将测试板平衡至室温并采用CellTiter-Glo试剂检测细胞活性，记为G3值。
根据以下公式计算细胞增殖率：细胞增殖率(％)＝(待测化合物孔G3平均值–G0平均值)/(DMSO对照孔G3平均值–G0平均值)*100。采用Graphpad Prism软件拟合抑制曲线并计算GI50值。
本申请制备得到的化合物表现优异的体内抗肿瘤活性。
实施例8
旁观杀伤活性实验
BxPC3(人胰腺癌细胞，ATCC,CRL-1687)和MiaPaCa2细胞(人胰腺癌细胞，biocytogen，B-HCL-014)分别用RPMI1640+10％FBS和DMEM/高葡萄糖+10％FBS培养，细胞用胰酶消化，新鲜培养基中和，1000rpm离心3分钟，弃上清，细胞用RPMI1640+10％FBS重悬。细胞计数后，将BxPC3细胞密度调整为6*104个/mL，将MiaPaCa2-luc细胞密度调整为1.5*104个/mL。12孔板板1中每孔加入500μL的BxPC3细胞和500μL的MiaPaCa2-luc细胞。12孔板板2中加入500μL的MiaPaCa2-luc细胞和500μL的含10％FBS血清的RPMIl640培养液。5％二氧化碳37℃培养24小时。
ADC样品配制成40x浓度的中间溶液(0.2μΜ)。各取25μL上述样品加入到12孔板相应孔中。设置溶剂对照组。5％二氧化碳37℃培养6天。12孔板中的细胞用胰酶消化，新鲜培养基中和，1000rpm离心3分钟，弃上清，用1mL的FACS缓冲液(PBS+2.5％FBS)重悬，取20μL的细胞加入20μL的台盼蓝，计数。板1的细胞，1000rpm离心3分钟，弃上清，用100uL的FACS Buffer重悬，加入2μL的单克隆抗体，冰上孵育30分钟。4℃，2000rpm离心1分钟，弃去上清，加入150uL FACS缓冲液重悬细胞。用BD FACSVerse检测。用Flowjo 7.6分析数据。
结果显示，本公开中的ADC有明确的旁观杀伤效果，ADC并不会杀伤靶点表达阴性的MiaPaCa2细胞，但将靶点表达BxPC3细胞与阴性细胞MiaPaCa2混合后，ADC对靶点表达阴性的细胞也有杀伤作用。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (52)

  1. 一种配体偶联物，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体，或其可药用的盐或水合物，其中所述配体偶联物包含式I所示的结构：
    其中，L为任选取代的连接体，其与P结构中的任意O原子、S原子或N原子相连；
    Ab为配体，a为大于0的数，a是小数或整数；较佳地，所述的a为1-16(如1、2、3、4、5、6、7、8、9、10、11、12、13、14、15或16)；更佳地，所述的a为2-8；
    P为如下式(II)所述结构脱氢形成的基团：
    其中，n为0或1；
    X选自下组：N或CR0；
    R0选自下组：H、D、卤素、C1-C8烷基、C1-C8烷氧基、OH、NH2、N3或NO2；
    R1选自下组：氢原子、氘原子、卤素、C1-C8烷基、C1-C8烷氧基、C1-C8卤代烷基、C1-C8卤代烷氧基、N3、NO2、NH2、NH-OH、-NR'R”、-COOR'、-CONR'R”、-NHR”'NR'R”；其中R'、R”和R”'各自独立地选自氢，氘，烷基，芳基，芳基烷基，酰基，烷氧羰基，芳基氧羰基；
    R2、R3、R4、R5和R6各自独立地选自下组：氢原子、氘原子、卤素、羟基、氰基、NH2、NO2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基、取代或未取代的C1-C8烷硫基、取代或未取代的C1-C8氘代烷基、-(CH2)m三(C1-C4烷基)硅基、-(CH2)m(C3-C8环烷基)、-(CH2)m(3-12元杂环基)、-(CH2)mN(R7)2、-(CH2)mS(CH2)pR7、-(CH2)mS(O)(CH2)pR7、-(CH2)mS(O)2(CH2)pR7、-(CH2)mNH(CH2)pR7、-(CH2)mNHC(O)(CH2)pR7、-(CH2)mOC(O)(CH2)pR7、-(CH2)mC(O)(CH2)pR7、-CH＝N(OtBu)；其中，m和p各自独立地为0、1、2、3或4；
    或者，R2和R3与其相连接的碳原子一起形成取代或未取代的C5-C8碳环或取代或未取代的5-12元杂环基；
    或者，R3和R4，或R4和R5与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱和或不饱和的5-12元碳环、未取代或被一个或多个Re取代的饱和或不饱和的5-12元杂环；所述Re为取代或未取代的选自下组的取代基：氢原子、氘原子、卤素、腈基、硝基、羟基、氨基、C1-C6烷基-NH-、(C1-C6烷基)2N-、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、烯丙基、苄基、C6-C12芳基、C1-C6烷氧基-C1-C6烷基、C1-C6烷氧基-羰基、苯氧羰基、C2-C6炔基-羰基、C2-C6烯基-羰基、C3-C6环烷基-羰基、C1-C6烷基-磺酰基、苯基、5-7元杂芳基、C3-C8环烷基、3-12元杂环基、-(CH2)mN(R7)2、-(CH2)mS(CH2)pR7、-(CH2)mS(O)(CH2)pR7、-(CH2)mS(O)2(CH2)pR7、-(CH2)mNH(CH2)pR7、-(CH2)mNHC(O)(CH2)pR7、-(CH2)mOC(O)(CH2)pR7、-(CH2)mC(O)(CH2)pR7；其中，m和p各自独立地为0、1、2、3或4，优选为0、1或2；
    R7选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基、C1-C8卤代烷基、C1-C8氘代烷基、取代或未取代的C1-C8烷氧基、羟基、氨基、氰基、硝基、巯基、取代或未取代的C1-C8亚烷基-OH、取代或未取代的C1-C8亚烷基-NH2、SO2Me、-OC(O)(取代或未取代的C1-C4烷基)、-C(O)(取代或未取代的C1-C4烷基)、取代或未取代的苯基、取代或未取代的5-7元杂芳基、取代或未取代的C3-C8环烷基、取代或未取代的3-12元杂环基；
    除非特别说明，所述的各个“取代”指基团上的一个或多个氢原子被选自下组的取代基所取代：氢原子、氘原子、卤素、腈基、硝基、羟基、氨基、C1-C6烷基-NH-、(C1-C6烷基)2N-、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、卤代C1-C6烷基、卤代C2-C6烯基、卤代C2-C6炔基、卤代C1-C6烷氧基、烯丙基、苄基、C6-C12芳基、C1-C6烷氧基-C1-C6烷基、C1-C6烷氧基-羰基、苯氧羰基、C2-C6炔基- 羰基、C2-C6烯基-羰基、C3-C6环烷基-羰基、C1-C6烷基-磺酰基、苯基、5-7元杂芳基、C3-C8环烷基、3-12元杂环基。
  2. 如权利要求1所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L具有如下式所示的结构：
    L1-L2-L3-L4-L5；
    其中，所述L1为任选取代的Rd为H、C1-C6烷基、C1-C6氘代烷基、C3-C8环烷基或C3-C8氘代环烷基；
    所述L2为选自下组的基团：任选取代的-(CHR)m1-X1-(CH2CH2O)n3-(CHR)m2-C(O)-、任选取代的-(CHR)m1-X1-X2-(CH2CH2O)n3-(CHR)m2-C(O)-，任选取代的-X1-(CHROCHR)m2-C(O)-、任选取代的-(CHR)p1-C(O)-、任选取代的-(CHR)m1-X1-(CHR)m2-C(O)-、任选取代的-(CHR)m1-X1-(CHR)n3-X2-(CHR)m2-C(O)-、任选取代的-X1-(CHR)m1-X2-(CHR)m2-C(O)-、任选取代的-(CH2CH2O)n3-C(O)-；
    X1和X2各自独立地选自以下组：-O-、-C(O)-、-C(O)-NR-、任选取代的C6-C10芳基、任选取代的5-9元杂芳基、任选取代的3-8元杂脂环基和任选取代的C3-C6脂环基；
    其中，所述的R各自独立地选自以下组：H、D、(CH2)n4OH、(CH2)n4NH2、(CH2O)n4(CH2CH2O)n5H、(CH2O)n4(CH2CH2O)n5CH3、(CH2)n4OCH3、(CH2CH2O)n5CH3、CH2C(O)NH(CH2O)n4(CH2CH2O)n5H、CH2C(O)NH(CH2O)n4(CH2CH2O)n5CH3；
    其中，m1、m2、n3、n4和n5各自独立地选自0、1、2、3、4、5、6、7、8、9、10、11、12；p1选自0、1、2、3、4、5、6、7或8；
    所述L3为肽残基；且所述的L3可以被一个或多个选自下组的取代基取代： CH2C(O)Rc；所述的Rc选自下组： 其中，n1和n2各自独立地为0、1、2、3、4、5、6、7、8、9、10、11、12；
    所述L4为任选取代的-L4a-(NRb)n6-R12-L4b-，其中，L4a不存在，或L4a为任选取代的其中n6为0或1；R12为化学键、CH2、或CD2；
    L4b不存在，或L4b为任选取代的其中，Ra和Rb各自独立地选自以下组：氢、任选取代的C1-C4烷基、和任选取代的C1-C4氘代烷基；
    所述L5不存在，或为任选取代的其中，Y选自下组：O、S或NH；v选自0、1、2、3、4、5、6、7、8、9、10；R10和R11各自独立地选自以下组：氢、氘、任选取代的C1-C4烷基、任选取代的C1-C4卤代烷基、任选取代的C3-C6环烷基和任选取代的C4-C8环烷基烷基，或R10和R11与其相连接的原子一起形成任选取代的3-6元环烷基，R10和R11各自独立地选自下组：氢原子、氘原子、卤素、任选取代的C1-C8烷基、任选取代的C1-C8卤代烷基和任选取代的C1-C8氘代烷基。
  3. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L1为
  4. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，X1和X2各自独立地选自以下组：-O-、-C(O)-、-C(O)-NR-、任选取代的苯基、任选取代的吡啶基、任选取代的C3-C6环烷基、任选取代的或任选取代的
  5. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的-(CH2)m1-X1-(CH2CH2O)n3-(CH2)m2-C(O)-；其中，X1为-C(O)-NH-；较佳地，m1和m2各自独立地选自1、2或3；n3选自0、1、2、3、4、5、6、7、8、9、10、11、12。
  6. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的-(CHR)m1-X1-X2-(CH2CH2O)n3-(CHR)m2-C(O)-；其中，X1为任选取代的或任选取代的X2为-C(O)-NR-；较佳地，m1和m2各自独立地选自0、1或2；n3选自1、2、3、4、5、6、7、8、9、10、11、12。
  7. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的-X1-(CHROCHR)m2-C(O)-；其中，X1为任选取代的芳基、任选取代的杂芳基；较佳地，m2选自0、1、2或3。
  8. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的(CHR)p1-C(O)-；p1选自0、1或2；R选自下组：H、(CH2)n4OH、(CH2O)n4(CH2CH2O)n5H；较佳地，n4和n5各自独立地选自0、1、2或3。
  9. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的-(CH2)m1-X1-(CH2CH2O)n3-(CHR)m2-C(O)-；其中，X1为-C(O)-；较佳地，m1和m2各自独立地选自0、1、2或3；n3选自0、1或2。
  10. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的-X1-(CH2)m1-X2-(CHR)m2-C(O)-；其中，X1为任选取代的芳基或任选取代的杂芳基；X2为-C(O)-；较佳地，m1、m2各自独立地选自0、1或2。
  11. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：-(CHR)m1-X1-(CHR)m2-C(O)-；其中X1为任选取代的3-8元杂脂环基或任选取代的C3-C6脂环基；较佳地，m1为0、1或2，m2为0。
  12. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的-(CHR)m1-X1-(CH2CH2O)n3-(CHR)m2-C(O)-；其中，X1为O；较佳地，m1，n3和m2各自独立地为0、1或2。
  13. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的L2为选自下组的基团：任选取代的-(CHR)m1-X1-(CHR)n3-X2-(CHR)m2-C(O)-；其中X1任选取代的-C(O)-NR-，X2为O；较佳地，m1，n3和m2各自独立地为1、2或3；R如权利要求2中所述。
  14. 如权利要求2中所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，所述L2为任选取代的选自下组的结构：
  15. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的氨基酸构成的肽残基：苯丙氨酸、异亮氨酸、亮氨酸、色氨酸、缬氨酸、甲硫氨酸、酪氨酸、丙氨酸、苏氨酸、组氨酸、丝氨酸、谷氨酰胺、精氨酸、赖氨酸、天冬酰胺、谷氨酸、脯氨酸、瓜氨酸、天冬氨酸和甘氨酸。
  16. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的氨基酸构成的肽残基：甘氨酸、丙氨酸、赖氨酸、苯丙氨酸、缬氨酸和瓜氨酸。
  17. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的肽残基：-甘氨酸-苯丙氨酸-甘氨酸-(-Gly-Phe-Gly-)、-甘氨酸-甘氨酸-苯丙氨酸-甘氨酸-(-Gly-Gly-Phe-Gly-)、-缬氨酸-瓜氨酸-(-Val-Cit-)、-瓜氨酸-缬氨酸-(-Cit-Val-)、-瓜氨酸-丙氨酸-(-Cit-Ala-)、-缬氨酸-丙氨酸-(-Val-Ala-)、-缬氨酸-精氨酸-(-Val-Arg-)、-缬氨酸-赖氨酸-(-Val-Lys-)、-缬氨酸-赖氨酸(Ac)-(-Val-Lys(Ac)-)、-赖氨酸-缬氨酸-(-Lys-Val-)、-亮氨酸-瓜氨酸-(-Leu-Cit-)、-异亮氨酸-瓜氨酸-(-Ile-Cit-)、-色氨酸-瓜氨酸-(-Trp-Cit-)、-苯丙氨酸-赖氨酸-(-Phe-Lys-)、-苯丙氨酸-赖氨酸(Ac)-(-Phe-Lys(Ac)-)、-苯丙氨酸-瓜氨酸-(-Phe-Cit-)、-苯丙氨酸-丙氨酸-(-Phe-Ala-)、-苯丙氨酸-精氨酸-(-Phe-Arg-)、-丙氨酸-赖氨酸-(-Ala-Lys-)、-丙氨酸-丙氨酸-(-Ala-Ala-)、-丙氨酸-丙氨酸-丙氨酸-(-Ala-Ala-Ala-)、-丙氨酸-丙氨酸-天冬酰胺-(-Ala-Ala-Asn-)、-丙氨酸-丙氨酸-天冬氨酸-(Ala-Ala-Asp-)、-赖氨酸-丙氨酸-丙氨酸-天冬酰胺-(-Lys-Ala-Ala-Asn-)、-赖氨酸-丙氨酸-丙氨酸-天冬氨酸-(-Lys-Ala-Ala-Asp-)、-(D)-缬氨酸-亮氨酸-赖氨酸-(-D-Val-Leu-Lys-)、-甘氨酸-甘氨酸 -精氨酸-(-Gly-Gly-Arg-)、-甘氨酸-甘氨酸-天冬酰胺-(-Gly-Gly-Asn-)、-甘氨酸-甘氨酸-苯丙氨酸-(-Gly-Gly-Phe-)、-缬氨酸-赖氨酸-甘氨酸-(-Val-Lys-Gly-)、-谷氨酸-丙氨酸-丙氨酸-(-Glu-Ala-Ala-)、-天冬氨酸-丙氨酸-丙氨酸-(-Asp-Ala-Ala-)、-缬氨酸-赖氨酸-甘氨酸-甘氨酸-(-Val-Lys-Gly-Gly-)和-赖氨酸-丙氨酸-天冬酰胺-(-Lys-Ala-Asn-)。
  18. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L3为未取代或被CH2C(O)Rc取代的选自以下组的结构：

  19. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L4为化学键，或为任选取代的选自下组的基团： 其中，所述Ra和Rb各自独立地选自以下组：氢、任选取代的C1-C4烷基、任选取代的C1-C4氘代烷基。
  20. 如权利要求19所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L4为化学键，或为任选取代的选自下组的结构：
  21. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述L5为化学键，或为选自以下组的结构：任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的任选取代的和任选取代的
  22. 如权利要求2所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的式II化合物选自下组：
  23. 如权利要求22所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述R4选自下组：氢原子、氘原子、卤素、羟基、氰基、NH2、NO2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基、取代或未取代的C1-C8烷硫基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C8环烷基)、-(CH2)m(3-12元杂环基)、-(CH2)mN(R7)2、-(CH2)mS(O)(CH2)pR7、-(CH2)mS(O)2(CH2)pR7、-(CH2)mNH(CH2)pR7；其中，m和p各自独立地为0、1或2，R7的定义如上文中所述；
    R5选自下组：氢原子、氘原子、卤素、NH2、OH、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基；
    或者，R4和R5与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱和或不饱和的5-6元碳环、未取代或被一个或多个Re取代的饱和或不饱和的5-6元杂环；其中，Re的定义如上文中所述。
  24. 如权利要求22所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，R2和R3各自独立地选自下组：氢原子、氘原子、卤素、NH2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C6环烷基)、-(CH2)m(3-6元杂环基)、-(CH2)mN(R7)2、-(CH2)mOC(O)R7；其中，m为0、1、2、3或4，R7的定义如上文中所述；
    或者，R2和R3与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱 和或不饱和的5-6元环、未取代或被一个或多个Re取代的饱和或不饱和的5-6元杂环；其中，Re的定义如上文中所述。
  25. 如权利要求22所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述R4和R5各自独立地选自下组：氢原子、氘原子、卤素、羟基、NH2、取代或未取代的C1-C4烷基；
    或者，R4和R5与其相连接的碳原子共同形成未取代或被一个或多个Re取代的氧杂5-6元杂环；其中，Re的定义如上文中所述。
  26. 如权利要求22所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，
    R2选自下组：氘原子、卤素、NH2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C6环烷基)、-(CH2)m(3-6元杂环基)、-(CH2)mN(R7)2、-(CH2)mOC(O)R7；其中，m为0、1、2、3或4；
    R3各选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基、取代或未取代的C1-C8氘代烷基、-(CH2)m(C3-C6环烷基)、-(CH2)m(3-6元杂环基)、-(CH2)mN(R7)2、-(CH2)mOC(O)R7；其中，m为0、1、2、3或4；
    或者，R2和R3与其相连接的碳原子共同形成选自下组的结构：未取代或被一个或多个Re取代的饱和或不饱和的5-6元环、未取代或被一个或多个Re取代的饱和或不饱和的5-6元杂环；
    R4选自下组：氢原子、氘原子、卤素、羟基、氰基、NH2、NO2、取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷氧基；
    R5选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基；
    或者，R4和R5与其相连接的碳原子共同形成未取代或被一个或多个Re取代的选自下组的基团：-OCH2O-或-O(CH2)2O-；
    R7选自下组：氢原子、氘原子、卤素、取代或未取代的C1-C8烷基、羟基、氨基、氰基、硝基、巯基；
    其中，Re的定义如上文中所述。
  27. 如权利要求22所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，所述的式II化合物选自下组：








  28. 如权利要求1所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，其中所述Ab为抗体或其抗原结合片段。
  29. 如权利要求28所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，其中所述抗体选自以下组：鼠源抗体、嵌合抗体、人源化抗体和全人源抗体。
  30. 如权利要求28所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，其中所述抗体为单克隆抗体、双特异抗体、多肽。
  31. 如权利要求28所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，其中所述抗原结合片段选自以下组：Fab，Fab′，Fv片段，F(ab')2，F(ab)2，scFv，di-scFv，VHH和dAb。
  32. 如权利要求1所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于，上述的配体偶联物选自下组：









  33. 如权利要求1所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其中所述配体偶联物包含式(I-a)所示的结构：
    其中，R4、R5和L如权利要求1中的定义，a为大于0的数，a是小数或整数。
  34. 如权利要求33所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其中所述配体偶联物为选自以下组的结构：



    其中a为大于0的数，a是小数或整数。
  35. 如权利要求1-34任一项所述的配体偶联物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐或水合物，其特征在于所述的抗体为IGF-1R特异性抗体。
  36. 如权利要求35所述的配体偶联物，其特征在于，所述IGF-1R包含来源于灵长类动物的IGF-1R。
  37. 如权利要求36所述的配体偶联物，其特征在于，所述抗体包含HCDR3，所述HCDR3包含SEQ ID NO：3所示的氨基酸序列。
  38. 如权利要求36所述的配体偶联物，其特征在于，所述抗体包含HCDR2，所述HCDR2包含SEQ ID NO：2所示的氨基酸序列。
  39. 如权利要求36所述的配体偶联物，其特征在于，所述抗体包含HCDR1，所述HCDR1包含SEQ ID NO：1所示的氨基酸序列。
  40. 如权利要求36所述的配体偶联物，其特征在于，所述抗体包含重链可变区VH，所述VH包含所述HCDR1、HCDR2和HCDR3，所述HCDR3包含SEQ ID NO：3所示的氨基酸序列；所述HCDR2包含SEQ ID NO：2所示的氨基酸序列；且所述HCDR1包含SEQ ID NO：1所示的氨基酸序列。
  41. 如权利要求36所述的配体偶联物，其特征在于，所述抗体包含重链可变区VH，所述VH包含SEQ ID NO：4所示的氨基酸序列。
  42. 如权利要求36所述的配体偶联物，其特征在于，所述的抗体具有如SEQ ID No.5所示的全长序列。
  43. 一种药物组合物，其含有权利要求1-42中任一所述的配体偶联物，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其药学上可接受的盐、前药或溶剂合物，以及任选的药学上可接受的载体。
  44. 权利要求1-42中任一所述的配体偶联物，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其药学上可接受的盐、前药或溶剂合物，和/或权利要求43所述的药物组合物在制备用于治疗和/或预防与所述的配体的靶点表达相关和/或异常表达相关的疾病或病症的药物中的用途。
  45. 如权利要求44所述的用途，所述与所述配体的靶点表达相关和/或异常表达相关的疾病或病症为肿瘤、癌症、自身免疫疾病或者感染性疾病；较佳地，所述肿瘤/癌症为所述配体的靶点高表达、中表达、低表达的肿瘤/癌症。
  46. 一种配体偶联物前体，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体，或其可药用的盐或水合物，其中所述配体偶联物前体包含式IA所示的结构：
    LA-P(IA)，
    其中，LA为L1A-L2-L3-L4-L5；其中，L1A为
    Rd、L2、L3、L4、L5和P定义如权利要求1-34任一中所述。
  47. 如权利要求46所述的配体偶联物前体，或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体，或其可药用的盐或水合物，其中所述配体偶联物前体选自下组：



  48. 一种如式(L)所示的连接体，其将药物单元与配体连接而成的配体-药物偶联物：
    L1-L2-L3-L4-L5(L)，
    其中，其中，所述L1,L2,L3,L4,L5的定义如权利要求1-34任一中所述。
  49. 如权利要求48所述的连接体，其特征在于，所述的连接体选自下组：




  50. 如权利要求48-49所述的连接体，其特征在于，所述的连接体通过L1段与配体相连，通过L5段与P1相连，形成配体药物偶联物；且所述的P1选自下组：糖肽类抗生素，例如博来霉素或平阳霉素；DNA拓扑异构酶抑制剂，例如拓扑异构酶I抑制剂(例如喜树碱、羟基喜树碱、9‐氨基喜树碱、SN‐38、伊立替康、伊喜替康、拓扑替康、贝洛替康或卢比替康、DXd等)，拓扑异构酶II抑制剂(例如放线菌素D、多柔比星、多卡米星，柔红霉素、米托蒽醌、鬼臼毒素或依托泊苷)；干扰DNA合成药物，例如甲氨蝶呤、5‐氟尿嘧啶、阿糖胞苷、吉西他滨、巯嘌呤、喷司他丁、氟达拉滨、克拉屈滨或奈拉滨；作用于结构蛋白的药物，例如微管蛋白抑制剂，长春花生物碱类、长春新碱、长春碱、紫杉醇、多西他赛或卡巴他赛；肿瘤信号通路抑制剂，例如丝氨酸/苏氨酸激酶抑制剂、酪氨酸激酶抑制剂、天冬氨酸激酶抑制剂或组氨酸激酶抑制剂；蛋白酶体抑制剂；组蛋白去乙酰化酶抑制剂；肿瘤新生血管生成抑制剂；细胞周期蛋白抑制剂；美登素衍生物(例如DM1、DM4等)；卡里奇霉素衍生物；奥瑞他汀衍生物(例如单甲基澳瑞他汀E(MMAE)、单甲基澳瑞他汀F(MMAF)、澳瑞他汀E、澳瑞 他汀F等)；Pyrrolobenzodiazepine dimers(PBD)衍生物；鹅膏毒素类衍生物(如α-Amanitin等)；蒽环类；杜卡霉素；艾日布林(eribulin)；美法仑；丝裂霉素C；苯丁酸氮芥；TLR激动剂；STING激动剂；糖皮质激素类以及其它抑制肿瘤细胞生长、促进肿瘤细胞凋亡或坏死的活性物质脱氢形成的基团。
  51. 一种如式(L-1)所示的连接体前体，其用于得到将药物单元与配体连接而成的配体-药物偶联物：
    LA-Rg(L-1)，
    其中，Rg为H、OH、O(C1-C6烷基)；其中LA的定义如权利要求46所述。
  52. 如权利要求51所述的连接体前体，其特征在于，所述的连接体前体选自下组：


PCT/CN2023/134190 2022-11-25 2023-11-26 一种抗肿瘤化合物及其应用 Ceased WO2024109949A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP23894038.1A EP4623937A1 (en) 2022-11-25 2023-11-26 Anti-tumor compound and use thereof
AU2023387509A AU2023387509A1 (en) 2022-11-25 2023-11-26 An anti-tumor compound and use thereof
CN202380079571.6A CN120265326A (zh) 2022-11-25 2023-11-26 一种抗肿瘤化合物及其应用
JP2025530407A JP2025538619A (ja) 2022-11-25 2023-11-26 抗腫瘍化合物及びその応用
KR1020257021206A KR20250111373A (ko) 2022-11-25 2023-11-26 항종양 화합물 및 이의 응용

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202211494434 2022-11-25
CN202211494434.2 2022-11-25
CN202310846979 2023-07-11
CN202310846979.3 2023-07-11

Publications (1)

Publication Number Publication Date
WO2024109949A1 true WO2024109949A1 (zh) 2024-05-30

Family

ID=91195219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/134190 Ceased WO2024109949A1 (zh) 2022-11-25 2023-11-26 一种抗肿瘤化合物及其应用

Country Status (6)

Country Link
EP (1) EP4623937A1 (zh)
JP (1) JP2025538619A (zh)
KR (1) KR20250111373A (zh)
CN (1) CN120265326A (zh)
AU (1) AU2023387509A1 (zh)
WO (1) WO2024109949A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025241869A1 (zh) * 2024-05-24 2025-11-27 明慧医药（杭州）有限公司 抗psma抗体药物偶联物及其应用
WO2026037321A1 (en) * 2024-08-13 2026-02-19 Lepu Biopharma Co., Ltd. Compounds, compositions and methods

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952484A (en) 1994-03-08 1999-09-14 Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US7238785B2 (en) 2002-03-01 2007-07-03 Immunomedics, Inc. RS7 antibodies
CN101321784A (zh) * 2005-10-11 2008-12-10 埃博灵克斯股份有限公司 针对egfr和igf－ir的纳米抗体tm和多肽
CN104755494A (zh) * 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
CN113766954A (zh) * 2019-04-26 2021-12-07 伊缪诺金公司 喜树碱衍生物
CN113766933A (zh) * 2019-06-28 2021-12-07 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
WO2021244590A1 (zh) 2020-06-02 2021-12-09 明慧医药（上海）有限公司 抗b7-h3抗体及其制备和应用
WO2022161479A1 (zh) * 2021-01-29 2022-08-04 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2022262789A1 (zh) 2021-06-17 2022-12-22 明慧医药（杭州）有限公司 一种抗肿瘤化合物及其应用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952484A (en) 1994-03-08 1999-09-14 Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US7238785B2 (en) 2002-03-01 2007-07-03 Immunomedics, Inc. RS7 antibodies
CN101321784A (zh) * 2005-10-11 2008-12-10 埃博灵克斯股份有限公司 针对egfr和igf－ir的纳米抗体tm和多肽
CN104755494A (zh) * 2012-10-11 2015-07-01 第一三共株式会社 抗体-药物偶联物
CN113766954A (zh) * 2019-04-26 2021-12-07 伊缪诺金公司 喜树碱衍生物
CN113766933A (zh) * 2019-06-28 2021-12-07 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
WO2021244590A1 (zh) 2020-06-02 2021-12-09 明慧医药（上海）有限公司 抗b7-h3抗体及其制备和应用
WO2022161479A1 (zh) * 2021-01-29 2022-08-04 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2022262789A1 (zh) 2021-06-17 2022-12-22 明慧医药（杭州）有限公司 一种抗肿瘤化合物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Uniprot", Database accession no. P08069
See also references of EP4623937A1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025241869A1 (zh) * 2024-05-24 2025-11-27 明慧医药（杭州）有限公司 抗psma抗体药物偶联物及其应用
WO2026037321A1 (en) * 2024-08-13 2026-02-19 Lepu Biopharma Co., Ltd. Compounds, compositions and methods

Also Published As

Publication number Publication date
KR20250111373A (ko) 2025-07-22
AU2023387509A1 (en) 2025-07-10
JP2025538619A (ja) 2025-11-28
CN120265326A (zh) 2025-07-04
EP4623937A1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
TWI820044B (zh) 抗體－吡咯并苯二氮呯衍生物複合體
JP2025032192A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート
JP2024520674A (ja) 薬物コンジュゲート及びその使用
KR20230022211A (ko) 고안정성 친수성 연결 단위를 갖는 캄프토테신 약물 및 이의 접합체
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
JP2018509908A (ja) Ｃｄ４８抗体及びその複合体
JP2019521114A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート
WO2024109949A1 (zh) 一种抗肿瘤化合物及其应用
JP2025523090A (ja) 抗体薬物複合体及びその製造方法と使用
KR20250150111A (ko) 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도
TW202430173A (zh) 一種抗體藥物偶聯物、製備方法及其應用
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
CN119300868B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
TW202535885A (zh) 配體-藥物偶聯物、偶聯連接子及其用途
WO2025148868A1 (zh) 一种抗体偶联药物及其用途
WO2025045015A1 (zh) 抗体-药物缀合物及其制备方法和用途
JP2026508115A (ja) リンカー薬物、その抗体－薬物コンジュゲート、並びにそれらの調製方法及び使用
US20260102507A1 (en) Camptothecin derivative for treating or preventing cancer and antibody-drug conjugate thereof
WO2026067624A1 (zh) 一种包含亲水基团的配体-药物偶联物及其在医药上的应用
TW202508638A (zh) 連結子化合物及配體－藥物接合物、其製備方法及用途
CN121712532A (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
TW202515913A (zh) Nectin-4抗體及抗體藥物結合物
TW202408590A (zh) 抗體藥物偶聯物及其製備方法和用途
WO2025073812A1 (en) Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
CN119212726A (zh) 降解循环蛋白的双功能分子

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23894038

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202380079571.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2025530407

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025530407

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202591619

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 822726

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: AU2023387509

Country of ref document: AU

Ref document number: 2023894038

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202503520Q

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 822726

Country of ref document: NZ

Ref document number: 11202503520Q

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 202380079571.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2023894038

Country of ref document: EP

Effective date: 20250625

ENP Entry into the national phase

Ref document number: 2023387509

Country of ref document: AU

Date of ref document: 20231126

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020257021206

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2023894038

Country of ref document: EP